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Abstract 
Tuberculosis (TB), a disease caused by the pathogenic bacterium Mycobacterium tuberculosis 
(Mtb), is responsible for killing over one million people each year with an alarming number 
categorized as multidrug resistant (MDR) or extensively drug resistant (XDR) infections. These 
high numbers, coupled with other factors such as the ability of Mtb to adapt to its host, its 
synergistic relationship with Human Immunodeficiency Virus (HIV) and the protracted treatment 
regimen required to treat TB has resulted in the urgent need for new TB drugs. In this regard, the 
peptidoglycan (PG) layer of the mycobacterial cell wall, which requires an array of enzymes for 
synthesis of this mesh-like polymer, have been of particular interest. The PG consists of sugars 
cross-linked by stem peptides and is synthesized, cross-linked and remodeled by carefully 
regulated enzymes such as penicillin binding proteins (PBPs) which perform the final cross-
linking step in PG biosynthesis. This study focuses on a specific group of low molecular weight 
PBPs, namely the DD-carboxypeptidases (DD-CPases), which are responsible for regulating the 
amount of cross-links found in the PG by cleaving the terminal D-Alanine (D-Ala) from the stem 
peptide of nascent PG units. To date, these proteins have remained largely uncharacterized in 
mycobacteria. To investigate the functions of these proteins in Mycobacterium smegmatis, two 
double knockout mutants lacking different combinations of the DD-CPase-encoding genes 
(MSMEG_1661, MSMEG_2432 and/or MSMEG_2433) were created using two-step allelic 
exchange and assessed using a range of phenotypic analyses. In addition recombinant protein 
production of these DD-CPases as well as MSMEG_6113 was attempted. We were unable to 
create a double knockout mutant lacking both MSMEG_2432 and MSMEG_2433 from an 
existing single mutant strain, suggesting that the operonic structure of these two genes may 
require a different approach. We were able to generate two double knockout mutants, 
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ΔMSMEG_1661 ΔMSMEG_2432 and ΔMSMEG_2433 ΔMSMEG_1661, lacking two DD-
CPases. Southern blot and gene expression analyses confirmed loss of the respective genes from 
M. smegmatis. The ΔMSMEG_1661 ΔMSMEG_2432 mutant and ΔMSMEG_2433 
ΔMSMEG_1661 mutant displayed no alterations in colony morphology, biofilm formation, 
sliding motility and sodium dodecyl sulphate (SDS) sensitivity. However, loss of two DD-CPases 
resulted in increased sensitivity of M. smegmatis to vancomycin and a range of β-lactams 
antibiotics. Analysis of cellular morphology using transmission electron microscopy (TEM) 
demonstrated that the septum was fully formed in all strains but in some cases was not degraded 
during daughter cell separation. Scanning electron microscopy (SEM) and spatial localization of 
new PG units using BODIPY-labeled vancomycin revealed that late division processes were 
hampered in these double knockout mutants with new PG inserted across the cell as well as cells 
with multiple unresolved septa. To create recombinant derivatives of MSMEG_6113, 
MSMEG_1661, MSMEG_2432 and MSMEG_2433, proteins were His-tagged and purified 
using affinity chromatography. However, under all conditions tested soluble protein could not be 
acquired. Collectively, these data provide the first evidence that the DD-CPases of M. smegmatis 
may play a direct role in the late cell division process that lead to daughter cell separation in 
mycobacteria. 
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1. Introduction 
1.1. Tuberculosis 
Tuberculosis (TB), previously known as consumption, has been around for millennia, being 
recorded as early in history as the Egyptian and Greco-Roman civilizations (De Backer et al., 
2006). In 2014, 9.6 million people fell ill with the TB disease, with 1.5 million succumbing 
(WHO, 2015). Additionally, approximately 480 000 people developed MDR TB with an 
estimated 190 000 cases resulting in death (WHO, 2015). 
The human pathogen Mycobacterium tuberculosis (Mtb) is the causative agent of TB and is 
currently classified as being responsible for the largest number of deaths due to a single 
bacterium (Chao and Rubin, 2010). Mtb has the capacity to cause a spectrum of disease in the 
human host, which ranges from latent, asymptomatic infection to active granulomatous 
disease. Active TB disease is treated with a Food and Drug Administration (FDA) approved 
regimen consisting of six months of antimicrobial drug treatment (Zhang, 2005, CDC, 2015). 
However, the ability of Mtb to adopt a dormant like state, adapt to the host environment and 
readily evolve resistance to drugs has resulted in TB disease remaining of global health 
concern (Zhang, 2005, Hett and Rubin, 2008). In addition to this, high rates of co-infection 
with Human Immunodeficiency Virus (HIV) contribute to TB incidence rates, especially in 
high burden countries such as South Africa, with 1.2 million HIV-infected individuals 
developing TB in 2014 (WHO, 2015). 
1.2. Treatment and vaccines 
Bacille Calmette-Guerin (BCG) is currently the only TB vaccine available and was developed 
almost a century ago (Malmros, 1948). BCG is administered intradermally, providing 
effective protection for TB meningitis in children. However, in adults variable protection (0 -
80%), if any, is achieved for pulmonary TB and BCG does not protect against latent TB 
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infection (LTBI) (CDC, 2015). Considering this, an urgent preventative vaccine with long-
lasting protective efficacy is urgently required to bolster prevention of TB transmission in the 
community setting. 
Drug sensitive (DS) TB is treated with chemotherapeutics over a six-month period, known as 
directly observed treatment short course (DOTS) (CDC, 2015, WHO, 2015). The first two 
months of treatment involves administration of the first-line antimicrobial drugs isoniazid 
(INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA) (Ducati et al., 2006, 
CDC, 2015, WHO, 2015). This is followed by treatment with INH and RIF for the remaining 
four months. In cases of drug resistant TB, several alternate drug combinations are 
implemented (CDC, 2015, WHO, 2015). There are numerous problems with TB treatment 
including non-compliance where patients fail to complete treatment, negative drug 
interactions with medications such as anti-retroviral therapy, poor drug availability in some 
communities and prescription of inappropriate treatment. This has resulted in an increase in 
composite forms of drug resistance such as MDR, XDR and totally drug resistant 
(XXDR/TDR) TB (Gandhi et al., 2006, Migliori et al., 2007, Velayati et al., 2009, WHO, 
2015). MDR Mtb strains are defined as those strains that are resistant to both the first line 
drugs, INH and RIF, whereas XDR strains are defined as being resistant to INH, RIF and two 
classes of the second line drugs: a fluroquinone and at least one of the injectable drugs 
(kanamycin, amikacin, and capreomycin) (Velayati et al., 2009, WHO, 2015). XXDR strains 
are resistant to all standard drugs, be it first line or second line chemotherapeutics (CDC, 
2015). 
There are ten FDA approved drugs for the treatment of TB (CDC, 2015). The first line drugs 
include INH, RIF, EMB, PZA, rifabutin and the recently added rifapentine (CDC, 2015). 
Second line drugs include but are not limited to cycloserine, ethiaonamide, streptomycin, 
amikacin, kanamycin and capreomycin (Cohen, 2013, CDC, 2015). These drugs can be 
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administered orally or can be injected. Second line drugs are quite expensive, toxic and are 
not as effective as first line medication.  
The above-mentioned drugs have been in use for over fifty years, with new medications only 
being introduced recently. Bedaquiline (BDQ) represents a novel addition to the TB 
chemotherapeutic arsenal and was recently approved by the FDA for treatment of MDR-TB, 
making it the first new drug to be added to the TB regimen in over five decades (Cohen, 
2013). BDQ is a diarylquinolone which inhibits adenosine triphosphate (ATP) synthase 
displaying a high specificity for the mycobacterial ATP synthase (Andries et al., 2005). When 
used in combination with PZA, BDQ has been shown to have increased activity (Diacon et 
al., 2012). Another drug clofazamine (CFZ), which has been used to treat leprosy for the past 
fifty years was repurposed for treating MDR-TB (Lechartier and Cole, 2015). CFZ is reduced 
by NADH dehydrogenase followed by reduction by oxygen which leads to the release of 
reactive oxygen species and eventually cell death (Yano et al., 2011).  Adding CFZ to a 
regimen could possibly cure MDR TB in 9 – 12 months (Van Deun et al., 2010). However, 
use of CFX results in side effects such as skin discoloration which makes it undesirable for 
patient treatment. 
Drug resistance can be acquired due to a number of reasons including lateral gene transfer, 
selective pressure under certain conditions and genetic mutations (Depardieu et al., 2007). 
Some microorganisms also have natural resistance to specific antibiotic classes. In 
mycobacteria, resistance to first line drugs is mainly due to mutations in the specific genes 
that encode drug targets. A number of genes are involved in EMB and INH resistance with 
the principle mutations occurring in the embB gene and the katG and inhA genes respectively 
(Banerjee et al., 1994, Ramaswamy et al., 2003). Mutations in the pncA gene confer 
resistance to PZA and those in the rpoB and embB genes confer resistance to RIF. (Telenti et 
al., 1993, Telenti, 1997, Ramaswamy et al., 2003, Zhang, 2005). 
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1.3. Pathogenesis 
Infection with Mtb occurs when an individual inhales aerosol particles containing infectious 
tubercle bacteria (WHO, 2015). Bacteria then encounter the alveolar macrophages in the host 
lungs and are phagocytosed. In the case of an individual with a strong immune system, the 
bacteria are cleared and disease does not progress. Alternatively, TB infection occurs 
resulting in one of two outcomes. Where conditions are favorable for the bacteria to 
proliferate, development of active disease in less than 10% of cases occurs. In the remaining 
individuals, infection does not progress to disease leading to a clinically latent state in 90-
95% of cases. However, it is estimated that these individuals carry a 10% lifetime risk of 
eventually progressing to active disease through a process termed reactivation disease (Bhatt 
and Salgame, 2007, Chao and Rubin, 2010). HIV infected or immune compromised 
individuals have an increased risk (~10% per year) of developing active disease when latently 
infected with TB (WHO, 2015). 
Mtb interacts with toll-like receptors (TLRs) on the surface of macrophages and dendritic 
cells for phagocytosis. Activation of TLRs induces chemokine and cytokine secretion, which 
recruit other immune cells to the infection site and granuloma formation is initiated. Three 
types of granulomas have been identified including the classic caseous granulomas and non- 
necrotizing granulomas found in active disease, which arise due to an imbalance of pro- and 
anti- inflammatory responses (Scanga and Flynn, 2010). The third type, fibrotic granulomas, 
are well structured with activated macrophages able to control proliferation of bacteria 
resulting in LTBI (Scanga et al., 1999, Barry et al., 2009a, Scanga and Flynn, 2010). 
1.4. Latent TB infection 
Individuals that are infected with TB but do not display any of the symptoms of the disease 
are classified as latently infected. This form of TB affects approximately one third of the 
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world’s population and since it is asymptotic, it generally goes undetected in most cases 
(WHO, 2015). Two hypotheses have been ascribed to bacterial physiology associated with 
LTBI, the first stating that LTBI is due to the transition from active growth to dormancy in 
the tubercle bacillus. The second hypothesis states that LTBI is due to a population of both 
growing and dying organisms that is maintained by an efficient immune system. 
Dormancy is a term used to describe bacteria, usually grown in the laboratory, that are 
quiescent and metabolically inactive. Bacteria enter a low metabolic state when faced with 
stressful conditions and this state can be reversed with resumption of growth under favorable 
conditions (Scanga et al., 1999). Strains from the genus Bacillus adopt a form of dormancy 
during harsh conditions through spore formation. Mycobacteria lack the genes necessary for 
entry into spore-like state akin to that found in Bacillus and consequently, it is unlikely that 
they transition to a non-replicating state using a similar mechanism (Feucht et al., 2003, 
Higgins and Dworkin, 2011). Mycobacterium smegmatis has been shown to produce ovoid 
cells which are suggestive of dormant forms of the organism, as these cells have been shown 
to have low metabolic activity, increased resistance to heat and antibiotics as well as the 
inability to be cultured on solid media (Anuchin et al., 2009). Although Mtb has been shown 
to adopt a dormant state in vitro (Shleeva et al., 2010), a strong association between this and 
LTBI has not been demonstrated. In bacterial infections, the dormant state contributes to the 
difficulty in eradicating the disease since many of the current chemotherapeutics target those 
processes required for active growth and these targets lose their vulnerability to drugs under 
non-replicating conditions, resulting in a drug tolerant state. 
Another phenomenon that is related to drug tolerance is bacterial persistence which is defined 
as a subpopulation of bacteria that persist and survive under harsh conditions (Kesavan et al., 
2009). Persisters form a small population that are resistant to antibiotic killing through 
various mechanisms (Lewis, 2010). The tolerant state in persisters is not genetically 
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transmitted to daughter cells, which remain drug sensitive (Mc Dermott, 1958). Mtb has been 
shown to survive prolonged antibiotic treatment which has been attributed to these persisters 
cells (Gomez and McKinney, 2004, Lewis, 2010). There are a few theories that explain the 
presence of persisters in bacterial cultures including the presence of cells that rapidly adapt to 
antibiotic stress, cells that are in some protective stage of the cell cycle (Miller et al., 2004) 
and defective programmed cell death (Wang and Wood, 2011). 
1.5. Bacterial cell growth and division 
The proposed ability of mycobacteria to remain in non-replicating states within an individual 
for years before reactivation disease occurs, points to exceptionally controlled cell growth 
and cell division processes in the tubercle bacillus. Unlike the rod-shaped bacteria 
Escherichia coli and Bacillus subtilis, which grow by incorporating nascent cell wall material 
across the lateral axis of the cell with a right- or left- hand helical pattern respectively, Figure 
1.1A. (Mendelson, 1976, Wang et al., 2012), mycobacteria grow by incorporating newly 
synthesized cell wall material at the sub-polar regions of the cell, Figure 1.1B and 1.1C 
(Brown et al., 2011). The proliferation process of bacterial cells can be divided into 
elongation and division of the parental cell. In most bacteria, cell division occurs at a similar 
rate producing two daughter cells of the same size (Trueba, 1982). In E. coli and B. subtilis, 
cell division and cell elongation occur separately and are controlled by the divisome and 
elongasome respectively, each containing a detailed set of proteins existing in complexes to 
perform these processes (Cabeen and Jacobs-Wagner, 2005). 
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Figure 1.1. Models of bacterial growth. (A) Lateral cell wall incorporation in E. coli and B. subtilis. The green 
colour indicates the insertion of new cell wall. Elongation occurs with nascent peptidoglycan generated across 
the lateral axis of the cell. This is followed by formation of the septum at midcell and subsequent separation of 
the cytoplasm or cytokinesis. Constriction results in the separation of the parental cell into two identical 
daughter cells of the same size. (B) Model describing mycobacterial growth. Elongation of the bacteria occurs 
with the incorporation of nascent peptidoglycan at the poles, with the new pole and old pole shown in dark 
green and light green respectively. After cytokinesis, the septum is constricted resulting in the V-snapping or 
separation of the parental cell into two daughter cells of different lengths. (C) A second model of mycobacterial 
growth. Elongation begins and nascent peptidoglycan is incorporated at the poles with the old pole, shown in 
light green, growing faster than the new pole throughout the cycle until division occurs.  V-snapping results in 
separation of the parental cell into two daughter cells of unequal sizes. (Santi et al, 2013) 
 
Many rod-shaped bacteria such as E. coli use the actin-like MreB protein during the 
elongation process. MreB interacts with MreC, MreD and RodZ and is required for rod-
shaped growth (Gitai et al., 2005, Young, 2010). Decreasing the expression of mreB results in 
increased diameter of cells that appear to have spherical morphology (Karczmarek et al., 
2007). In B. subtilis, MreB and another protein, Mb1, are implicated in controlling the width 
and length of the lateral axis of the cell respectively (Jones et al., 2001). This mode of growth 
results in inert peptidoglycan (PG) at the poles. 
The division process of E. coli and B. subtilis is regulated by the tubulin-like protein FtsZ 
which forms a ring-like structure at midcell called the Z-ring (Bi and Lutkenhaus, 1991, 
A B C
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Adams and Errington, 2009, Typas et al., 2011). The Z-ring initiates cell division and serves 
as a scaffold for recruiting many essential cell division proteins which together form the 
divisome (Typas et al., 2011). Both organisms control FtsZ assembly through the use of 
‘negative control systems’ such as the Min system and nucleoid occlusion. In E. coli, the Min 
system comprises the MinCDE complex whereas in B. subtilis it comprises MinCD and 
DivIVA (Hett and Rubin, 2008). This system directs the assembly of the divisome away from 
the poles by preventing Z-ring formation and cell constriction at the poles. The nucleoid 
occlusion system comprises a protein called SlmA in E. coli and Noc in B. subtilis which 
inhibits FtsZ assembly near the nucleoid and prevents inadvertent guillotining of the 
chromosome by the cell division apparatus (Hett and Rubin, 2008). Both systems are 
triggered when the cell reaches the appropriate length, producing a division event resulting in 
identical daughter cells, each of which contains a nucleoid. 
Mycobacterial elongation and division involves a number of proteins and complexes found in 
the cell wall, however, these organisms do not possess many of the cell division proteins used 
by E. coli and B. subtilis. The MreB proteins are not present in mycobacteria although it is 
possible that other actin-like proteins could perform similar functions. Due to the lack of 
MreB it is hypothesized that the FtsZ homologue in mycobacteria is responsible for both 
elongation and septation (Hett and Rubin, 2008). The FtsZ stabilizing proteins, FtsA and 
ZipA, are also not found in mycobacterial species although recently, SepF has been identified 
as an essential protein that interacts with FtsZ (Gola et al., 2015, Gupta et al., 2015). SepF 
has been identified as a key component of the cell division machinery (Gupta et al., 2015) 
with depletion of the protein resulting in elongated cells as well as a loss in growth and 
viability (Gola et al., 2015).  FtsZ hydrolyses guanosine triphosphate (GTP) and forms the Z-
ring structure at the midcell in mycobacteria which determines the future cell division site 
(Hett and Rubin, 2008). Once the Z-ring forms, several proteins are recruited to form multi-
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protein complexes. The mycobacterial DivIVA homologue, Wag31, is essential for septal and 
polar PG synthesis and is recruited to the septum when division is nearly complete (Kang et 
al., 2008, Cava et al., 2013, Meniche et al., 2014). 
Mycobacteria lack both FtsZ negative control systems found in E. coli and B. subtilis 
resulting in Z-ring formation not always being found at midcell (Singh et al., 2010). Cells 
grow and divide asymmetrically producing two daughter cells of unequal sizes. This unique 
growth pattern of mycobacteria produces a heterogeneous population of cells that vary in 
growth rate, size and composition of the cell wall (Aldridge et al., 2012, Joyce et al., 2012, 
Singh et al., 2013). Two modes of polar cell growth have been described for mycobacterial 
cells. Like all other rod-shaped bacteria, mycobacteria contain two poles termed the old and 
new pole (Aldridge et al., 2012). The old pole refers to the pole which is inherited from the 
parental cell and the new pole refers to the pole which is synthesized during division 
(Aldridge et al., 2012). The first model of growth uses cytokinesis to define cell division, 
Figure 1.1B (Santi et al., 2013, Kieser and Rubin, 2014). In this model it is proposed that the 
poles grow at equal rates until cytokinesis. After cytokinesis until the cells separate, growth is 
said to occur predominantly at the old pole. Once the cells separate both poles once again 
grow at the same rate until the next cytokinesis event. The second model of polar growth uses 
the initiation of constriction to define cell division, Figure 1.1C (Aldridge et al., 2012, Kieser 
and Rubin, 2014). In this model, it is proposed that the poles grow at different rates 
throughout the cell cycle, with the old pole always growing faster than the new pole with cell 
division being asymmetric. Both of these proposed models of polar growth result in the 
generation of daughter cells of unequal lengths. These models also show that the daughter 
cell that inherits the old pole elongates faster after separation and is larger than its sibling 
cell, rendering the longer daughter cell genetically identical but phenotypically different 
(different cell size, cell age and nature of cell poles) when compared to its smaller counterpart 
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(Kieser and Rubin, 2014). These phenotypic differences could possibly play a role in 
antibiotic resistance thus contributing to the success of the species. 
The final step of mycobacterial cell division is referred to as snapping, which is identified by 
the V-shape form cells take on during the late stages of cell division, Figure 1.1B and 1.1C 
(Hett and Rubin, 2008).  
1.6. The mycobacterial cell wall 
The complex mycobacterial cell wall is a key contributor to the success of mycobacterial 
pathogens. Expansion of the cell wall is important for cell growth, virulence and resistance to 
antibiotics (Barry et al., 2007, Kaur et al., 2009, Bansal-Mutalik and Nikaido, 2014). 
Mycobacterial cell walls have been classified as gram variable since they differ from both 
gram positive and gram negative bacterial cell walls (Hett and Rubin, 2008). The structure of 
the mycobacterial cell wall is similar to that found in gram positives in that it contains a thick 
PG layer and no true outer membrane. However, mycobacteria do contain porins which are 
found in gram negative cell walls. The cell wall consists of three main components: a plasma 
membrane, cell wall core and a capsule (Alsteens et al., 2008). The cell wall core is made up 
of cross-linked PG which is covalently linked to arabinogalactan (AG), which in turn is 
linked to mycolic acids (MA) via a phosphodiester bond (Brennan, 2003), Figure 1.2. 
Together these components form an efficient barrier, protecting the bacterium from external 
stresses. 
The mycobacterial capsule is the outermost layer and consists of lipids, polysaccharides and 
proteins (Daffe and Etienne, 1999, Lee et al., 2012).This outer layer of lipids and proteins 
intercalates into the MA acid layer which is composed of a variety of saturated short α-alkyl 
and long β-hydroxyl fatty acids containing between 20-26 and 60-90 carbons per chain  
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Figure1.2. Diagrammatic representation of the structure of the mycobacterial cell wall. The phospholipid 
bilayer is shown by the blue circles and yellow lines which indicate the hydrophilic and hydrophobic 
components of the plasma membrane. The green rectangles represent the peptidoglycan layer with the dark 
green lines representing the peptide cross-links between N-acetylmuramic acid residues. The purple diamonds 
represent the arabinogalactan layer; pink circles represent the mycolic acid layer with a porin shown in orange. 
The red rectangle represents the outer capsule-like layer. (Hett and Rubin, 2008) 
respectively (Besra and Brennan, 1997, Crick et al., 2001). These lipid chains lie at a 90° 
angle to the cell surface and are generated by the FASI and FASII biosynthetic systems 
(Kieser and Rubin, 2014). They are processed and mature through the activity of a cascade of 
enzymes resulting in three meromycolate variants (alpha-, methoxy-, and keto- meromycolic 
acids) which are required for virulence during infection, stimulation of immune responses 
and various roles in pathogenicity (Takayama et al., 2005, Barry et al., 2007, Verschoor et al., 
2012).  The MA layer contributes to cell wall impermeability, antimicrobial resistance and 
virulence (Takayama et al., 2005, Barry et al., 2007, Hett and Rubin, 2008, Sani et al., 2010) 
with the long carbon chains responsible for the thick waxy lipid coat characteristic of 
mycobacteria (Hett and Rubin, 2008). Other molecules in the cell wall include the lipids such 
as lipoarabinomannan (LAM), phtiocerol dimycocerosate (DIM/pDIM), cord factor and 
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trehalose-6, 6-dimycolate (TDM), with the latter two being responsible for cord-like 
formations and clumping in mycobacteria (Brennan, 2003).  
The majority of MAs are covalently linked to the AG by an ester link and are found as 
tetramycolyl-pentaarabinofuranosyl clusters on the AG (Besra and Brennan, 1997, Hett and 
Rubin, 2008). AG is a unique polymer consisting of branched arabinan chains attached to a 
galactan core with both sugars in the furanose configuration (Brennan, 2003). The galactan is 
linear and consists of ~30 residues arranged in alternating 1→5, 1→6 linkages with arabinan 
attached to the fifth carbon of the galactan (Daffe et al., 1990, Crick et al., 2001). This results 
in some galactan residues which do not have arabinan (Daffe et al., 1990, Crick et al., 2001). 
The AG layer plays an important role in cell wall integrity and anchors the MA layer to the 
PG layer (Hett and Rubin, 2008). AG is attached to the PG via a phosphoryl-N-
acetylglucosaminosyl-rhamnosyl linkage known as a linker region (McNeil et al., 1990, 
Mikusova et al., 1996, Crick et al., 2001). 
1.6.1. Peptidoglycan 
PG is a linear polymer which surrounds the plasma membrane and is unique to bacteria, thus 
making it an excellent drug target as evidenced by decades of successful antibiotic therapy 
with penicillin. The PG layer is responsible for maintaining cell shape and size and consists 
of long glycan strands and peptides. The glycan strands form the sugar backbone of PG and 
consists of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), which are cross-
linked by peptides that are attached to the NAM residue. These peptides vary across species 
with the mycobacterial stem peptide made up of L-alanyl (L-Ala), D-iso-glutaminyl (D-Glu), 
meso-diaminopimelic acid (mDAP) and a terminal D-Ala-D-Ala (Vollmer et al., 2008a). 
Mycobacterial PG has unique properties including the occurrence of N-glycosylated muramic 
acid, amidated L-glutamate and mDAP residues, extensively cross-linked PG and increased 
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resistance of the PG to lysozyme (Dhople, 1983, Mahapatra et al., 2005, Lavollay et al., 
2008, Kumar et al., 2012). In mycobacteria 75% of the PG is cross-linked with the 80% of 
the cross-links in stationary phase consisting of 3→3 cross-linkages occurring between two 
mDAP residues of different stem peptides (Crick et al., 2001, Lavollay et al., 2008). These 
cross-linkages have been shown to be important for virulence and polar growth of 
mycobacteria. Another type of cross-link known as 3→4 cross-linkages forms between the 
mDAP residue on one stem peptide and the D-Ala residue of an adjacent stem peptide, which 
is the type of cross-link predominantly found in other bacterial species (Vollmer et al., 
2008a).   
1.6.1.1 Biosynthesis of PG 
The PG precursor – Lipid II – is generated in the cytoplasm and is translocated to the 
periplasm where it is incorporated into existing, cross-linked PG by the penicillin binding 
proteins (PBPs) encoded by ponA1 and ponA2 and distinct glycosyl transferases (Hett and 
Rubin, 2008, Vollmer and Bertsche, 2008). 
Synthesis of PG requires a number of enzymes and reactions that occur in both the cytoplasm 
and periplasm, Figure 1.3. The first step of synthesis begins when uridine diphosphate (UDP) 
is linked to a NAG residue forming UDP-NAG. Enol pyruvate is added to NAG which is 
then reduced to form NAM. A series of reactions then occur to attach the stem peptide 
beginning with L-Ala, then D-Glu, mDAP and then finally the addition of the two terminal D-
Ala residues simultaneously to NAM. Lipid I is formed by the removal of UDP and UDP-
NAG is linked to the NAM pentapeptide residue forming Lipid II which is then flipped 
across the plasma membrane into the periplasm. Lipid II is then incorporated into existing PG 
through a transglycosylase reaction and the PG is then further strengthened by cross-linking 
of the stem peptide through a transpeptidase reaction (Crick et al., 2001).  
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Figure 1.3. Diagrammatic representation of peptidoglycan biosynthesis pathway. The pathway begins with 
the linkage of uridine diphosphate to N-acetylglucosamine followed by the addition of enol pyruvate. Enol 
pyruvate is then reduced to form N-acetylmuramic acid and the stem peptide is then attached through a series of 
steps resulting in the formation of Lipid II which is flipped across into the periplasm where it is incorporated 
into the existing peptidoglycan. The red box indicates the racemization of L-Alanine and the condensation of 
two D-Alanine molecules by alanine racemase and D-alanine ligase respectively. The antibiotics vancomycin 
and D-cycloserine are also indicated. (Vollmer et al, 2008b) 
 
1.7. Antibiotics that target PG 
1.7.1. β-lactam antibiotics 
β-lactam antibiotics are broad spectrum antibiotics that include penicillins, cephalosporins 
and carbapenems and are distinguished by a four-membered β-lactam active ring (Waxman 
and Strominger, 1983). They are substrate analogues of the PBPs that bear structural 
similarity to the D-Ala-D-Ala motif and inhibit PBPs by forming an irreversible intermediate 
within the active site of the enzyme (Waxman and Strominger, 1983). This leads to blockage 
of transpeptidation reactions resulting in weakened PG, inhibition of growth and in some 
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cases, cell lysis (Tipper and Strominger, 1965).  β-lactams have been in use for decades,  
which has resulted in the emergence of a number of resistance mechanisms including the 
expression of low affinity PBPs, increased efflux of antibiotic, subtle changes in the PG to 
render it resistant,  expression of LD-transpeptidases (Ldts) and degradation of β-lactams by 
β-lactamases (Nikolaidis et al., 2013). Expression of Ldts allows bypassing of the 3→4 cross-
linking step and has resulted in a high prevalence of ampicillin resistance and a moderate 
increase in resistance to ceftriaxone. The expression of β-lactamases results in hydrolysis of 
the β-lactam ring which causes inactivation of the antibiotic before it reaches its target 
(Nikolaidis et al., 2013). PBPs involved in β-lactam resistance have mutations across the 
entire protein sequence, with the majority found around the active site (Nikolaidis et al., 
2013). 
1.7.2. Vancomycin 
Vancomycin is a glycopeptide used to treat gram positive bacterial infections such as 
methicillin resistant Staphylococcus aureus (MRSA) (Weigel et al., 2003). The antibiotic 
binds to the D-Ala-D-Ala residues of the stem peptide preventing the cross-linking of stem 
peptides within the PG, Figure 1.3 (Barna and Williams, 1984). Vancomycin resistance in S. 
aureus has been attributed to the vanG gene which produces a D-Ala-D-Ala dimer (Weigel et 
al., 2003). This dimer is incorporated into the stem peptide during PG biosynthesis, thus 
decreasing the binding affinity of vancomycin by 1000-fold (Bugg et al., 1991).  
1.7.3. D-cycloserine 
D-cycloserine, known also as seromycin, is a broad spectrum antibiotic produced by some 
Streptomyces species (Barreteau et al., 2008). It is a cyclic structural analogue of D-Ala and is 
commonly used as a second line drug for the treatment of MDR and XDR TB (Caminero et 
al., 2010). The synthesis of D-Ala-D-Ala requires racemization of L-Ala and condensation of 
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two D-Ala molecules carried out by alanine racemase (Alr) and D-alanine ligase (Ddl) 
respectively, Figure 1.3 (Barreteau et al., 2008). D-cycloserine inhibits both Alr and Ddl but 
has been shown  to preferentially interact with Ddl (Prosser and de Carvalho, 2013). In M. 
smegmatis, resistance to D-cycloserine is acquired through overexpression of the Alr 
encoding gene which occurs due to a mutation in the promoter region (Caceres et al., 1997). 
1.8. PG remodeling enzymes 
A number of enzymes are involved in remodeling the PG including synthases and hydrolases 
(Vollmer and Bertsche, 2008, Vollmer et al., 2008b).  This constant remodeling of the PG is 
required for cell expansion, cell separation and signaling (Vollmer et al., 2008a). In order for 
remodeling to occur, existing PG needs to be degraded so that new subunits can be 
incorporated. Remodeling of the PG is carried out by hydrolases which break down a number 
of bonds, with a specific enzyme existing for each structurally distinct bond in the PG, Figure 
1.4. Glycosidases hydrolyze glycosidic bonds (Vollmer et al., 2008a). Amidases and 
peptidases hydrolyze amide and peptide bonds respectively (Vollmer et al., 2008a). 
Hydrolases digest the PG into small fragments and if they are not carefully controlled, their 
activity could result in autolysis. Consequently, these enzymes have also been termed 
autolysins (Vollmer et al., 2008b).  
Ldts are responsible for forming the 3→3 cross-links between stem peptides by cleaving 
between the D-Ala and mDAP of two separate peptides, followed by subsequent linkage 
between two mDAP residues of the stem peptides, Figure 1.4 (Mainardi et al., 2002). It has 
been demonstrated that the 3→3 cross-links are found in the stationary phase of 
mycobacterial growth however, recent evidence suggests that these cross-links predominate 
during all stages of mycobacterial growth (Wietzerbin et al., 1974, Lavollay et al., 2008, 
Kumar et al., 2012). Mtb encodes five Ldts – LdtMT1, LdtMT2, LdtMT3, LdtMT4 and LdtMT5 
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(Gupta et al., 2010, Sanders et al., 2014). Deletion of LdtMT1 only and LdtMT1 combined with 
LdtMT2, resulted in decreased virulence, altered morphology, increased sensitivity to 
vancomycin, decreased growth in liquid culture, altered localization of some proteins and an 
increased sensitivity to amoxicillin-clavulanate with some of these phenotypes more 
pronounced in the double deletion mutants, indicating that these proteins may be functionally 
redundant (Gupta et al., 2010, Schoonmaker et al., 2014).  
 
Figure 1.4. Diagrammatic representation of the structure of peptidoglycan illustrating peptidoglycan 
remodeling enzymes and cleavage sites. Amidases hydrolyze the bond connecting the stem peptide to the N-
acetylmuramic acid residue; resuscitation promoting factors, lysozymes, lytic transglycosylases and N-
glucosaminidases hydrolyze bonds in the glycan strand; endopeptidases and DD-carboxypeptidases hydrolyze 
bonds within the stem peptide, with the latter resulting in the release of the terminal D-Alanine. High molecular 
weight penicillin binding proteins remove the terminal D-Ala and form a 3→4 cross-link between stem peptides, 
shown by the black dashed line, whereas LD-transpeptidases form 3→3 cross-links, shown by the red dashed 
line. (Vollmer et al, 2008b) 
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1.8.1. N-acetylmuramyl-L-alanine-amidases 
N-acetylmuramyl-L-alanine-amidases, henceforth referred to as amidases, are zinc 
metalloenzymes responsible for hydrolyzing the amide bond between NAM and the first  L-
Ala of the stem peptide, which results in separation of the peptide stem from the glycan 
strand, Figure 1.4 (McCall et al., 2000, Heidrich et al., 2001). Amidases carry a signal 
peptide at their N-terminus which allows for transport of the protein across the cytoplasmic 
membrane (Vollmer et al., 2008b). LytA is an amidase found in the cytoplasm of 
Streptococcus pneumoniae, which has been indicated as an essential disease causing factor 
and been shown to interact with the PG substrates (Hirst et al., 2008, Mellroth et al., 2013). E. 
coli has five amidases – AmiA, AmiB, AmiC, AmiD and AmpD – with AmiA, AmiB, AmiC 
and AmiD localizing in the periplasm and AmpD localizing in the cytoplasm (Heidrich et al., 
2001, Korsak et al., 2005a).  After removal of the signal peptide, AmiA - AmiC are soluble in 
the periplasm and AmiD is synthesized as a prelipoprotein (Heidrich et al., 2001, Korsak et 
al., 2005a). AmiA - AmiC only hydrolyzes PG in the cross-linked confirmation found in the 
cell wall whereas AmpD can only hydrolyze PG in the form of anhydromuropeptides. On the 
other hand, AmiD is able to hydrolyze PG irrespective of conformation (Heidrich et al., 2001, 
Korsak et al., 2005a). Mutational analysis in E. coli has identified a role for these enzymes in 
degradation of septal PG. This is evidenced by the demonstration that an E. coli triple mutant 
lacking AmiA, AmiB and AmiC produced miniature cells, which were part of long cell 
chains reflective of cells that were unable to complete cell separation (Heidrich et al., 2001). 
Additionally, this triple amidase mutant displayed increased sensitivity to certain antibiotics 
suggesting that the amidases play a role in cell growth and division as well as antibiotic 
resistance with chaining occurring due to a defect in septal cleavage (Heidrich et al., 2001). 
In order for the amidases to efficiently hydrolyze PG in E. coli, these proteins must be 
activated by LytM domain proteins (Peters et al., 2011). The known activators of E. coli 
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amidases are EnvC and NlpD with EnvC activating AmiA and AmiB and NlpD activating 
AmiC (Uehara et al., 2009, Uehara et al., 2010). The binding of the activators results in an 
open active site conformational change of the amidases and subsequent binding and 
hydrolysis of PG (Yang et al., 2012).  
AmiD is bound to the plasma membrane and has been proposed to play a role in immune 
evasion due to its ability to hydrolyze PG in any conformation (Uehara and Park, 2007). 
AmpD is a cytoplasmic PG amidase and has been indicated in control of β-lactamase 
expression by hydrolyzing anhydromuropeptides, which serve as signaling molecules that 
activate β-lactamase expression (Jacobs et al., 1994, Heidrich et al., 2001).  
Mtb encodes four amidase containing genes – ami1, ami2, ami3 and ami4 (Machowski et al., 
2014) with ami1 and ami2 containing an amidase_3 domain and ami3 and ami4 containing an 
amidase_2 domain (Vollmer et al., 2008b, Machowski et al., 2014). A study conducted at the 
CBTBR (where this MSc was carried out) demonstrated that in M. smegmatis, Ami2 is 
essential and Ami1 plays a role in cell division (Senzani et al., unpublished). The Ami1 
homologue encoded by Rv3717 in Mtb lacks a cell wall binding domain and is probably 
directed to PG by a partnering protein or other distinct mechanisms that have yet to be 
identified (Kumar et al., 2013). The enzymatic activity of Rv3717 was not required for 
growth in vitro, however its biochemical activity on PG suggests a possible role in recycling 
of the PG, which has not been established in mycobacterial species (Prigozhin et al., 2013). 
Another amidase in Mtb, Rv3915, is homologous to E. coli AmiC, with the ability to 
hydrolyze cell wall fragments and cross-linked PG (Prigozhin et al., 2013, Sharma et al., 
2015). 
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1.8.2. Resuscitation Promoting Factors 
Resuscitation promoting factors (RPFs) are a group of cell wall hydrolyzing enzymes that are 
found in the culture filtrate of growing cells and were first described in M. luteus 
(Mukamolova et al., 1998). These enzymes have been shown to play a role in the reactivation 
of dormant bacteria through an as yet unknown mechanism (Mukamolova et al., 1998, 
Mukamolova et al., 2002). Rpf-like homologues are found in GC-rich, gram positive bacteria 
including mycobacteria with Mtb encoding five homologues, RpfA – RpfE, which are 
collectively essential for resuscitation from a dormant state in vitro (Kana et al., 2008, 
Machowski et al., 2014). Various deletion studies conducted in Mtb have identified a level of 
functional specialization between Rpf homologues. Single deletion mutants lacking one of 
the five Rpfs were viable and grew similarly to wild type with each of the enzymes 
differentially expressed at various growth phases (Tufariello et al., 2004). The deletion of 
rpfB singularly and in combination with rpfA resulted in delayed reactivation of growth from 
dormancy and defects in colony morphology (Tufariello et al., 2006, Russell-Goldman et al., 
2008), with two different triple mutants – ΔrpfA ΔrpfC ΔrpfB and ΔrpfA ΔrpfC ΔrpfD – 
showing poor resuscitation ability (Downing et al., 2005). A functional hierarchy between the 
Rpfs in Mtb has also been established with RpfB and RpfE ranking highest with respect to 
their ability to restore the colony forming defect in a quintuple Rpf-deletion mutant (Kana et 
al., 2008). These two Rpfs have also been shown to interact with the Rpf Interacting Protein 
A (RipA), with this interaction serving as the driving force for septal PG hydrolysis (Hett et 
al., 2007).   
1.8.3. N-acetyl-β-D-muramidases 
N-acetyl-β-D-muramidases (N-muramidases) cleave -1,4-glycosidic bonds between NAG and 
NAM residues and are subdivided into lysozymes and lytic transglycosylases (LTs) based on 
21 
 
cleavage products, Figure 1.4 (Vollmer et al., 2008b). Lysozymes are produced in a number 
of organisms including fungi, phages, bacteria, vertebrates and invertebrates. These are 
endolytic hydrolases that cleave within the glycan strands and are predicted to play a role in 
septation (Vollmer et al., 2008b). Modification of the NAM residue during catalysis results in 
the formation of a 1-6 anhydromuramyl ring produced by LTs (Vollmer et al., 2008b). LTs 
are exolytic hydrolases that produce the 1,6 anhydromuropeptide by cleaving the terminal 
NAM residue (Vollmer et al., 2008b).  
1.8.4. N-acetyl-β-D-glucosaminidases 
N-acetyl-β-D-glucosaminidases (N-glucosaminidases) hydrolyze the glycosidic bonds 
between the NAG and adjacent NAM residues, Figure 1.4 (Vollmer et al., 2008b). These 
enzymes are widely spread in bacteria and often have one or several PG binding domains 
(Vollmer et al., 2008b). No substantive research has been done on these enzymes although, 
they have been shown to play a role in cell wall turnover (Vollmer et al., 2008b).  
1.8.5. Penicillin binding proteins 
PBPs are a family of acyl-serine transferases that have been the primary target of β-lactam 
antibiotics for over fifty years and are ubiquitous in bacteria that have PG (Ghuysen, 1991, 
Sauvage et al., 2008). These enzymes are important for PG biosynthesis and remodeling as 
they perform the final steps of synthesis by polymerization and cross-linking of the PG 
(Sauvage et al., 2008, Vollmer et al., 2008a, Derouaux et al., 2013). PBPs are divided into 
high molecular weight (HMW) and low molecular weight (LMW) counterparts based on their 
mobility during SDS polyacrylamide gel electrophoresis (PAGE). HMW PBPs can be 
subdivided into class A and class B with the former comprising bifunctional enzymes 
possessing both transglycosylase and transpeptidase functions and class B enzymes 
possessing transpeptidase activity only (Sauvage et al., 2008). LMW or class C PBPs consist 
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of endopeptidases and carboxypeptidases (Sauvage et al., 2008). Most PBPs are anchored to 
the cytoplasmic membrane with the active site in the periplasm. All PBPs possess one of the 
following motifs – SXXK, SXN or KTG – which are responsible for enzymatic activity with 
‘X’ being a variable amino acid (Sauvage et al., 2008). The serine residue of the SXXK motif 
is central to the catalytic core and mediates acylation and deacylation reactions during PG 
synthesis (Sauvage et al., 2008). In B. subtilis, these enzymes have been shown play a role in 
synthesis of PG during vegetative growth, cell division and sporulation (Sauvage et al., 
2008). 
1.8.5.1. HMW PBPs 
HMW PBPs have been shown to be important for cell elongation, maintenance of cell 
morphology and septation. The bifunctional class A HMW PBPs possess an N-terminal 
glycosyltransferase domain and a C-terminal transpeptidase domain, which are responsible 
for catalyzing the polymerization of the glycan strand and cross-linking of the stem peptides 
between the glycan strands respectively, Figure 1.4 (Sauvage et al., 2008). Class B PBPs 
possess only a C-terminal transpeptidase domain and have been shown to be important for 
elongation in some organisms (Sauvage et al., 2008). Transglycosylation results in the 
extension of glycan strands, while transpeptidation results in linkage of the amino group of 
the mDAP of one stem peptides to the carbonyl group of D-Ala in an adjacent stem peptide, 
together with the release of the terminal D-Ala (Sauvage et al., 2008).  
Most organisms contain a number of bifunctional PBPs with the exception of Neisseria 
gonorrhea, which possesses a single essential bifunctional PBP (PBP1), as well as one class 
B PBP, PBP2 (Sauvage et al., 2008). In E. coli, the class A PBPs - PBP1a and PBP1b – can 
be deleted individually but loss of both proteins is not tolerated (Denome et al., 1999). 
Similarly, the class B PBP2 and PBP3 have been shown to be essential for elongation and 
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division respectively (Sauvage et al., 2008). In B. subtilis, PBP1 is required for sporulation 
(Scheffers and Errington, 2004) and PBP2b is required for cell division (Daniel et al., 2000). 
S. pneumonia encodes three class A PBPs which are all dispensable for growth, indicating 
functional redundancy between the homologues (Paik et al., 1999). In addition, S. pneumonia 
has two essential class B PBPs, PBP2x and PBP2b, which play a role in septum formation 
and peripheral PG synthesis respectively (Kell et al., 1993, Sham et al., 2012). Mtb encodes 
two class A PBPs, PBP1 and PBP1a, encoded by ponA1 and ponA2 respectively and three 
class B PBPs, PBPa, PBP2 and PBP-lipoprotein, encoded by pbpA, pbpB and Rv2864c 
respectively (Sauvage et al., 2008, Machowski et al., 2014). 
1.8.5.2. LMW PBPs 
LMW PBPs consist of endopeptidases and carboxypeptidases (Sauvage et al., 2008, Vollmer 
et al., 2008b) and play a role in symmetrical cell division with their activity proposed to be 
linked to FtsZ as mutants defective for these enzymes have misshapen and branched cells 
(Frirdich and Gaynor, 2013). Endopeptidases cleave various non-terminal LD- and DD- bonds 
within the peptide stem, Figure 1.4, and can interact with teichoic acids (Vollmer et al., 
2008b). E. coli encodes two LMW endopeptidases, these include PBP4 which displays DD-
CPase activity and PBP7 plays a role in biofilm formation and septum cleavage (Ghosh et al., 
2008, Sauvage et al., 2008, Vollmer et al., 2008b). The best characterized endopeptidase in 
Mtb is RipA, which is essential for growth in vitro and has been associated with reactivation 
from a dormant state due to its synergistic relationship with RpfB and RpfE (Hett et al., 
2007). The RpfB-RipA interaction releases muropeptides which are able to resuscitate 
dormant cells (Nikitushkin et al., 2015). 
The enzymatically redundant DD-CPases are proposed to be responsible for regulating the 
amount of cross-linking that occurs in the PG (Ghuysen, 1991). They act by cleaving the 
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terminal D-Ala from the pentapeptide side chain, Figure 1.4 (Ghosh et al., 2008, Sauvage et 
al., 2008, Vollmer et al., 2008b). This is achieved through a three step mechanism beginning 
with the formation of a reversible non-covalent complex between the enzyme and the PG 
stem pentapeptide, leading to the formation of an acyl-enzyme intermediate (Sauvage et al., 
2008). In the case of a carboxypeptidation reaction, this is followed by deacylation, which 
occurs through hydrolysis resulting in the release of the terminal D-Ala, Figure 1.5B 
(Sauvage et al., 2008). A transpeptidation reaction differs in that the deacylation of the 
enzyme results in cross-linking of two stem peptides, Figure 1.5A (Sauvage et al., 2008). As 
the DD-CPases do not form cross-links per se, their activity is postulated to control the total 
amount of cross-linking as removal of the terminal D-Ala creates a tetrapeptide which cannot 
serve as a substrate for the formation of 3→4 cross-links (Hammes and Seidel, 1978).  
E. coli contains four DD-CPases –PBP4, PBP5, PBP6 and PBP6b – encoded by dacB, dacA 
dacC and dacD genes respectively (Ghosh et al., 2008, Sauvage et al., 2008). These enzymes 
are non-essential for the growth of E. coli (Denome et al., 1999). PBP4 acts primarily as an 
endopeptidase in E. coli but has both endopeptidase and DD-CPase activity, with a single 
mutant showing no altered morphological or growth defects (Korat et al., 1991, Meberg et al., 
2004, Ghosh et al., 2008). PBP5 of E. coli is the most abundant and best studied DD-CPase, 
playing an important role in maintaining the morphology, diameter and contour of E. coli 
cells (Sauvage et al., 2008). Deletion of PBP5 in an AmiC deletion background increased the 
chaining defect of the single amidase mutant (Priyadarshini et al., 2006), while 
overexpression of PBP5 is detrimental, resulting in the growth of spherical cells that 
eventually lyse (Ghosh et al., 2008). A PBP E. coli mutant, containing PBP5 but lacking 
PBP4, PBP6, PBP7, AmpC, AmpH and either PBP1 or PBP2 remained viable and displayed 
normal rod- shaped morphology (Denome et al., 1999). However, deletion of PBP5 in a 
mutant lacking the above-mentioned PBPs and other PBP mutant backgrounds resulted in  
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Figure 1.5. Diagrammatic representation of high molecular weight penicillin binding proteins and DD-
carboxypeptidase activity within the stem peptides of peptidoglycan. (A) Activity of high molecular weight 
penicillin binding proteins. Nascent peptidoglycan is cross-linked by high molecular weight penicillin binding 
proteins which act by cleaving the terminal D-Alanine and through a transpeptidation reaction cross-links two 
stem peptides. (B) Activity of DD-carboxypeptidases. The terminal D-Alanine is cleaved by a DD-
carboxypeptidases which is then removed by hydrolysis and does not result in crosslinking of the peptidoglycan. 
(Vollmer et al, 2008b) 
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increased cell lysis, enhanced antibiotic sensitivity, inhibition of biofilm formation and 
morphological defects (Denome et al., 1999). These phenotypes were restored when wild 
type PBP5 was expressed in the mutants, with restoration dependent on both the DD-CPase 
activity of PBP5 as well as the C-terminal domain (Ghosh et al., 2008). PBP6, which shares 
65% identity with PBP5, is unable to compensate for loss of PBP5 and does not revert these 
phenotypic defects (Ghosh et al., 2008). PBP5 and PBP6 share the bolA transcriptional 
regulator with both enzymes being able to restore cell division in a PBP3 single deletion 
mutant (Ghosh et al., 2008).  The deletion of PBP6 or PBP6b does not alter morphology with 
expression of these proteins increased during stationary and mid log phase respectively 
(Baquero et al., 1996, Santos et al., 2002). Although PBP5, PBP6 and PBP6b share similar 
primary structures, it is likely that they have distinct functions in vivo during the different 
stages of growth (Broome-Smith et al., 1988, Ghosh and Young, 2003, Ghosh et al., 2008).  
B. subtilis encodes numerous PBPs including PBP4a, PBP5, PBP5* and DacF, with PBP5* 
being the best characterized DD-CPase (Sauvage et al., 2008). PBP4a is equivalent to PBP4 
of E. coli and PBP5 has been found in vegetative growth, with no role in PG synthesis in 
Bacillus spores (Sauvage et al., 2008). A mutant lacking PBP5 has an increased ratio of 
pentapeptides to tripeptides in the PG (Atrih et al., 1999) confirming the role of DD-CPases in 
cleaving the terminal D-Ala. PBP5* and DacF are functionally redundant to some extent, 
with both proteins shown to regulate the amount of cross-linking in the PG of the spore 
(Popham et al., 1995, Popham et al., 1999).   
Some bacterial species such as Helicobacter pylori and Caulobacter crescentus do not 
possess obvious DD-CPase homologues (Sauvage et al., 2008). Other bacterial species such 
as S. aureus contains only one LMW PBP (PBP4), which is equivalent to PBP5, and 
possesses secondary transpeptidase activity (Wyke et al., 1981). Listeria monocytogenes 
possesses one class C PBP (PBP5), with deletion resulting in altered shape and morphology 
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as well as a thicker cell wall (Korsak et al., 2005b, Guinane et al., 2006). S. pneumonia has a 
single class C PBP (PBP3), which plays a role in organization of growth and division 
processes with the deletion mutant displaying morphological and cell division defects 
(Morlot et al., 2004, Morlot et al., 2005). In Vibrio cholerae four LMW PBPs have been 
identified with two, DacA-1 and DacA-2, being DD-CPases (Moll et al., 2015). Deletion of 
the LMW PBPs with the exception of DacA-1 did not result in any changes (Moll et al., 
2015). Deletion of DacA-1 has been shown to impair the growth and morphology of V. 
cholerae in standard laboratory media, an effect that is exacerbated in media with increased 
salt concentrations, suggesting that DacA-1 plays a role in adaptation to salt stress (Moll et 
al., 2015).  These examples, in addition to sequence homology retained across species, 
indicate the importance of DD-CPases in cell wall homeostasis. 
The role of LMW PBPs from mycobacterial species in bacterial growth and expansion of PG 
remains unknown. The mycobacterial species Mtb and M. smegmatis both harbor a number 
of LMW PBPs (Sauvage et al., 2008, Machowski et al., 2014). Mtb possesses three class C 
PBPs encoded by Rv3627c, dacB1 and dacB2 with homologues of these proteins identified in 
M. smegmatis as MSMEG_6113 (referred to as DacB) corresponding to Rv3627c, 
MSMEG_1661 corresponding to dacB1, and the duplicated  MSMEG_2432 and 
MSMEG_2433 both corresponding to dacB2 (Sauvage et al., 2008, Machowski et al., 2014). 
MSMEG_1990 has been found in the environmental strains as well as M. abscessus but is not 
present in other pathogenic mycobacterial species. A recent study showed that 
overproduction of Mtb dacB2 in M. smegmatis resulted in altered colony morphology, 
reduced growth, defects in sliding motility and biofilm formation, while the deletion of 
dacB2 lead to reduced growth in minimal media under acidic conditions and low oxygen 
availability (Bourai et al., 2011). Treatment with the β-lactam antibiotic meropenem directly 
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inhibited dacB2, leading to the accumulation of pentapeptides and lysis of cells (Kumar et al., 
2012). 
At the CBTBR, single knockout mutants lacking MSMEG_1661, MSMEG_2432 or 
MSMEG_2433 were created by Dr. C. Ealand and displayed no changes in growth rates, cell 
morphology, drug susceptibility or incorporation of new PG (Ealand et al., unpublished data). 
In addition, Dr. Ealand was unable to delete dacB, suggesting that this gene is essential. 
Additionally, these four proteins were also shown to play a role in cell size maintenance as 
heterologous expression of a single one of these DD-CPases resulted in cell length changes of 
an E. coli mutant lacking three PBPs (Ealand et al., unpublished).  
1.9. Aims 
Research in a diversity of organisms have highlighted functional redundancy in LMW PBPs, 
necessitating the deletion of more than a single DD-CPase to identify any notable phenotypic 
differences. Considering this, and the lack of any growth/cell division or morphological 
defects in single DD-CPase mutants of M. smegmatis, this MSc was aimed at generating and 
characterizing combinatorial mutants of M. smegmatis that are deficient for two DD-CPases 
in different combinations. We also attempted to create recombinant forms of these enzymes 
to test catalytic proficiency. The specific objectives were:  
 To create knockout mutants of M. smegmatis, lacking two or three DD-CPases, using 
existing single deletion mutants. Mutants targeted for generation were: 
ΔMSMEG_2433 ΔMSMEG_2432, ΔMSMEG_2432 ΔMSMEG_1661 and 
ΔMSMEG_1661 ΔMSMEG_2433 and ΔMSMEG_2433 ΔMSMEG_2432 
ΔMSMEG_1661.  
 Characterizing phenotypic effects of these gene deletions on the growth and 
morphology of M. smegmatis.  
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 To create recombinant forms of the four DD-CPases (dacB, MSMEG_1661, 
MSMEG_2432 and MSMEG_2433) from M. smegmatis. 
We hypothesize that deletion of multiple DD-CPases will result in abnormal colony 
morphology, defective growth rates, delayed biofilm formation, altered sliding motility and 
increased antibiotic sensitivity. We also hypothesize that deletion of the DD-CPases will 
affect cell growth and division M. smegmatis.  
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2. Methods 
2.1 Reagents 
A detailed list of reagents used in this study can be found in Appendix A.  
2.2 Bacterial strains and culture conditions 
For E. coli strains, cultures were grown in Luria-Bertani broth (LB) or agar (LA) 
supplemented with the appropriate antibiotics at the following concentrations: Kanamycin 
(Kan) 50 µg/ml, Hygromycin (Hyg) 200 µg/ml, Ampicillin (Amp) 100 µg/ml and 
Chloramphenicol (Camp) 34 µg/ml. Cultures were incubated at 37 °C for strains containing 
plasmids smaller than 8 kbp, whereas cultures with strains containing plasmids larger than 8 
kbp were incubated at 30 °C. Liquid cultures grown in LB were done so with shaking at 250 
rpm.  
For M. smegmatis strains, cultures were grown in Middlebrook 7H9 broth (Difco) 
supplemented with 0.5% glycerol, 0.2% glucose, 0.085% NaCl and 0.05% Tween 80 with 
shaking or on Middlebrook 7H10 agar (Difco) supplemented with 0.5% glycerol, 0.2% 
glucose and 0.085% NaCl. Media was supplemented with the appropriate antibiotic at the 
following conditions: Kan 25 µg/ml, Hyg 50 µg/ml.  
All strains and plasmids used/generated in this study are listed in Table 2.1.  
Table 2.1. Strains and plasmids 
 Description Source/ 
Reference 
Strains 
E. coli 
DH5α Cloning strain with high transformation 
efficiency 
Promega 
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BL21 (DE3) pLysS Protein expression strain with IPTG-inducible 
gene for T7 RNA polymerase. Camp
r
 
Promega 
M. smegmatis 
mc
2
155 efficient plasmid transformation mutant of 
mc26 
(Snapper et al., 
1990) 
ΔMSMEG_1661 Derivative of mc2155 carrying an unmarked, 
in-frame deletion in M. smegmatis 
MSMEG_1661 (1158 bp internal region 
excised) 
(Ealand et al., 
unpublished) 
ΔMSMEG_2432 Derivative of mc2155 carrying an unmarked, 
out-of-frame deletion in M. smegmatis 
MSMEG_2432 (786 bp internal region 
excised) 
(Ealand et al., 
unpublished) 
ΔMSMEG_2433 Derivative of mc2155 carrying an unmarked, 
out-of-frame deletion in M. smegmatis 
MSMEG_2433 (870 bp internal region 
excised) 
(Ealand et al., 
unpublished) 
ΔMSMEG_1661 
ΔMSMEG_2432 
Derivative of ΔMSMEG_1661 carrying an 
unmarked , out-of-frame deletion in M. 
smegmatis MSMEG_2432 (786 bp internal 
region excised) 
This study 
ΔMSMEG_2433  
ΔMSMEG_1661 
Derivative of ΔMSMEG_2433 carrying an 
unmarked , in-frame deletion in M. smegmatis 
MSMEG_1661 (1158 bp internal region 
excised) 
This study 
ΔMSMEG_1661  
ΔMSMEG_2432:: 
MSMEG_1661 
Derivative of ΔMSMEG_1661 
ΔMSMEG_2432 carrying a full length copy of 
MSMEG_1661 (1194 bp) at the attB site. 
Constructed by electroporation with the 
pMV1661 vector; Hyg
r 
This study 
ΔMSMEG_2433 
ΔMSMEG_1661:: 
MSMEG 1661 
Derivative of ΔMSMEG_2433 
ΔMSMEG_1661 carrying a full length copy of 
MSMEG_1661 (1194 bp) at the attB site. 
This study 
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Constructed by electroporation with pMV1661 
vector; Hyg
r
 
Plasmids 
p2NIL E. coli cloning vector, Kan
r
 (Parish and 
Stoker, 2000) 
pGOAL19 Plasmid carrying lacZ-sacB-Hyg
r
 markers as a 
PacI cassette; Hyg
r
 
(Parish and 
Stoker, 2000) 
p2NIL_PAC_1661 Knockout vector for creating ∆MSMEG_1661 
mutant.  The 1.2 kbp upstream region 
including 18 bp of the 5’ sequence of 
MSMEG_2433 was PCR-amplified to 
incorporate HinDIII and NdeI restriction sites.  
The 1.2 kbp downstream was similarly 
obtained but incorporated at NdeI and Acc65I 
restriction sites.  The fragments were cloned 
into p2NIL and the PacI cassette from 
pGOAL19 was inserted; Kan
r 
Hyg
r
. 
(Ealand et al., 
unpublished) 
p2NIL_PAC_2432 Knockout vector for creating ∆MSMEG_2432 
mutant.  The 1.2 kbp upstream region 
including 18 bp of the 5’ sequence of 
MSMEG_2432 was PCR-amplified to 
incorporate HinDIII and NdeI restriction sites.  
The 1.2 kbp downstream was similarly 
obtained but incorporated at NdeI and Acc65I 
restriction sites.  The fragments were cloned 
into p2NIL and the PacI cassette from 
pGOAL19 was inserted; Kan
r
Hyg
r
.   
(Ealand et al., 
unpublished) 
p2NIL_PAC_2433 Knockout vector for creating ∆MSMEG_2433 
mutant.  The 1.2 kbp upstream region 
including 18 bp of the 5’ sequence of 
MSMEG_2433 was PCR-amplified to 
incorporate HinDIII and NdeI restriction sites.  
The 1.2 kbp downstream was similarly 
(Ealand et al., 
unpublished) 
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obtained but incorporated at NdeI and Acc65I 
restriction sites.  The fragments were cloned 
into p2NIL and the PacI cassette from 
pGOAL19 was inserted; Kan
r
Hyg
r
. 
pMV306H E. coli-Mycobacterium integrating shuttle 
vector. Integrates at the L5 attB site in 
mycobacteria. Hyg
r
 
H. Boshoff 
pMV1661 Derivative of pMV306H carrying a full length 
copy of MSMEG_1661 (1194 bp) plus 150 bp 
upstream of start codon representative of 
native promoter sequence; Hyg
r
 
(Ealand et al., 
unpublished) 
pET29a E. coli protein expression vector carrying a C- 
terminal His-tag. Kan
r
 
Novagen 
pET29a_dacB Derivative of pET29a carrying a full length 
copy of dacB 
This study 
pET29a_1661 Derivative of pET29a carrying a full length 
copy of MSMEG_1661 
This study 
pET29a_2432 Derivative of pET29a carrying a full length 
copy of MSMEG_2432 
This study 
pET29a_2433 Derivative of pET29a carrying a full length 
copy of MSMEG_2433 
This study 
 
2.3 DNA extractions 
 2.3.1 Plasmid DNA extraction from E. coli 
  2.3.1.1 Mini-prep using alkaline lysis method 
Plasmids of interest were grown using a single colony for inoculation into 2 ml LB overnight 
with appropriate antibiotics, from which 1 ml was used for the extraction of DNA. Cultures 
were centrifuged at 10 392 × g and the pellet was resuspended in 100 µl of cold Solution I 
(50 mM Glucose, 25 mM Tris-HCl (pH 8), 10 mM EDTA). Thereafter 200 µl of Solution II 
(1% SDS, 0.2 M NaOH) was added, mixed by inversion and incubated at room temperature 
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for 5 min. Following incubation, 150 µl of Solution III (3 M Potassium acetate, 11.5% Acetic 
acid) was added and the sample was incubated on ice for 5 min. Samples were then 
centrifuged at room temperature for 10 min and the supernatant was transferred to a clean 
Eppendorf tube. A 1 µl aliquot of RNaseA (10 mg/ml) was added to the supernatant and 
incubated at 42 °C for 15 min. Plasmid DNA was precipitated by the addition of 600 µl of 
Isopropanol, washed with 70% ethanol and resuspended in sterile distilled water (sdH2O). 
DNA was then subjected to ethanol precipitation by adding 1/10 volume of 3 M sodium 
acetate (pH 5.3) and 3× volume of 100% cold ethanol. DNA was collected by centrifugation 
at 10 392 × g for 20 min at 4 °C. The pellet was then washed with 70% ethanol, dried using 
an Eppendorf Concentrator 5301, resuspended in sdH2O and quantified using the Nanodrop. 
 2.3.1.2 Maxi-prep using Nucleobond kit 
Bulk DNA extractions from E. coli were done by either up-scaling the mini-prep method 
described above or by using the Machery-Nagel Nucleobond plasmid extraction kit. DNA 
extractions using the kit were done as per manufacturer’s instructions. Briefly, cells were 
harvested by centrifugation at 3082 × g for 15 min. The pellet was resuspended thoroughly in 
Buffer S1 containing RNaseA followed by the addition Buffer S2, mixed by gently inverting 
and incubated at room temperature for 3 min. Following incubation, Buffer S3 was added to 
lyse the sample, mixed gently by inversion and incubated on ice for 5 min.  The lysate was 
then cleared by centrifugation at 3082 × g for 30 min. While the sample was in the centrifuge, 
a Nucleobond AX100 column was equilibrated by allowing Buffer N2 to flow through the 
column. After centrifugation, the lysate was loaded on the column and allowed to flow 
through. The column was washed with Buffer N3 and the flow through was discarded. 
Plasmid DNA was eluted from the column using Buffer N5 and collected in a sterile tube. 
DNA was precipitated by adding 3.5 ml isopropanol followed by centrifugation at max speed 
for 30 min. The pellet was washed in 70% ethanol, followed by ethanol precipitation and then 
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dried using an Eppendorf Concentrator 5301. The dried pellet was resuspended in sdH2O and 
quantified using the Nanodrop. 
 2.3.2 Chromosomal DNA extraction from mycobacteria 
2.3.2.1 Small scale DNA extraction 
Half of a single colony was resuspended in 100 µl sdH2O and incubated at 65 °C for 15 min. 
Thereafter, 100 µl of chloroform was added to the suspension and mixed by inversion. The 
sample was centrifuged at max speed for 5 min and the aqueous layer was placed into a new 
Eppendorf, from which 5 µl was used for PCR.  
  2.3.2.2 CTAB DNA extraction 
This method was used for the extraction of large amounts of chromosomal DNA from M. 
smegmatis. Cells were grown to confluence on 7H10 agar plates for 3-4 days with 
appropriate antibiotic if necessary. Four loopfuls of cell were resuspended in 500 µl of TE 
buffer and incubated at 65 °C for 35 min to heat-kill the cells. Thereafter, 50 µl of lysozyme 
(10 mg/ml) was added to the sample and incubated at 37 °C for 1 hour. This was followed by 
the addition of 70 µl of 10% SDS and 6 µl of Proteinase K (10 mg/ml) to the sample and 
incubation at 65 °C for 2 hours. Following incubation, 100 µl of 5M NaCl and 80 µl of pre-
warmed CTAB/NaCl were added to the sample. This resuspension was incubated at 65 °C for 
10 min. An equal volume of chloroform: isoamyl (24:1 v/v) was added, mixed vigorously and 
centrifuged for 5 min at room temperature. The top aqueous layer was transferred to a new 
Eppendorf to which 600 µl of isopropanol was added and DNA was precipitated by 
centrifugation at 10 392 × g for 20 min. The pellet was washed in 70% ethanol, followed by 
ethanol precipitation as described in section 2.3.1.1 and then dried using an Eppendorf 
Concentrator 5301. The dried pellet was resuspended in sdH2O and quantified using the 
Nanodrop as described in section 2.4. 
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2.4 DNA quantification 
All DNA and RNA was quantified using the Nanodrop ND-100 Spectrophotometer 
(NanoDrop Technologies) and measuring absorbance of the sample at a wavelength of 260 
nm.  
2.5 DNA manipulation 
 2.5.1 Restriction digestion 
Restriction enzymes were purchased either from Fermentas, New England Biolabs (NEB) or 
Roche Applied Science (Roche). Restriction digestions were carried out as per 
manufacturer’s instructions with the appropriate buffers and addition of bovine serum 
albumin (BSA) to a final concentration of 10 µg/ml, when necessary. Briefly, 1 µg DNA was 
digested with 1 U enzyme and 1× appropriate buffer with the addition of sdH2O to a final 
volume of 20 µl and incubated at 37 °C for 1 hour. The reaction was heat inactivated at 65 °C 
for 15 min unless prescribed otherwise by supplier. 
 2.5.2 Dephosphorylation of DNA 
To prevent self-ligation of vectors during cloning, removal of phosphate groups from the 
termini of linearized vector was carried out. Dephosphorylation of plasmid DNA was carried 
out using Antarctic Alkaline Phosphotase (Roche) in 20 µl reactions containing 1 µg digested 
DNA, 1 U enzyme, 1× supplied buffer and sdH2O. The reaction was incubated at 37 °C for 1 
hour and then heat inactivated at 65 °C for 20 min.  
 2.5.3 DNA ligation 
Ligations were carried out using T4 DNA Ligase enzyme (Epicentre Biotechnologies Fast-
Link DNA Ligation Kit). A constant amount of vector DNA, 50 ng, was used in all ligations 
and the amount of insert DNA required for a 1:1 molar ratio of vector: insert was calculated 
using the following equation: 
37 
 
  Amount of insert DNA (ng) =   
50 𝜂𝑔 𝑥 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑏𝑝) 
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑏𝑝)
 
Ligation reactions contained the calculated volume of DNA, 5 U of enzyme, 0.75 µl of ATP, 
1 µl of the supplied buffer and sdH2O to a final volume of 15 µl. The reactions were 
incubated at room temperature for 20 min and heat inactivated at 65 °C for 10 min prior to 
transformation and visualization on a gel.  
2.6 DNA visualization and purification 
 2.6.1 Agarose gel electrophoresis 
Agarose gels (0.8% – 2%), Table A6, were prepared in TAE buffer with the addition of 0.5 
µg/ml ethidium bromide. Electrophoresis was conducted at 80 – 100 V in electrophoresis 
tanks (Bio-Rad laboratories) containing TAE buffer. In all cases molecular weight markers 
were included on the gels to allow for size determination. Gels were visualized using a G-
Box SYNGENE system with GeneSnap image acquisition software (Syngene). 
 2.6.2 DNA fragment purification 
Fragment purification was done using the NucleoSpin Extract II Kit (Machery-Nagel). This 
kit allowed for the purification of PCR products as well as fragments excised from agarose 
gels. The protocol was carried out as per the manufacturer’s instructions. Gel fragments were 
melted in binding buffer at 65 °C before being loaded onto the column, whereas PCR 
products were mixed with binding buffer and loaded directly onto the column. The column 
was washed with wash buffer and thereafter, DNA was eluted using 30 – 50 µl sterile 
distilled water. 
 2.6.3 DNA sequencing 
Sequencing was performed by the DNA Sequencing Facility of Stellenbosch University and 
was carried out on all constructs generated in this study to ensure that no mutations had been 
38 
 
introduced into the gene of interest. Finch TV version 1.4 and the EditSeq module of the 
Lasergene suite software were used to analyze the sequencing data. 
2.7 DNA amplification 
Primers were designed using the online tool Primer3 (http://primer3.ut.ee/) using the 
following parameters: 
Table 2.2. Primer3 parameters used for primer design 
__________________________________________ 
  Size (bp) Tm (°C) % GC  
Minimum 18  55  55 
Maximum 22  65  65 
Optimum 20  60  62____ 
  
2.7.1 Roche Fast Start Taq PCR 
PCR screens for clones or mutants were carried out with the non-proof reading DNA 
polymerase enzyme, Fast Start Taq (Roche), following the manufacturers’ instructions. PCR 
reactions were set up with the following components: dNTPs to a final concentration of 0.2 
mM each, DNA template between 10-100 ng/µl, forward and reverse primers to a final 
concentration of 1 µM each, 1× GC Rich, 1× recommended buffer and 2 U Taq polymerase, 
made up with nuclease free water to 25 µl. These reactions were incubated in a thermo cycler 
using the following cycling conditions: one cycle of an initial denaturation at 94 °C for 4 
min; 30-35 cycles of 30 sec denaturation at 94 °C, 30 sec annealing at temperature specific 
for primer set and 30-90 sec elongation at 72 °C, which was followed by a final elongation 
step at 72 °C for 5-7 min. 
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 2.7.2 Phusion High Fidelity DNA polymerase 
PCR products to be used for cloning were amplified with the high-fidelity, proof reading 
enzyme Phusion polymerase (Finnzymes) which ensures no second site mutations are 
introduced into the PCR product. PCR reactions were set up with the following components: 
dNTPs to a final concentration of 0.2 mM each, DNA template between 10-100 ng, forward 
and reverse primers to a final concentration of 1 µM each, 3% dimethyl sulfoxide (DMSO), 
1× recommended buffer and 1 U Phusion polymerase. The final reaction was made up with 
nuclease free water to 25 µl. These reactions were incubated in a thermo cycler using the 
following cycling conditions: one cycle of an initial denaturation at 98 °C for 4 min; 30-35 
cycles of 30 sec denaturation at 98 °C, 30 sec annealing at temperature specific for primer set 
and 30-90 sec elongation at 72 °C which was followed by a final elongation step at 72 °C for 
5-7 min. 
2.8 Bacterial transformations 
 2.8.1 E. coli transformations 
Chemically competent cells were prepared and transformed using rubidium chloride. Briefly, 
E. coli cells were grown to mid–log phase (OD600nm 0.4-0.6) in 100 ml LB. Cells were cooled 
on ice for 15 min and harvested by centrifugation at 4 °C and 3900 × g  for 5 min (Beckman 
Coulter Allegra™ X-22R Centrifuge). The cell pellet was then resuspended in 20 ml TfbI 
solution (30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium chloride, 50 
mM manganese chloride, and 15 % v/v glycerol - pH 5.8), and cooled on ice for 15 min. 
Cells were harvested as before and the pellet resuspended in TfbII (10 mM MOPS, 75 mM 
calcium chloride, 10 mM rubidium chloride, 15 % v/v glycerol – pH 6.5) followed by cooling 
on ice for 15 min and 500 μl aliquots of the cell suspension were prepared and either used 
immediately or quick-frozen in ethanol prior to storage at - 80˚ C.  
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For transformations, plasmid DNA was added to 100 µl of chemically competent cells and 
incubated on ice for 10 min. This was followed by heat shock at 42 °C for 2 min, incubation 
on ice for 2 min, addition of 400 µl 2× TY and incubation at 37 °C for 1 hour. Cells were 
then plated on LA containing the appropriate antibiotic to allow for selection of positive 
transformants.  
 2.8.2 M. smegmatis electroporations 
Cells were grown to mid-log phase (OD600nm 0.5-0.8) in 50-100 ml of media and harvested at 
2360 × g at 4 °C for 10 min. The bacterial cell pellet was resuspended in 10% glycerol and 
harvested as before - this wash step was done three times in total. After the final wash step, 
the pellet was resuspended in 2 ml ice cold 10% glycerol and these competent cells were used 
immediately.  
Between 1 – 5 µg of DNA was added to 0.2 cm electroporation cuvettes into which 400 μl of 
electro-competent M. smegmatis cells were added and gently mixed. The BIO-RAD Gene 
PulserXCell™ system was used to perform electroporations with the following parameters: 
2500 V, 25 μF, 1 000 Ω, 0.2 cm. Immediately after the pulse, cells were rescued by the 
addition of 1 ml 2X TY and incubation at 37 °C for 3 -16 hours. Transformed cells were 
selected on 7H10 containing the appropriate antibiotics and/or supplements for 3 – 7 days.  
2.9 Generation of M. smegmatis knockout strains 
M. smegmatis knockout mutants were generated using two-step allelic exchange by 
homologous recombination (Gordhan and Parish, 2001). A schematic representation of this 
procedure, using the MSMEG_1661 locus as an example, can be found in Figure 2.1. This 
method involves the incorporation of a suicide vector which carries a mutated copy of the 
gene of interest by fusing together homologous upstream and downstream regions. A single 
recombination event occurs when the suicide vector is integrated into the chromosome of M. 
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smegmatis at one of the regions of homology resulting in a single cross-over (SCO) strain. 
Positive SCO homologous recombinants can be identified as blue colonies growing on 7H10 
agar supplemented with Kan, Hyg and X-gal since the suicide vector carries the selectable 
markers aph, hyg and lacZ. The suicide vector also contains a sacB gene which encodes the 
secreted enzyme, levansucrase. When grown in the presence of sucrose, the enzyme 
hydrolyses sucrose to levans which is toxic to the bacteria and results in cell death. Therefore, 
the sacB gene facilitates counter selection for the second recombination event resulting in the 
expulsion of the suicide vector from the chromosome, yielding either a knockout mutant or 
reversion to wild type. Cells which have successfully undergone the second recombination 
event can be identified as white colonies with the ability to grow on 7H10 agar in the 
presence of X-gal and sucrose. Since these cells can either be knockout mutants or wild type,  
 
Figure 2.1.  Schematic of allelic exchange mutagenesis procedure using MSMEG_1661 as an example. The 
suicide vector p2NIL_PAC_1661, carrying the aph, hyg and lacZ marker genes, is electroporated into an 
existing single knockout strain generating a SCO strain with the vector either upstream or downstream from the 
wild type gene. Selection for a double crossover event is carried out in the presence of sucrose which results in 
either a successful knockout mutant or reversion to wild type. Δ indicates a mutant gene, US and DS represents 
the upstream and downstream regions of the gene. 
PCR screens were performed to determine the genotype. Suicide vectors, previously created 
by Dr. Christopher Ealand at the CBTBR, to generate the single knockout mutants 
Marker genes
1661
Δ
Δ
Δ
Δ 1661
1661
1661 Marker genes Marker genes
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US US
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Single crossover event
Double crossover event
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ΔMSMEG_1661, ΔMSMEG_2432 and ΔMSMEG_2433 were used to create double deletion 
mutants in this study. Consequently, double deletion mutants were created from pre-existing 
single deletion mutants (Table 2.1). 
2.9.1 Generation of ΔMSMEG_1661 ΔMSMEG_2432 double knockout mutant 
To generate the ΔMSMEG_1661 ΔMSMEG_2432 double knockout mutant, the suicide 
vector P2NIL_PAC_2432 (Table 2.1) was electroporated into the single deletion 
ΔMSMEG_1661 parental strain. A SCO was selected by incubation on 7H10 agar 
supplemented with Kan, Hyg and X-gal for 5 days at 30 °C to obtain blue colonies. A blue 
colony was selected and grown in 7H9 broth with Kan and X-gal overnight at 37 °C, 
followed by inoculation into fresh 7H9 broth without antibiotics to allow for the second 
recombination event to occur. Cells were harvested at 4000 rpm for 10 min and the pellet was 
resuspended in 400 µl of 7H9. A dilution series from 10
0
 – 107 was prepared, using 100 µl of 
the cell suspension, from which 100 µl was used for plating on 7H10 agar containing X-gal 
and 7H10 agar containing X-gal and 5% sucrose. Plates were incubated at 37 °C for 5 days. 
White colonies were picked from the plates containing sucrose and spotted onto 7H10 agar 
containing X-gal with or without Kan to ensure that the suicide vector was removed. White 
colonies, sensitive to Kan, were picked and screened by PCR to confirm the genotype. 
 2.9.2 Generation of double knockout mutants 
To generate a ΔMSMEG_2433 ΔMSMEG_1661 double knockout mutant, the suicide vector 
P2NIL_PAC_1661 (Table 2.1) was electroporated into a single deletion ΔMSMEG_2433 
parental strain. To generate a ΔMSMEG_2432 ΔMSMEG_2433 double knockout mutant, the 
suicide vector P2NIL_PAC_2433 (Table 2.1) was electroporated into a single deletion 
ΔMSMEG_2432 parental strain and to generate a ΔMSMEG_2433 ΔMSMEG_2432 double 
knockout mutant, the suicide vector P2NIL_PAC_2432 (Table 2.1) was electroporated into a 
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single deletion ΔMSMEG_2433 parental strain. Selection for single and double 
recombination events were carried out as described in 2.9.1.   
2.10 Southern blot analysis 
Southern blots were used for genotypic confirmation of mutants generated in this study. 
Recipes for solutions can be found in Table A8. 
 2.10.1 Electro-blotting 
Restriction digests were performed overnight using 2 µg chromosomal DNA and 5 U of 
selected enzyme. The digested DNA was separated on a 0.8% agarose gel for 2 – 3 hours at 
80 V and imaged alongside a ruler using the G-Box SYNGENE system. The gel was then 
incubated in depurination solution (0.2 M HCl) for 15 min at room temperature with shaking. 
The depurination solution was decanted, followed by incubation in a denaturation solution 
(0.5 M NaOH, 1.5 M NaCl) for 30 min at room temperature with shaking. The gel was then 
equilibrated in 1X TBE. A transfer cassette, which contained the following: a nylon 
membrane packed against the agarose gel and sandwiched between two layers of Whatman 
filter paper and sponges was prepared. The DNA was then transferred to the membrane at 
600 mA for 2 hours. The membrane was then exposed to UV radiation twice, at 2500 mJ/cm
3
 
in order to cross-link the DNA to the membrane.  
 2.10.2 Probe labelling 
For Southern blots, the probes were generated using the commercially available kit PCR DIG 
Probe Synthesis Kit (Roche) which allows for specific labelling of probes with alkali-labile 
digoxygenin (DIG) dUTP. Primers used to generate probes are listed in Table B2. 
Incorporation of DIG dUTP into the fragment was confirmed on agarose gels by comparing 
labelled and unlabeled reactions. The DIG-labelled fragment is expected to run slower than 
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the unlabeled fragment. Once synthesized, probes were either used immediately or stored at -
20 °C until required.  
 2.10.3 Hybridization 
Hybridization of probes was carried out in roller bottles (Hybaid HB-OV-BM) in a 
hybridization oven (Hybaid Micro-4). Membranes were incubated in 12 ml DIG Easy Hyb 
solution (Roche) at 54 °C for 30 min. Probes were denatured by boiling at 95 °C for 5 min 
followed by immediate cooling on ice. Probes were then added to the hybridization solution 
using a volume of 2 µl per ml of hybridization buffer and hybridization performed at 54 °C 
overnight. Following hybridization, the membrane was washed in Solution I (2X SSC, 0.1% 
SDS) with shaking for 5 min at room temperature. This was followed by two washes in 
Solution II (0.5X SSC, 0.1% SDS) for 15 min each at 68 °C. 
 2.10.4 Immunological detection 
Unless stated differently, all wash steps and incubations were performed at room temperature 
with shaking. The membrane was rinsed in wash buffer (0.1 M Maleic Acid Buffer, 0.3% 
Tween 20) for 5 min followed by incubation in 1x blocking solution for 30 min. This was 
followed by incubation in antibody (Anti-Digoxygenin-AP) solution for 30 min. The 
membrane was then washed twice with wash buffer for 15 min each followed by 
equilibration in detection buffer for 5 min. The membrane was transferred to a hybridization 
bag with the DNA side facing up and 1 ml CSPD substrate was spread evenly across the 
membrane. All air bubbles were removed and the membrane was incubated for 5 min. All 
excess substrate was removed and the membrane was incubated at 37 °C for 10 min followed 
by exposure to X-ray film for 30 – 60 min. The X-ray films were developed using the Axim 
automated developer. 
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2.11 Generation of M. smegmatis complementation strains  
In order to confirm whether phenotypic variation seen in mutant strains are the result of the 
loss of a specific gene and not polar effects, genetic complementation is necessary. In this 
study, genetic complementation was achieved using an integrating vector carrying the full 
length   gene of interest, for example MSMEG_1661, plus 150 bp upstream of the start codon 
to include the native promoter region. This approach allows for integration of a functional 
gene into the attB phage attachment for regulation and expression by the appropriate 
mechanisms in mycobacteria. The appropriate integrating vectors were electroporated into 
both double knockout mutant strains using 1, 3 and 5 µg of DNA. The transformants were 
plated on 7H10 agar containing Hyg and incubated at 37 °C for 4 days. Clones were picked 
and the DNA extracted using the colony boil method as described in section 2.3.2.1. Site 
specific integration of the plasmid was confirmed by PCR using the primers listed in Table 
C3. 
2.12 Gene expression analysis 
2.12.1 RNA extraction  
RNA was extracted using the Nucleospin RNA II kit (Machery Nagel) as per manufacturer’s 
instructions. Cells were grown to overnight at 37 °C to an OD600nm of 0.3 in 10 ml 7H9 broth. 
Cells were then harvested at 3082 × g for 10 min at 4 °C followed by resuspension in 500 µl 
TE (10 mM Tris-HCl and 1 mM EDTA, pH 8), 350 µl lysis buffer and 3.5 µl β- 
mercaptoethanol. The suspension was transferred to MagNA Lyser Green Beads (Roche) 
lysing matrix and ribolyzed three times using the MagNA Lyser (Roche) for 35 secs (speed 
6000) with cooling on ice for 2 min between each ribolysis. Lysates were transferred to 
Nucleospin Filters and centrifuged for 1 min at 11000 × g. RNA binding conditions were 
adjusted by mixing 350 µl 70% ethanol with the flowthrough which was then transferred to a 
Nucleospin RNA Column and centrifuged for 30 sec at 11000 × g. The flowthrough was 
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discarded, 350 µl Membrane Desalting Buffer (MDB) was added to the column followed by 
centrifugation for 1 min at 11 000 × g to dry the membrane. DNA was digested on the 
column by the addition of 100 µl DNase reaction mixture which contains 10 µl reconstituted 
rDNase and 90 µl reaction buffer for rDNase to the column and incubated at room 
temperature for 15 min. Following incubation, the column was washed with 200 µl of Buffer 
RAW2 and centrifuged for 30 secs at 11000 × g. This was followed by two washes with 600 
µl Buffer RA3 and 250 µl Buffer RA3. Washes were carried out by centrifugation for 30 secs 
or 2 min at 11000 × g respectively. Following the washes, the column was placed into a 
nuclease-free Eppendorf tube and RNA was eluted with 50 µl RNase-free water by 
centrifugation for 1 min at 11000 × g. RNA was quantified using the Nanodrop – as 
described above for DNA. 
2.12.2 Reverse Transcriptase PCR (RT-PCR) 
Prior to RT-PCR, 1 µg of RNA was treated with 1 µl TURBO DNaseI (Life Technologies) 
for 30 min at 37°C to remove residual genomic DNA. DNaseI was inactivated by the addition 
of 7 µl DNaseI removal resin followed by centrifugation for 5 min at 10 392 × g. A 23 µl 
aliquot was used for RT-PCR. A 2.5 µM reverse primer mix containing MSMEG_1661, 
MSMEG_2432, MSMEG_2433 and sigA reverse primers was prepared and 2 µl of this 
mixture was added to TURBO DNase treated RNA. The housekeeping sigA gene allows for 
normalization because the gene is expressed at a consistent level throughout all growth 
phases. PCR reactions were performed using the following parameters: 94 °C for 90 secs, 65 
°C for 3 min and 57 °C for 3 min followed by incubation on ice. RT reactions were carried 
out using SuperScript III reverse transcriptase (Invitrogen) as per manufacturer’s instructions. 
Briefly, a 25 µl RT+ reaction was set up using 12.5 µl of the annealed product, 4 µl 25 mM 
MgCl2 , 5 µl 5× First Strand Buffer, 2 µl 0.1 M DTT, 1 µl 10 mM dNTPs and 0.8 µl 
SuperScript III. The RT- reaction was set up with nuclease-free water replacing SuperScript 
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III in the reaction. cDNA synthesis was carried out using the following parameters: 50 °C for 
50 min and 85 °C for 5 min. The resulting cDNA was used for quantitative PCR. 
2.12.3 Quantitative real-time PCR (qPCR)  
qPCR was performed using Sso Fast Evagreen Supermix (Biorad) as per manufacturer’s 
instructions. Briefly, 20 µl reactions were set up, each containing 10 µl Evagreen Supermix, 
0.75 µl forward primer (10 µM), 0.75 µl reverse primer (10 µM), 2 µl cDNA and nuclease-
free water. Primers used for gene expression analysis are listed in Table B4. All reactions 
were incubated in the CFX96 Real-Time PCR detection system (Biorad) using the following 
parameters: 98 °C for 2 min followed by 39 cycles consisting of three steps – 98 °C for 5 sec, 
60 °C for 5 sec and 72 °C for 5 sec with SYBR Green quantification at the end of each cycle. 
Melt curve analysis was conducted from 65 °C with a gradual increase in 0.5 °C increments 
every 0.05 sec to 95 °C with SYBR Green quantification conducted continuously throughout 
this stage. The raw data was analyzed using the Biorad CFX Manager 3.0 Software (Biorad). 
2.13 Phenotypic analyses of M. smegmatis knockout strains 
 2.13.1 Growth rate determination in standard media 
To assess the growth rates of wild type and mutant strains, growth curve experiments were 
performed. A pre-culture was started using either a single colony or 1 ml of frozen culture in 
10 ml media containing appropriate antibiotics and incubated at 37 °C and 100 rpm shaking 
overnight. The pre-culture was diluted to an OD600nm of 0.01 in 50 ml media containing 
appropriate antibiotics and incubated at 37 °C with shaking at 100 rpm. Growth rates were 
determined by recording the OD600nm reading at three hour intervals and data was used to 
generate a scatter plot.  
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 2.13.2 Growth rate analysis in Sauton’s media 
To assess the effect of acid stress in minimal media on the growth rate of wild type and 
mutant strains, growth curve experiments in Sauton’s media at different pH (5.5 and 7.3) 
were performed. Growth rates were determined as above in standard media. 
 2.13.3 Colony forming ability 
Bacterial spotting assays were performed to assess the morphology of wild type and mutant 
strains on solid agar. Cells were grown to log phase in 7H9 broth. A 10-fold serial dilution 
ranging between 10
0 – 107 was prepared and 10 µl from each dilution was spotted onto 7H10 
agar plates with appropriate antibiotic where necessary. Plates were incubated at 37 °C for 3-
5 days before images were captured using the Zeiss Stereo Microscope (1.3× magnification). 
 2.13.4 Biofilm formation 
Cells were grown overnight in 7H9 media to an OD600nm> 2. Cells were harvested by 
centrifugation at 3500 rpm and washed twice in Sauton’s media. The pellets were 
resuspended in Sauton’s media and the OD600nm was adjusted to 2. A 10-fold serial dilution 
ranging from 10
0
 -10
5
 was prepared and 100 µl of each dilution was added to a 6-well plate 
containing 10 ml Sauton's media (1:100). Plates were incubated at 37 °C for 7-10 days before 
images were captured using the Zeiss Stereo Microscope (1.3× magnification). 
 2.13.5 Sliding motility 
Wild type and mutant strains were streaked to single colonies on 7H10 agar plates and 
incubated at 37 °C for 3 days. A single colony was picked and placed onto the center of 7H9 
agar plates containing 0.3% agar. Plates were incubated at 37 °C for 4-5 days before being 
photographed using the G-Box SYNGENE system. 
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 2.13.6 Antibiotic sensitivity 
  2.13.6.1 Minimum Inhibitory Concentration (MIC) determination 
To determine MIC concentrations, wild type and mutant strains were grown overnight at 37 
°C to an OD600nm of 0.3. An initial 1:10 dilution of the overnight cultures was carried out 
followed by a 1:50 dilution. The broth microdilution method (Domenech et al., 2005) was 
used to set up 96 well plates. The following antibiotics were tested: Ampicillin, 
Erythromycin, Vancomycin, Rifampicin, Cefoxitin, Cefotaxime, Cefamandole, Cefapirin and 
Cefatriaxone. Plates were incubated for 5 days at 37 °C and assessed visually with the MIC 
being determined as the lowest drug concentration that inhibited growth. 
2.13.6.2 Antibiotic sensitivity Spotting Assay 
Wild type and mutant strains were grown overnight at 37 °C to an OD600nm of 0.3. A ten-fold 
dilution series ranging between 10
0
 -10
7 
was carried out and 10 µl of each dilution was 
spotted on 7H10 agar plates (145 x 20 mm) containing the appropriate antibiotic at the 
predetermined MIC concentration. A control plate containing no antibiotic was included. 
Plates were incubated for 5 days at 37 °C before being photographed using the G-Box 
SYNGENE system (upper white setting).  
 2.13.7 SDS sensitivity 
  2.13.7.1 SDS killing curves 
Cells were grown overnight in 7H9 broth to an OD600nm of 0.3. From the overnight culture, 1 
ml was removed - 100 µl of this was used to prepare serial dilutions for CFUs and the 
remainder was used for visualization on the microscope. To the remaining culture, 0.2% SDS 
was added and the culture was incubated at 37 °C. After 3 and 6 hours, 1 ml of culture was 
removed and used for CFUs. 
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  2.13.7.2 SDS spotting assay 
Cells were grown overnight in 7H9 broth at 37 °C to an OD600nm of 0.3. A ten-fold dilution 
series ranging between 10
0
 -10
7
 was carried out and 10 µl of each dilution was spotted on 
7H10 agar plates (145 x 20 mm) containing either 0.01%, 0.005% 0.0025% or 0.001% SDS. 
A control plate containing no SDS was included. Plates were incubated for 5 days at 37 °C 
before being photographed using the G-Box SYNGENE system (upper white setting).  
2.13.8 Microscopic analysis 
 2.13.8.1 Scanning Electron Microscopy 
Cells were grown in 50 ml 7H9 broth overnight at 37 °C to an OD600nm of 0.6. Cells were 
harvested by centrifugation at 4000 rpm for 10 min, followed by two washes with PBS and 
then resuspended in 2.5% gluteraldehyde in PBS overnight at 4 °C. Cells were washed twice 
with PBS and resuspended in 100 µl osmium tetraoxide in PBS and incubated for 1 hour at 
room temperature. Following incubation, cells were washed twice with PBS and then 
dehydrated with a series of ethanol concentrations: 30%, 50%, 70% and twice at 100%, for 2 
min each. Cells were stored in 100% ethanol until they could be viewed. Before visualization, 
cells were spotted on a filter, carbon coated twice and then viewed using the FEI Nova 
NanoSEM 230. 
 2.13.8.2 Transmission Electron Microscopy 
Cells were grown in 50 ml 7H9 broth overnight at 37 °C to an OD600nm of 0.6. Cells were 
harvested by centrifugation at 3082 × g  for 10 min, washed twice with PBS and resuspended 
in fixing solution containing 2% (v/v) formaldehyde, 2.5% (v/v) gluteraldehyde, 0.1 mM 
HEPES and 0.05% (v/v) ruthedium red, followed by incubation for 1 hour at room 
temperature. After incubation, cells were washed twice with PBS and then dehydrated with a 
series of ethanol concentrations: 30%, 50%, 70% and twice at 100%, for 2 min each. After 
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dehydration, samples were washed in propylene oxide and 50% resin mixture (15 g DDSA, 
7.75 g epon 812 and 5.62 g araldite). The propylene oxide resin mixture was removed and 
cells were resuspended in 100% resin and incubated overnight at room temperature. 
Following overnight incubation, cells were pelleted, the resin was removed and fresh resin 
containing DMP at a ratio of 40: 1 (g: g) was added to the cells and incubated for 48 hours at 
60 °C. The solidified resin was sectioned using a Relchert Ultracut Ultramicrotome (Circa) 
and viewed using a Tecnai F20 TEM. 
2.13.8.3 Fluorescence Microscopy 
Cells were grown in 10 ml of 7H9 broth overnight at 37 °C to an OD600nm of 0.6. Cells were 
harvested by centrifugation at 3082 × g for 10 min, washed twice in PBS and resuspended in 
1 ml 7H9 broth. Thereafter, 1 µl of 1 mg/ml BODIPY- fluorescent vancomycin (Invitrogen) 
and 0.2 µl of 5 mg/ml vancomycin was added to the suspension followed by incubation for 
1.5 hours at 37 °C with shaking. Following incubation, cells were washed twice with 7H9, 
resuspended in 100 µl 7H9 and 5 µl was spread onto a 2% agarose pad on a slide. A drop of 
fluoramount (Sigma) was used to mount the coverslip onto the slide. The slides were viewed 
on the Zeiss Axio Observer z1 base and images were processed using the ZEN black version 
software (Zeiss).  
2.14 Recombinant protein expression 
For expression analysis, the pET29a-c, T7 expression vector was used. T7 promoters found 
on the vector only recognize the T7 RNA polymerase and not RNA polymerase generated by 
E. coli. However, the gene for T7 RNA polymerase is engineered into commercially available 
E. coli (DE3) strains. Additionally, the gene for T7 lysozyme, which prevents background 
expression of T7 RNA polymerase from expressing protein prior to induction, is engineered 
into commercially available E. coli pLysS strains. Isopropyl β-D-1- thiogalactopyranoside 
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(IPTG) is structurally similar to lactose and can bind to the Lac repressor encoded by the lacI 
gene, which leads to a conformational change and release of the repressor from the lac 
operator. This allows native E. coli RNA polymerase to bind and the lac operator then 
transcribes high numbers of T7 RNA polymerase. The T7 DNA polymerase can then bind to 
the T7 promoter sequence on the vector which is located upstream of the gene of interest, 
thus promoting transcription of the target gene. 
2.14.1 Generation of inducible vectors for protein purification 
Genes of interest (dacB, MSMEG_1661, MSMEG_2432 and MSMEG_2433) were amplified 
using Phusion PCR as described in 2.7.2 and cloned into the inducible promoter pET29a-c 
(Novagen), referred to as pET29a from this point forward, which carries a C-terminal His-tag 
sequence. Different variants of dacB were amplified using Phusion, with the primers listed in 
Table B5, and cloned into pET29a. These variants included the DacB catalytic domain only, 
the DacB domain lacking 50 amino acids and the DacB domain plus an additional flanking 
sequence. These plasmids were then transformed into E. coli DH5α and confirmed by 
restriction mapping as well as sequencing using primers listed in Table B6, as well as T7 
promoter and T7 terminator primers. Once strains were confirmed, plasmids were 
transformed into the expression E. coli BL21 (DE3) pLysS host and successful transformants 
were confirmed by PCR. A schematic representation of this procedure using MSMEG_2432 
as an example can be found in Figure 2.2. 
2.14.2 Induction of protein expression 
Cultures carrying the inducible plasmid were grown to an OD600nm between 0.3-0.6 at which 
point IPTG was added to the culture at a final concentration of 1 mM or 0.3 mM. The 
cultures were grown for three hours followed by protein extraction with a sample being 
collected every hour to determine optimal induction time. 
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Figure 2.2. Schematic representation of cloning for recombinant protein production using MSMEG_2432 
as an example. The gene of interest is cloned into pET29a which incorporates a His tag at the C-terminal end of 
the protein. The vector containing the gene is then induced using IPTG. 
 
Cells were grown in 10 - 20 ml cultures with appropriate antibiotics and harvested by 
centrifugation at 3082 × g for 10 min. Pellets were then resuspended in 250 – 500 µl B-PER 
(Fischer Scientific) cocktail solution and incubated with shaking at room temperature for 10 
min. The B-PER lysis solution allows for lysing of bacterial cells without the need for 
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mechanical methods. Soluble (supernatant) and insoluble fractions were separated by 
centrifugation at 10 392 × g for 15 min. An equal volume of 5× SDS Buffer was added to all 
samples.  
2.14.3 SDS-PAGE 
SDS-PAGE is a common method used to separate proteins based on their size. Acrylamide 
gels were prepared as outline in Table A11. Prior to loading gels, equal amounts of different 
protein samples in loading buffer were denatured at 95 °C for 5 min. Proteins were separated 
at 100 V in running buffer (Table A10) for 2 – 3 hours. Gels were stained overnight with 
Coomassie blue at room temperature with shaking followed by destaining at room 
temperature until bands could be visualized.  
2.14.4 Protein purification 
After separation of soluble and insoluble fractions, 250 µl of Ni-NTA resin (Qiagen) was 
added to a clean Eppendorf tube and centrifuged at 3082 × g for 30 secs. The top layer was 
removed and resin was equilibrated by the addition of 500 µl Buffer A (50 mM Tris, 500 mM 
NaCl, 20% glycerol and 10 mM imidazole) followed by centrifugation at 3082 × g  for 30 
sec. The top layer was discarded and the equilibration step was repeated. DNase I was added 
to the BPER II lysed soluble fraction from induced cells and then centrifuged for 10 min at 
10 392 × g. The supernatant was transferred to a clean tube and the pellet was resuspended in 
250 µl of Buffer A.  From the supernatant, 250 µl was added to the resin and incubated for 10 
min on ice. Following incubation, the resin was washed thrice using 1 ml Buffer A and 
centrifugation for 10 secs at 2360 × g. After each centrifugation the ‘flowthrough’ was 
collected. Following the final wash, the protein was eluted using 100 µl of Buffer B (50 mM 
Tris, 500 mM NaCl, 20% glycerol and 250 mM imidazole) and centrifuged for 10 sec at 3500 
rpm. The top layer was containing the eluted protein and a sample of the resin was collected. 
55 
 
2.14.5 Western blotting 
 2.14.5.1 Electro-blotting 
Following SDS-PAGE separation, proteins were transferred to a nitrocellulose blotting 
membrane (Pall Life Sciences) by preparing a cassette containing the following: a 
nitrocellulose membrane packed against the SDS-PAGE gel and sandwiched between two 
layers of Whatman filter paper and sponges. The proteins were transferred to the membrane 
at 100 V for 70 min at 4 °C. 
 2.14.5.2 Immunological detection 
Unless stated differently, all wash steps and incubations were performed at room temperature 
with shaking. To prevent non-specific binding of the primary antibody, the membrane was 
incubated at 4 °C overnight in blocking solution (Table A14). Following incubation, the 
membrane was washed three times with Tris buffered saline with Tween 20 (TBST) for 5 
min each. The membrane was incubated for 1 hour in blocking solution containing the 
primary antibody, in this case a monoclonal Anti-polyHistidine (Sigma) at a final 
concentration of 10 µg/ml. This was followed by three TBST washes for 5 min each. The 
membrane was then incubated in blocking solution for 1 hour with the secondary antibody, 
Rabbit Anti-Mouse IgG (Sigma) at a dilution of 1: 25000. This was followed by three TBST 
washes for 5 min each. The membrane was transferred to a hybridization bag, treated with a 
Chemiluminescent Peroxidase Substrate (CPS) and incubated at room temperature for 5 – 10 
min. All excess substrate was removed and the membrane was exposed to X-ray film for 30–
60 secs. The X-ray films were developed manually using the Axim automated developer. 
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3. Results 
3.1 Generation of M. smegmatis double knockout DD-CPase mutants 
Prior to all electroporations, all suicide vectors were extensively mapped using restriction 
enzymes to ensure the correct vector was being used. The results of these restriction analyses 
are given in Figure D1- D3 (pages 126 - 128), in all cases, the genetic integrity of the vector 
was confirmed.  
3.1.1 Generation of ΔMSMEG_1661 ΔMSMEG_2432 
The strategy for constructing combinatorial mutants is shown in Figure 3.1 with the single 
deletion mutant created by electroporation of P2NIL_PAC_1661 (Table 2.1) into wild type 
M. smegmatis. Using the P2NIL_PAC_2432 vector created by Dr. C. Ealand, a double 
knockout mutant was created as described in section 2.9.1. A single colony, representative of 
a SCO was obtained from the electroporation reaction with P2NIL_PAC_2432 (Table 2.1) 
into ΔMSMEG_1661 single knockout mutant. This SCO colony was taken forward and 
grown in the absence of antibiotics, followed by selection in the presence of sucrose. White 
colonies were picked and spotted onto 7H10 agar supplemented with X-gal and sucrose. 
Eleven of the colonies that remained white were screened using a PCR strategy. 
 
Figure 3.1. Construction of ΔMSMEG_1661 ΔMSMEG_2432 and its complemented derivative. A single 
knockout mutant was previously created by deleting MSMEG_1661 from the mc
2
155 wild type strain. This was 
followed by deletion of MSMEG_2432 and subsequent complementation with pMV1661. Red arrows indicate 
deletion and green arrow indicates genetic complementation.  
 
The PCR strategy used to screen knockouts contains three primers in a single reaction – two 
primers flank the gene (Primer 1 and 3) and the other is situated within the deleted region of 
the gene (Primer 2). A schematic of the expected amplicon sizes can be found in Figure 3.2. 
mc2155 ΔMSMEG_1661
ΔMSMEG_1661 
ΔMSMEG_2432
ΔMSMEG_1661 
ΔMSMEG_2432::
MSMEG_1661
-MSMEG_1661 -MSMEG_2432 +MSMEG_1661
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In wild type and SCO DNA, all three primers have the ability to anneal to the template. The 
product amplified by Primers 1 and 3, which flank the gene, is 1028 bp and Primers 1 and 2 
generate a 500 bp product, both of which represented the wild type gene, Figure 3.2A. 
However, in all cases the smaller band created by Primer 1 and 2 is preferentially amplified 
due to competition for PCR reagents such as dNTPs. For deletion of MSMEG_2432, the 
region for Primer 2 binding should be absent in the mutant and only Primers 1 and 3 will 
bind. This would result in the generation of a smaller product, 236 bp band, indicating the 
presence of the mutant allele. Of the eleven colonies screened, five appeared to be mutants, as 
confirmed by the 236 bp band observed in lanes 5, 7-9 and 15 of Figure 3.2B. The remaining 
six colonies appeared to be wild type revertants as confirmed by the 500 bp band found in 
lanes 6 and 10-14. Colonies corresponding to lanes 5 and 7-9 were picked and the genotype 
was further confirmed by Southern blot analysis. 
 
Figure 3.2. PCR screening of ΔMSMEG_1661 ΔMSMEG_2432 knockout mutants. (A) Schematic 
representation of genomic maps of wild type and mutant MSMEG_2432 region. Primer positions (red arrows) 
and expected amplicon sizes are shown. P1 = Primer 1, P2= Primer 2, P3 = Primer 3. (B) PCR screen for 
MSMEG_2432 deletion. Lane 1: Marker VI, Lane 2: No DNA, Lane 3: wild type, Lane 4: suicide vector, Lane 
5 to 15: Clones 1 to 11. The 1028 bp band is not seen in any of the wild type strains due to competition of 
reagents resulting in preferential amplification of the 500 bp band. 
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All probes were synthesized for southern blots with DIG dUTP from the appropriate vector. 
Agarose gels for probes are given in Figures D4 – D6 (page 129). As expected the DIG 
labeled probe migrates higher than the corresponding unlabeled fragment.  
Genomic DNA was extracted from wild type and the putative mutants using the CTAB DNA 
extraction method described in section 2.3.2.2. The enzymes chosen to perform Southern blot 
analysis on the MSMEG_1661 upstream and MSMEG_2432 upstream regions were MluI and 
PvuII respectively, as these allowed for accurate differentiation between wild type and 
mutant strains. Restriction digestions were set up using the above mentioned enzymes and 2 
µg CTAB DNA for each reaction. Southern blot analysis was carried out as described in 
section 2.10. In this study, double mutants defective for two DD-CPases encoding genes were 
generated and characterized. For this single deletion mutants were used and during genotypic 
analysis, the integrity of the pre-existing deletion in the parental strain was also confirmed to 
ensure that no chromosomal rearrangements took place during allelic exchange. To determine 
that the parental strain was correct, the probe created from the suicide vector 
P2NIL_PAC_1661 (Table 2.1) which corresponds to the region upstream of MSMEG_1661, 
was used, Figure 3.3A. To identify possible double knockout mutants, deficient in 
MSMEG_2432, in the background of the ΔMSMEG_1661 mutant, the probe created from the 
P2NIL_PAC_2432 suicide vector (Table 2.1) which corresponds to the region upstream of 
MSMEG_2432 was used, Figure 3.3C. The results of the Southern blots for the 
MSMEG_1661 and MSMEG_2432 upstream probes are shown in Figure 3.3B and 3.3D 
respectively with the expected sizes shown in Figure 3.3A and 3.3C respectively. From the 
Southern blot of the parental strain, Figure 3.3A and 3.3B, it can be seen that there is a size 
difference between the wild type and mutant strains in the region probed. The MluI digests 
produced a smaller band in the mutant strain (3.79 kbp vs 4.95 kbp in the mutant vs wild type 
respectively) due to the decrease in size of the MSMEG_1661 gene. This confirms that the  
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Figure 3.3. Screening of ΔMSMEG_1661 ΔMSMEG_2432 possible double crossover mutants. (A) 
Schematic representation of genomic maps of wild type and mutant MSMEG_1661 regions. Probes, restriction 
enzymes and expected fragment sizes are shown. (B) Southern blot with MSMEG_1661 upstream probe. Lane 
1: MluI digested wild type DNA, Lane 2 to 6: MluI digested ΔMSMEG_1661 ΔMSMEG_2432 DNA. (C) 
Schematic representation of genomic maps of wild type, single crossover and mutant MSMEG_2432 regions. 
Probes, restriction enzymes and expected fragment sizes are shown. (D) Southern blot with MSMEG_2432 
upstream probe. Lane 1: PvuII digested wild type DNA, Lane 2: PvuII digested single crossover DNA, Lane 3 
to 6: PvuII digested ΔMSMEG_1661 ΔMSMEG_2432 DNA. 
parental strain is in fact a MSMEG_1661 knockout mutant. Confirmation of the loss of 
MSMEG_2432 in this background can be seen by the reduction in size of the band observed 
for the PvuII digest (1.35 kbp vs 2.14 kbp in the mutant vs wild type respectively) in the 
mutant strain, Figure 3.3C and 3.3D.  This decrease in size is due to the decrease in size of 
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the MSMEG_2432 gene confirming that this strain is also a MSMEG_2432 knockout mutant. 
The SCO for this strain displays all expected band sizes confirming that no mutations 
occurred during recombination. Since this is a double knockout strain, both the upstream and 
downstream regions of both the genes deleted need to be confirmed. One colony was chosen 
and further analyzed by Southern blot analysis using the restriction enzyme BamHI which 
allows accurate differentiation between the wild type and mutant strains. 
Genomic DNA was extracted from wild type, the single knockout mutants ΔMSMEG_1661 
and ΔMSMEG_2432 as well as the double knockout clone that was selected. The parental 
strain was confirmed by using the probes shown in Figure 3.4A which correspond to the 
upstream and downstream regions used to generate the suicide vector P2NIL_PAC_1661 
(Table 2.1). The Southern blot results for MSMEG_1661 upstream and downstream probes 
are shown in Figure 3.4B and 3.4C respectively. An increase in the band observed for the 
BamHI digests in the mutant strains is due to loss of a restriction site present in the wild type 
gene. This can be seen with the upstream (5.08 kbp vs 2.82 kbp in the mutant vs wild type 
respectively) and the downstream (5.08 kbp vs 3.42 kbp in the mutant vs wild type 
respectively) probes confirming that MSMEG_1661 is deleted in the ΔMSMEG_1661 single 
knockout and the double knockout mutant strains. To confirm deletion of the second DD-
CPase gene in the ΔMSMEG_1661 background, probes shown in Figure 3.4D which 
corresponds to the upstream and downstream regions used to generate the suicide vector 
P2NIL_PAC_2432 (Table 2.1) were used. A decrease in the band observed for the BamHI 
digests in the mutant strains is due to the decrease in size of the MSMEG_2432 gene. This 
can be seen with both the upstream (1.08 kbp vs 1.87 kbp in the mutant vs wild type 
respectively) and the downstream (1.08 kbp vs 1.87 kbp in the mutant vs wild type 
respectively) probes. Together these data provide definitive evidence that both 
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MSMEG_1661 and MSMEG_2432 are deleted in this strain, now designated as 
ΔMSMEG_1661 ΔMSMEG_2432 (Δ1661 Δ2432 in images). 
 
Figure 3.4. Genotypic confirmation of the ΔMSMEG_1661 ΔMSMEG_2432 strain. (A) Schematic 
representation of genomic maps of wild type and mutant MSMEG_1661 regions. Upstream and downstream 
probes are shown in purple and grey respectively. Restriction enzyme sites and expected fragment sizes are also 
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shown. (B) Southern blot with MSMEG_1661 upstream probe. (C) Southern blot with MSMEG_1661 
downstream probe. (D) Schematic representation of genomic maps of wild type and mutant MSMEG_2432 
regions. Upstream and downstream probes are shown in purple and grey respectively. Restriction enzyme sites 
and expected fragment sizes are also shown. (E) Southern blot with MSMEG_2432 upstream probe. (F) 
Southern blot with MSMEG_2432 downstream probe. Lane 1: BamHI restricted wild type DNA, Lane 2: 
BamHI restricted ΔMSMEG_1661 DNA, Lane 3: BamHI restricted ΔMSMEG_2432 DNA, Lane 4: BamHI 
restricted ΔMSMEG_1661 ΔMSMEG_2432 DNA. 
 
3.1.2 Generation of ΔMSMEG_2433 ΔMSMEG_1661 
Using the P2NIL_PAC_1661 (Table 2.1) vector created by Dr. C. Ealand, a double knockout 
mutant was created as described in section 2.9.1. A single colony representative of a SCO 
was obtained from the electroporation reaction with P2NIL_PAC_1661 (Table 2.1) into 
ΔMSMEG_2433 single knockout mutants, Figure 3.5. This SCO colony was taken forward 
and grown in the absence of antibiotics, followed by selection in the presence of sucrose. 
White colonies were picked and spotted onto 7H10 agar supplemented with X-gal and 
sucrose. Seven of the colonies that remained white were screened using a PCR strategy, that 
was similar to one mentioned above.  
 
Figure 3.5. Construction of ΔMSMEG_2433 ΔMSMEG_1661 and its complemented derivative. A single 
knockout mutant was previously creating by removing MSMEG_2433 from the mc
2
155 wild type strain. This 
was followed by deletion of MSMEG_1661 in the single knockout background and subsequent 
complementation with pMV1661. Red arrows indicate deletion and green arrow indicates complementation. 
 
In this case, the product amplified by Primers 1 and 3, which flank the gene, is 1394 bp and 
the Primers 1 and 2 generate a 701 bp product, both of which represent the wild type gene. A 
schematic of the expected amplicon sizes can be found in Figure 3.6A. In the knockout 
mutant, the MSMEG_1661 gene should be absent, resulting in the generation of a smaller 
236 bp band product, indicating the presence of the mutant allele. Of the seven colonies, five 
appeared to be mutants, as confirmed by the 236 bp band observed in lanes 9-13 of Figure 
mc2155 ΔMSMEG_2433
ΔMSMEG_2433 
ΔMSMEG_1661
ΔMSMEG_2433 
ΔMSMEG_1661::
MSMEG_1661
-MSMEG_2433 -MSMEG_1661 +MSMEG_1661
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3.6B. Of the remaining colonies, one appeared to be a wild type revertant as confirmed by the 
701 bp band found in lane 14 and the other appeared to be a SCO as confirmed by the 
presence of both the wild type and mutant bands in lane 15. Colonies corresponding to lanes 
9-13 were picked and the genotype was further confirmed by Southern blot analysis. 
 
Figure 3.6. PCR screening for ΔMSMEG_1661 ΔMSMEG_2432 knockout mutants. (A) Schematic 
representation of genomic maps of wild type and mutant MSMEG_1661 region. Primer positions (red arrows) 
and expected amplicon sizes are shown. P1 = Primer 1, P2= Primer 2, P3 = Primer 3. (B) PCR screen for 
MSMEG_1661 deletion. Lane 1: Marker VI, Lane 2: No DNA, Lane 3 to 5: primer controls, Lane 6: wild type, 
Lane 7: SCO, Lane 9 to 15: Clones 1 to 7. Once again, the bigger band (1394 bp) is not seen in any of the wild 
type strains due to competition of reagents resulting in preferential amplification of the 701 bp band. 
 
Genomic DNA was extracted from wild type, SCO and the selected colonies using the CTAB 
DNA extraction method described in section 2.3.2.2. The enzyme chosen to perform 
Southern blot analysis on the MSMEG_2433 upstream and MSMEG_1661 upstream regions 
was NcoI with digestions set up as mentioned previously, followed by Southern blot analysis. 
Once again, the integrity of the pre-existing deletion in the parental strain was confirmed to 
ensure that no chromosomal rearrangements took place during allelic exchange.  To 
determine if the parental strain was correct, the probe used to create the suicide vector 
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P2NIL_PAC_2433 (Table 2.1), which corresponds to the region upstream of MSMEG_2433 
was used, Figure 3.7A. To identify possible double knockout mutants, the probe created from 
the P2NIL_PAC_1661 (Figure 2.1) suicide vector which corresponds to the region upstream 
of MSMEG_1661 was used, Figure 3.7C. The results of the Southern blots for the 
MSMEG_2433 and MSMEG_1661 upstream probes are shown in Figure 3.7B and 3.7D 
respectively, with the expected sizes shown in Figure 3.7A and 3.7C respectively. From the 
Southern blot of the parental strain, Figure 3.7A and 3.7B, it can be seen that there is a size 
difference between the wild type and mutant strains in the region probed. The NcoI digests 
produced a smaller band in the mutant strain (0.82 kbp vs 1.67 kbp in the mutant vs wild type 
respectively) due to the decrease in size of the MSMEG_2433 gene. This confirms that the 
parental strain is indeed a MSMEG_2433 knockout mutant. Confirmation of the loss of 
MSMEG_1661 in this background can be seen by the reduction in size of the band observed 
for the NcoI digest (1.35 kbp vs 2.5 kbp in the mutant vs wild type respectively) in the mutant 
strain, Figure 3.7C and 3.7D.  This decrease in size is due to the decrease in size of the 
MSMEG_1661 gene, confirming that this strain is also a MSMEG_1661 knockout mutant. 
The SCO for this strain displays all expected band sizes confirming that no mutations 
occurred during recombination. These data confirmed the deletion of MSMEG_1661 from 
ΔMSMEG_2433 background. However, the integrity of both the upstream and downstream 
regions, of both the genes, required confirmation. One clone was selected and further 
analyzed by Southern blot analysis using the restriction enzyme MluI. Genomic DNA was 
extracted from wild type, the single knockout mutants ΔMSMEG_1661 and ΔMSMEG_2433 
as well as the selected double knockout mutant. The parental strain was confirmed by using 
the probes shown in Figure 3.8A which correspond to the upstream and downstream regions 
used to generate the suicide vector P2NIL_PAC_2433 (Table 1). The Southern blot results  
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Figure 3.7. Screening of ΔMSMEG_2433 ΔMSMEG_1661 possible double crossover mutants. (A) 
Schematic representation of genomic maps of wild type and mutant MSMEG_2433 regions. Probes, restriction 
enzymes and expected fragment sizes are shown. (B) Southern blot with MSMEG_2433 upstream probe. Lane 
1: NcoI digested wild type DNA, Lane 2 to 7: NcoI digested Δ2433Δ1661 DNA. (C) Schematic representation 
of genomic maps of wild type, SCO and mutant MSMEG_1661 regions. Probes, restriction enzymes and 
expected fragment sizes are shown. (D) Southern blot with 1661 upstream probe. Lane 1: NcoI digested wild 
type DNA, Lane 2: NcoI digested SCO DNA, Lane 3 to 7: NcoI digested ΔMSMEG_2433 ΔMSMEG_1661 
DNA. The 13 kbp band did not appear. 
for MSMEG_2433 upstream and downstream probes are shown in Figure 3.8B and 3.8C 
respectively. A decrease in the band observed for the MluI digests is due to the decrease in 
size of the MSMEG_2433 gene. This can be seen with the upstream (0.82 kbp vs 1.67 kbp in 
the mutant vs wild type respectively) and the downstream (0.82 kbp vs 1.67 kbp in the mutant  
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Figure 3.8. Genotypic confirmation of the ΔMSMEG_2433 ΔMSMEG_1661 strain. (A) Schematic 
representation of genomic maps of wild type and mutant MSMEG_2433 regions. Upstream and downstream 
probes are shown in purple and grey respectively. Restriction enzyme sites and expected fragment sizes are also 
shown. (B) Southern blot with MSMEG_2433 upstream probe. (C) Southern blot with MSMEG_2433 
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downstream probe. (D) Schematic representation of genomic maps of wild type and mutant MSMEG_1661 
regions. Upstream and downstream probes are shown in purple and grey respectively. Restriction enzyme sites 
and expected fragment sizes are also shown. (E) Sothern blot with MSMEG_1661 upstream probe. (F) Southern 
blot with MSMEG_1661 downstream probe. (C to F) Lane 1: MluI restricted wild type DNA, Lane 2: MluI 
restricted ΔMSMEG_1661 DNA, Lane 3: MluI restricted ΔMSMEG_2433 DNA, Lane 4: MluI restricted 
ΔMSMEG_2433 ΔMSMEG_1661 DNA 
vs wild type respectively) probes confirming that MSMEG_2433 is deleted in the 
ΔMSMEG_2433 single knockout and the double knockout mutant strains. To confirm 
deletion of MSMEG_1661, probes shown in Figure 3.8D which corresponds to the upstream 
and downstream regions used to generate the suicide vector P2NIL_PAC_1661 (Table 1) 
were used. A decrease in the band observed for the MluI digests in the mutant strains is due 
to the decrease in size of the MSMEG_1661 gene. This can be seen with both the upstream 
(3.79 kbp vs 4.95 kbp for the mutant vs the wild type respectively), Figure 3.8E, and the 
downstream (3.79 kbp vs 4.95 kbp for the mutant vs the wild type respectively) probes, 
Figure 3.8F. Together these data prove that both MSMEG_2433 and MSMEG_1661 are 
deleted in this strain, now designated as ΔMSMEG_2433 ΔMSMEG_1661 (Δ2433 Δ1661 in 
images). 
3.1.3 Generation of a double knockout mutant lacking MSMEG_2432 and 
MSMEG_2433 
Using the P2NIL_PAC_2433 (Table 2.1) vector created by Dr. C. Ealand, a double knockout 
mutant was created as described in section 2.9.1. A single colony representative of a SCO 
was obtained from the electroporation reaction with P2NIL_PAC_2433 (Table 2.1) into 
ΔMSMEG_2432 single knockout mutants. This SCO colony was taken forward and grown in 
the absence of antibiotics, followed by selection in the presence of sucrose. White colonies 
were picked and spotted onto 7H10 agar supplemented with X-gal and sucrose. Colonies that 
remained white were screened using a PCR strategy. 
68 
 
The product amplified by Primer 1 and 3, which flank the gene, is 1091 bp and Primers 1 and 
2 generate a 500 bp probe both of which represent the wild type gene, Figure 3.9A. In the 
knockout mutant, the MSMEG_2433 gene should be absent in the mutant therefore resulting 
in the primer situated within the gene will be unable to anneal to the template. This would 
result in the generation of a smaller 236 bp band product from Primers 1 and 3, indicating the 
presence of the mutant band. A schematic of the expected amplicon sizes can be found in 
Figure 3.9A. Of the eight colonies, one appeared to be a mutant, as confirmed by the 236 bp 
band observed in lane 9 of Figure 3.9B. The remaining six colonies appeared to be wild type 
revertants as confirmed by the 500 bp band found in lanes 5-6, 8 and 10-12. The colony 
corresponding to lane 9 was picked and the genotype was further confirmed by Southern blot 
analysis. 
 
Figure 3.9. Analysis of possible ΔMSMEG_2432 ΔMSMEG_2433 double crossover mutants. (A) 
Schematic representation of genomic maps of wild type and mutant MSMEG_2433 region. Primer positions 
(red arrows) and expected amplicon sizes are shown. P1 = Primer 1, P2= Primer 2, P3 = Primer 3. (B) PCR 
screening of possible ΔMSMEG_2432 ΔMSMEG_2433 DCO mutants. Lane 1: marker VI, Lane 2: no DNA, 
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Lane 3: wild type, Lane 4: suicide vector, Lane 5-12: possible mutants. The 1091 bp band is not seen in any of 
the wild type strains due to competition of reagents resulting in preferential amplification of the 500 bp band. 
 
The enzyme chosen to perform Southern blot analysis on the MSMEG_2433 upstream region 
was MluI, as it allows for differentiation between wild type and mutant strains. Restriction 
digestions and Southern blot analysis was carried out as described above. To identify possible 
double knockout mutants, the probe created from the P2NIL_PAC_2433 (Table 1) suicide 
vector, Figure 3.10A, which corresponds to the region upstream of MSMEG_2433 was used. 
The result of the Southern blot for the MSMEG_2433 upstream probe is shown in Figure 
3.10B. The MluI digests for the wild type strain generated the bands expected – 2.65 kbp and 
1.67 kbp. However, both the mutant and SCO MluI digests displayed an extra band (~2.9 kb), 
indicated by the blue arrow. The extra band in the SCO strain is a possible indication of  
 
Figure 3.10. Screening of ΔMSMEG_2432 ΔMSMEG_2433 possible double crossover mutant. (A) 
Schematic representation of genomic maps of wild type, single crossover and mutant MSMEG_2433 regions. 
Probes, restriction enzyme sites and expected fragment sizes are also shown. (B) Southern blot of 
ΔMSMEG_2432 ΔMSMEG_2433 with MSMEG_2433 upstream probe. Blue arrow indicates additional band in 
single crossover and mutant strains. 
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mutation or rearrangement that occurred during recombination. In order to resolve this, 
various SCO strains were used to generate possible DCO mutants. However, of all the 
colonies screened none appeared to be mutants (data not shown), but the products of 
illegitimate recombination or wild type. 
To circumvent this, another strategy was attempted which involved the electroporation of 
P2NIL_PAC_2432 (Table 2.1) into ΔMSMEG_2433 single knockout mutant. A SCO colony 
generated from this electroporation reaction was taken forward and grown in the absence of 
antibiotics, followed by selection in the presence of sucrose. White colonies were picked and 
spotted onto 7H10 agar supplemented with X-gal and sucrose. Colonies that remained white 
were screened using a PCR strategy. 
As discussed previously, the product amplified by Primers 1 and 3 which flank the gene, is 
1028 bp and Primers 1 and 2 generate a 500 bp product, both of which represent the wild type 
gene, Figure 3.2A. In the knockout mutant, the MSMEG_2432 gene should be absent 
therefore resulting in the generation of a smaller 236 bp band product indicating the presence 
of the mutant band. A schematic of the expected amplicon sizes can be found in Figure 3.2A. 
Of all the colonies screened none appeared to be mutants. All, except one which represented 
a SCO demonstrated in Lane 12 (top gel) of Figure 3.11, appeared to be wild type revertants 
as evidenced by the presence of a 500 bp band. Together, these data suggest that deletion of 
MSMEG_2432 in a ΔMSMEG_2433 background strain or deletion of MSMEG_2433 in a 
ΔMSMEG_2432 background strain proved to be problematic using the above-mentioned 
approaches. This could be due to the operonic nature of these genes. Consequently, no further 
attempt were made to construct a mutant lacking both MSMEG_2432 and MSMEG_2433. 
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Figure 3.11. PCR screenings of possible ΔMSMEG_2433 ΔMSMEG_2432 double crossover mutants. Lane 
1: Marker VI, Lane 2: no DNA, Lane 3: wild type, Lane 4: SCO, Lane 5: suicide vector, Lane 6-13: possible 
mutants. A schematic of the primer binding sites can be found in Figure 3.2A. Once again the 1028 bp product 
is not observed due to competition for PCR reagents. 
 
3.2 Complementation of DD-CPase mutants with a single DD-CPase 
Prior to electroporations, pMV1661 was extensively mapped using restriction enzymes, 
Figure D7 (page 130), to ensure that the correct vector was used.  
Genetic complementation of both double knockout mutants was achieved by electroporation 
of the integrating vector pMV1661 (Table 2.1) into both ΔMSMEG_1661 ΔMSMEG_2432 
and ΔMSMEG_2433 ΔMSMEG_1661 resulting in the re-introduction of the wild type allele 
into the genome as described in section 2.11. The pMV1661 vector is a derivative of the 
E.coli-Mycobacterium shuttle vector carrying a full length copy of MSMEG_1661 which 
integrates at the L5 attB site. A schematic of the integration process and the expected 
amplicon sizes can be found in Figure 3.12.  
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Figure 3.12. Schematic representation of integration of pMV1661 into the chromosome of M. smegmatis. 
The pMV1661 vector uses an L5 based integration system. The attachment site (orange block) integrates at the 
tRNA
Gly
 locus on the chromosome (green arrow), which results in the incorporation of the tRNA
Gly
 locus on 
either the left or right side of the plasmid, attL and attR. Primers used to confirm the site specific integration of 
pMV1661 and expected amplicon sizes are shown. 
 
Six colonies were selected and screened by PCR to confirm site-specific integration of the 
complementation vector. Site specific integration of pMV1661 was confirmed using the 
upstream region of the integration site which is represented by the presence of a 320 bp 
amplicon as visualized in Figure 3.13A and 3.13C. Figure 3.13B and 3.13D confirms 
integration using the downstream region as evidenced by the 282 bp amplicon. This data 
confirmed that the ΔMSMEG_1661 ΔMSMEG_2432 and ΔMSMEG_2433 ΔMSMEG_1661 
strains were successfully complemented with pMV1661 and will now be referred to as 
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ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661 (Δ1661 Δ2432C in images) and 
ΔMSMEG_2433 ΔMSMEG_1661::MSMEG_1661 (Δ2433 Δ1661C in images) respectively. 
 
Figure 3.13. PCR confirmation of site specific integration of pMV1661 into the double knockout mutants. 
(A) ΔMSMEG_1661 ΔMSMEG_2432 amplicons for primer set attBS2 + attL4, (B) ΔMSMEG_1661 
ΔMSMEG2432 amplicons for primer set attBS1 + attL2, (C) ΔMSMEG_2433 ΔMSMEG_1661 amplicons for 
primer set attBS2 + attL4, (D) ΔMSMEG_2433 ΔMSMEG_1661 amplicons for primer set attBS1 + attL2. Lane 
1: Marker VI, Lane 2: No DNA, Lane 3: wild type, Lane 4: ΔMSMEG_1661 ΔMSMEG_2432 or 
ΔMSMEG_2433 ΔMSMEG_1661, Lane 5-10: possible clones carrying the complementation vector. See Figure 
3.12 for primer binding regions. 
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3.3 Gene expression analysis of DD-CPases to confirm deletion and genetic 
complementation 
Gene expression analysis was performed as described in section 2.12 in order to confirm 
deletion of genes as well as to assess whether these deletion results in compensatory gene 
expression changes in the remaining DD-CPases.  
The expression profile for MSMEG_2432 can be found in Figure 3.14. The data revealed that 
all strains deficient of this gene (ΔMSMEG_2432, ΔMSMEG_1661 ΔMSMEG_2432 and 
ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661) displayed no detectable levels of 
MSMEG_2432 mRNA, as expected. Strains in which MSMEG_2432 was present such as the 
wild type, ΔMSMEG_1661, ΔMSMEG_2433, ΔMSMEG_2433 ΔMSMEG_1661 and 
ΔMSMEG_2433 ΔMSMEG_1661::MSMEG_1661 all contained MSMEG_2432 mRNA  
 
Figure 3.14. Expression analysis of cellular mRNA for MSMEG_2432 relative to sigA standard. Analysis 
was done on three different sets of RNA with the data indicating an average of these three experiments. Error 
bars indicate standard error. 
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expressed at an equivalent level. The levels of MSMEG_2432 mRNA detected in these 
strains were roughly similar to wild type except in the case of ΔMSMEG_2433 
ΔMSMEG_1661::MSMEG_1661 where levels of transcript were decreased but this 
difference was not statistically significant. These data indicated that the MSMEG_2432 gene 
was successfully deleted in the ΔMSMEG_2432, ΔMSMEG_1661 ΔMSMEG_2432 and 
ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661 strains. The data also shows that there is 
no compensatory increase in expression of MSMEG_2432 when other DD-CPases are 
deleted. 
The expression profile for MSMEG_2433 can be found in Figure 3.15. The data for 
MSMEG_2433 was similar to that of MSMEG_2432 in that strains deficient for 
MSMEG_2433 (ΔMSMEG_2433, ΔMSMEG_2433 ΔMSMEG_1661 and ΔMSMEG_2433 
ΔMSMEG_1661::MSMEG_1661) all displayed no detectable levels of the MSMEG_2433 
mRNA transcript. Expression levels of the transcript were increased in the ΔMSMEG_2432  
 
Figure 3.15. Expression analysis of cellular mRNA for MSMEG_2433 relative to sigA standard. Analysis 
was done on three different sets of RNA with the data indicating an average of these three experiments. Error 
bars indicate standard error. 
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single knockout mutant when compared to the wild type and decreased in the 
ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661 strain with the latter being statistically 
significant (p < 0.05). These data indicated that MSMEG_2433 was successfully deleted in 
the ΔMSMEG_2433, ΔMSMEG_2433 ΔMSMEG_1661 and ΔMSMEG_2433 
ΔMSMEG_1661::MSMEG_1661 strains. The data also demonstrates that when 
MSMEG_2432 is deleted, a higher level of MSMEG_2433 mRNA is observed, although this 
difference was not statistically significant. 
The expression profile for MSMEG_1661 can be found in Figure 3.16. The data for 
MSMEG_1661 mRNA expression revealed that all strains deficient for the MSMEG_1661 
gene yielded a basal level of expression. SYBR green is a fluorescent dye that binds all 
double stranded molecules. Since the data collected for the MSMEG_1661 gene in 
corresponding mutant strains were not as expected, the melt curve data was analyzed shown 
in Figure D8 (page 131). The data revealed that the signal produced in the mutant strains was  
 
 Figure 3.16. Expression analysis of cellular mRNA for MSMEG_1661 relative to sigA standard. Analysis 
was done on three different sets of RNA with the data indicating an average of these three experiments. Error 
bars indicate standard error. 
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due to a non-specific product being amplified from the template cDNA as seen by the shift in 
the melt peaks as well as a change in the melt peak temperature when compared to genomic 
standards for MSMEG_1661. Similar levels of MSMEG_1661 were detected in the wild type 
and MSMEG_2433 and MSMEG_2432 deletion strains suggesting no compensatory changes 
in gene expression. Lower levels of MSMEG_1661 mRNA was detected in the 
complemented strains when compared to the wild type strain indicating that full restoration of 
MSMEG_1661 was not achieved, however, melt peak temperature of the complemented 
derivatives were specific for MSMEG_1661. This data confirms the absence of 
MSMEG_1661 from the mutant strains – ΔMSMEG_1661, ΔMSMEG_1661 
ΔMSMEG_2432 and ΔMSMEG_2433 ΔMSMEG_1661.  
3.4 The role of DD-CPases in cell growth 
3.4.1 Regulation of M. smegmatis growth kinetics 
Growth analysis was performed on the wild type, double knockout mutants and their 
complemented derivatives to determine if DD-CPases have an impact on regulating growth 
kinetics. This was achieved by carrying out three independent experiments using different 
batches of 7H9 broth and different freezer stocks. Growth analysis was also carried out in 
Sauton’s minimal media at pH 7.3 and pH 5.5. Growth experiments were set up as described 
in section 2.12.1. The data collected at every time point was represented using scatter plots, 
Figure 3.17A- 3.17C.  
The data revealed that when grown in standard 7H9 broth, there were no significant 
differences in growth kinetics between the strains in the first 18 hr of growth. A slight, but 
non-significant, difference could be seen in the stationary phase of growth, with the wild type 
reaching a higher OD600nm reading than the other strains. These data suggest that DD-CPases  
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Figure 3.17. Growth kinetics of strains lacking DD-CPases. (A) Graph depicting growth in standard 7H9 
broth. (B) Graph depicting growth in Sauton’s minimal media pH 7.3. (C) Graph depicting growth in Sauton’s 
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minimal media pH 5.5. Each graph demonstrates an average of three independent experiments with error bars 
representing standard error.  
do not play a significant role in regulating M. smegmatis growth kinetics under standard 
conditions. 
Growth in Sauton’s minimal media at pH 7.3 also revealed no significant differences in 
growth kinetics between wild type and any of the mutant strains at any stage of growth, again 
suggesting that DD-CPases do not play a significant role in regulating growth kinetics of M. 
smegmatis under nutrient depravation as demonstrated in Figure 3.17B. 
Growth at pH 5.5 in Sauton’s minimal media revealed changes in growth for all strains after 
24 hours, Figure 3.17C. The single knockout mutant ΔMSMEG_1661 grew at a much slower 
rate than all the other strains including wild type. The remaining single knockout mutants – 
ΔMSMEG_2432 and ΔMSMEG_2433 – as well as the double knockout mutant 
ΔMSMEG_2433 ΔMSMEG_1661 grew at similar rates to that of the wild type. The 
complemented strains and the ΔMSMEG_1661 ΔMSMEG_2432 double knockout mutant 
appeared to grow at a faster rate than the wild type strain during the log phase of growth with 
these differences being statistically different (p < 0.05). This data, in addition to the Sauton’s 
pH 7.3 data, suggest that acid stress affects growth kinetics of M. smegmatis in the absence of 
one or two DD-CPases. 
3.4.2 Maintenance of M. smegmatis colony morphology 
In Mtb, overexpression of DacB2 resulted in defective smooth colonies suggestive of a role 
in colony formation (Bourai et al., 2011). However, the loss of DacB did not alter colony 
morphology possibly due to the remaining DD-CPases in the organism (Bourai et al., 2011).  
Hence, to determine if M. smegmatis DD-CPases play a role in colony morphology, all strains 
were spotted onto 7H10 agar as described in section 2.12.3. 
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The data indicated that in the absence of one or two DD-CPase genes, colony morphology of 
M. smegmatis was not compromised as shown in Figure 3.18. All strains produced colonies 
of the same size, colour and cording as expected of M. smegmatis. This suggests that DD-
CPases do not play a role in colony formation in mycobacteria. 
Figure 3.18. The effect of DD-CPase deletions on colony morphology. Image shows one dilution for each 
strain. Top depicts center of colony and bottom depicts the edge of the same colony. Picture is representative of 
three experiments.  
3.4.3 Maintenance of M. smegmatis biofilm formation 
E. coli mutants lacking PBP5, PBP6 and PBP7 in different combinations have impaired 
biofilm forming ability (Gallant et al., 2005). Therefore, we investigated if M. smegmatis DD-
CPases play a role in biofilm formation. The formation of biofilms at the liquid air interface 
of stationary phase cultures were observed as described in section 2.12.4. Both M. smegmatis 
and Mtb have been shown to form biofilms, which contribute to drug resistance and the 
ability of the bacteria to persist in the host (Ojha et al., 2005, Ojha et al., 2008). Mycolic acid 
biosynthesis in M. smegmatis has been linked to biofilm formation with a disruption in this 
pathway leading to defective biofilm formation (Ojha et al., 2005). Mtb biofilms have been 
shown to harbor persister cells, with the extracellular matrix structure containing an 
abundance of free mycolic acids (Ojha et al., 2008). 
Biofilm formation for the wild type, mutant and complemented strains, shown in Figure 3.19, 
was measured by the formation of a pellicle on the surface of the liquid cultures. The image 
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represents serial dilutions ranging from 10
0
 – 105 for each strain. All strains grew at a similar 
rate with biofilm formation observed in all dilutions. No significant differences can be  
 
Figure 3.19. Biofilm formation in strains lacking DD-CPases. Images are representative of three experiments. 
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0
 to 10
5
. [1] 10
0
, [2] 10
1
, [3] 10
2
, [4] 10
3
, [5] 10
4
, 
[6] 10
5
. Initial CFUs for stating inoculums of biofilms are indicated under strain names. Red arrow indicates 
long ruffles. Picture is representative of three experiments. 
detected in the 10
0
 – 104 dilutions. However, slight differences were observed in the highest 
dilution (10
5) of some strains. The single knockout mutants ΔMSMEG_1661 and 
ΔMSMEG_2433 as well as ΔMSMEG_1661 ΔMSMEG_2432 and ΔMSMEG_2433 
ΔMSMEG_1661::MSMEG_1661 produced ruffles that appear to be longer than those of wild 
type, indicated by the red arrows. These long ruffles were not seen in the double knockout 
ΔMSMEG_2433 ΔMSMEG_1661 mutant or any of the strains deficient for MSMEG_2432 
(ΔMSMEG_2432, and ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661). These data 
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suggest that MSMEG_1661 and/or MSMEG_2433 could play a role in biofilm formation. 
However, the phenotype is marginal and requires further confirmation. 
3.4.4. Maintenance of M. smegmatis sliding motility 
Mycobacteria have the ability to translocate on semi-solid media by a sliding mechanism 
where bacteria spread as a monolayer of cells away from the point of inoculation (Martinez et 
al., 1999). This sliding ability is due to the presence of certain lipids and macromolecules on 
the outer surface of cells (Martinez et al., 1999). Since the deletion DD-CPases could affect 
the structure of the cell wall and possibly affect sliding capacity, we tested the sliding 
motility of our mutants as described in section 2.12.5. There were no significant differences 
in mycobacterial sliding between the wild type and any of the mutant or complemented 
strains tested, as witnessed in Figure 3.20. All strains displayed typical mycobacterial sliding 
with the initial growth found on the surface of the agar at the point of inoculation after which 
growth spread outward. These data suggest that DD-CPases do not play a significant role in 
sliding motility of M. smegmatis.  
 
Figure 3.20. Sliding motility of the wild type and DD-CPase knockout strains. Growth was found on the 
surface of the agar for all strains. Picture is representative of four experiments. 
 
3.5 DD-CPases play a role in antibiotic sensitivity  
Deletion of multiple LMW PBPs in E. coli render the organism more susceptible to treatment 
with β- lactam antibiotics (Denome et al., 1999). In Mtb treatment with carbapenems results 
in pentapeptide accumulation, indicating that a DD-CPase may be the target of the antibiotic 
(Kumar et al., 2012). We have previously demonstrated that loss of a single DD-CPase does 
wild type Δ2432 Δ2433
Δ1661
Δ2432
Δ2433
Δ1661
Δ1661
Δ2432C
Δ2433
Δ1661CΔ1661
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not alter mycobacterial susceptibility to antibiotics (Ealand et al., unpublished). Hence we 
tested the antibiotic sensitivity of mutants lacking two DD-CPases by MICs as described in 
section 2.12.6. Since deletion of DD-CPases could alter cell wall integrity, a range of 
antibiotics able to damage the cell wall was used, as well as general drugs used to treat TB. 
MICs were determined in 7H9 broth and the results are shown in Table 3.1. The antibiotics 
that target the cell wall – Ampicillin, Vancomycin, Imipenem and the Cephalosporins – 
yielded differential susceptibility for one or both of the double knockout mutants. In some 
cases, mutants were up to 2-fold more susceptible to antibiotics – Cefamandole, Ceftriaxone 
Table 3.1. MIC concentrations (µg/ml) of wild type, double knockout mutants and 
complemented strains.  
 
Purple boxes indicate a decrease in the MIC when compared to the wild type strain whereas green boxes 
indicate an increase in the MIC when compared to the wild type strain. This data is representative of three 
experiments. 
ANTIBIOTIC Wild type
ΔMSMEG_1661
ΔMSMEG_2432
ΔMSMEG_2433
ΔMSMEG_1661
ΔMSMEG_1661
ΔMSMEG_2432C
ΔMSMEG_2433
ΔMSMEG_1661C
Ampicillin 37.5 - 75 18.7 37.5 37.5 37.5 - 75
Vancomycin 0.391 – 0.781 0.195 0.195 – 0.391 0.391 – 0.781 0.195 - 0.391
Imipenem 6.25 – 12.5 1.563 – 3.125 3.125 – 6.25 3.125 6.25 – 12.5
Cefamandole 125 62.5 - 125 125 125 - 250 125 - 250
Cefoxitin 20 10 10 - 20 20 20
Cefotaxime 93.75 - 187.5 46.875 - 93.75 46.875 93.75 93.75
Cefatriaxone 125 - 250 62.5 - 125 125 125 - 250 125 - 250
Cefapirin 50 - 100 12.5 - 25 25 – 50 50 50 - 100
Rifampicin 0.625 0.625 0.625 0.625 0.625
Erythromycin 0.039 0.0195 0.0195 - 0.039 0.039 0.078
D- cycloserine 26.25 – 52.5 26.25 – 52.5 26.25 – 52.5 52.5 52.5
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and Cefapirin. In general, the ΔMSMEG_1661 ΔMSMEG_2432 double knockout mutant 
appeared to be more susceptible than the ΔMSMEG_2433 ΔMSMEG_1661 mutant. Genetic 
complementation partially restored antibiotic susceptibility. 
As differences were marginal, antibiotic susceptibility was also tested on agar plates that 
contained antibiotics at the concentrations of the MIC determined above. A control plate with 
no antibiotic was included. Dilutions of cells ranging from 10
0
 – 105 were spotted onto agar 
plates containing antibiotic and susceptibility was determined by visualising growth. CFUs 
were included to ensure there was no bias in initial inoculum between strains. The 
ΔMSMEG_1661 ΔMSMEG_2432 mutant strain appeared to be more susceptible to 
Ampicillin, Cefamandole, Cefapirin, Cefoxitin, Ceftriaxone and Vancomycin when compared 
to the wild type and its complemented derivative as demonstrated in Figure 3.21. The 
ΔMSMEG_2433 ΔMSMEG_1661 mutant appeared to be more susceptible to Cefamandole, 
Cefapirin, Cefoxitin and Cefatriaxone as witnessed by the reduced growth of this strain in 
Figure 3.21. The ΔMSMEG_2433 ΔMSMEG_1661 mutant also appeared to have increased 
sensitivity to vancomycin. Both complement strains, equivalent to single knockout mutants, 
display no sensitivity to antibiotics and behave similarly to the wild type, as expected. These 
data suggest that sensitivity to cell wall antibiotics is increased only in the absence of two 
DD-CPases. 
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Figure 3.21. Drug susceptibility of wild type and double DD-CPase knockout mutants. 1 to 8 indicates a 
serial dilution of the initial inoculum from 10
0
 to 10
7
. [1] 10
0
, [2] 10
1
, [3] 10
2
, [4] 10
3
, [5] 10
4
, [6] 10
5
, [7] 10
6
,
 
[8] 10
7
. CFU counts for plates (cfu/ml): wild type = 1.6 x10
8, ΔMSMEG_1661 ΔMSMEG_2432 = 1.5 x108, 
ΔMSMEG_2433 ΔMSMEG_1661 = 1.4 x108, ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661 = 1.6 x108, 
ΔMSMEG_2433 ΔMSMEG_1661::MSMEG_1661 = 1.4 x108. AMP75 = ampicillin at 75 µg/ml, CAD62.5 = 
cefamandole at 62.5 µg/ml, CAP50 = cefapirin at 50 µg/ml, COX20 = cefoxitin at 20 µg/ml, CTX250 = 
ceftriaxone at 250 µg/ml, IMI12.5 = imipenem at 12.5 µg/ml and VAN6.25 = vancomycin at 6.25 µg/ml. 
Picture is representative of three experiments. 
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3.6 Effect of SDS on DD-CPase knockout mutants 
In order to determine if enhanced antibiotic susceptibility was due to changes in permeability 
of double knockout mutants, SDS susceptibility was tested as described in section 2.12.7. In 
liquid media, all strains did not form colonies after 3 hours treatment with SDS, Figure 
3.22A. The double knockout mutants behave similarly to wild type on agar plates 
supplemented with SDS, Figure 3.22B. Together, these data suggest that the inherent 
susceptibility to the detergent was not affected by the deletion of DD-CPases. Alternatively, 
the presence of the remaining DD-CPases may provide sufficient protection against SDS. 
3.7 DD-CPases play a role in cell shape and size 
3.7.1 Role of DD-CPases on maintaining cell shape 
To observe if deletion of DD-CPases affected the cell surface of the bacteria, SEM was 
performed as described in section 2.12.9.1. An E. coli mutant lacking multiple LMW PBPs, 
in addition PBP5, displayed unusual kinks, bends and branches (Typas et al., 2011). A 
number of robust phenotypes were observed in our mutants: abnormal septa, V-form, division 
scars, budding, chaining, kinks, binary fission, fattening of cells and polar bulging as 
demonstrated in Figure 3.23. These phenotypes were quantified and displayed as a histogram 
in Figure 3.24, which depicts the four phenotypes that were robustly different between wild 
type and the double knockout mutants (p < 0.01 or p < 0.05). These four phenotypes include 
abnormal septa, division scars, kinks at one end of the cell and chaining formation of cells. 
Abnormal septa demonstrated by the dark blue arrow in Figure 3.23 were identified as double 
septa or ringlets and occurred more frequently in the two double knockout mutant strains. 
Division scars indicated by the pink arrows and kinks indicated by the light blue arrows in 
Figure 3.23 also occurred more frequently in both double knockout mutant strains as seen in 
Figure 3.24. Chaining formation of cells indicated by the light green arrows in Figure 3.23  
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Figure 3.22. SDS killing of wild type and double DD-CPase knockout mutants. (A) Scatter plot depicting 
killing with 0.2% (w/v) SDS. Graph is representative of three experiments with error bars indicating standard 
deviation. (B) Photographs depicting killing with different concentrations of SDS on agar plates. 1 to 8 indicates 
a serial dilution of the initial inoculum from 10
0
 to 10
7
. [1] 10
0
, [2] 10
1
, [3] 10
2
, [4] 10
3
, [5] 10
4
, [6] 10
5
, [7] 10
6
,
 
[8] 10
7
. Picture is representative of three experiments. 7H10 agar plate and CFU counts for initial inoculum is 
the same as Figure 3.21.  
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Figure legend on next page. 
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Figure 3.23. SEM images of phenotypes found in wild type and double knockout DD-CPase mutants. (A-
B) wild type, (C-D) ΔMSMEG_1661 ΔMSMEG_2432, (E-F) ΔMSMEG_2433 ΔMSMEG_1661, (G-H) 
ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661, (I-J) ΔMSMEG_2433 ΔMSMEG_1661::MSMEG_1661. 
Arrows indicated the following phenotypes: dark blue = abnormal septa, purple = v-form, pink = division scars, 
white = budding, light green = chaining, light blue = kinks, orange = fattening of cells and dark green = polar 
bulging. Picture is representative of three experiments. 
occurred more frequently in the ΔMSMEG_1661 ΔMSMEG_2432 strain. This phenotype 
was also found in the ΔMSMEG_2433 ΔMSMEG_1661 strain but at a lower frequency.  The 
large error bars for this phenotype seen in the ΔMSMEG_2433 ΔMSMEG_1661 mutant 
could possibly be due to that fact that often cells in this mutant spanned the entire image grid. 
This resulted in cells that could not be captured from one end to the other, which were then 
excluded from analysis, causing variation between experiments. 
G H
I J
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The remaining phenotypes – polar bulging, fattening of cells, v-form and budding 
demonstrated by the dark green, orange, purple and white arrows respectively - did not differ 
significantly between the wild type and mutant strains as demonstrated in Figure D9 (page 
132).  
 
Figure 3.24. Quantification of SEM phenotypes found in wild type and double knockout DD-CPase 
strains. A significant increase was observed in the ΔMSMEG_1661 ΔMSMEG_2432 mutant in most 
phenotypes with the ΔMSMEG_2433 ΔMSMEG_1661 mutant showing variation. Graph is representative of 
three experiments and p values were calculated using the t-test.  
 
3.7.2 The role of DD-CPases on maintaining cell size 
Using the SEM images, cell lengths were obtained and grouped according to the following 
sizes: 0-2 µM, 2.1-4 µM, 4.1-6 µM, 6.1-8 µM and 8.1-10 µM as shown in Figure 3.25. As 
expected, wild type cells were predominantly found in the range of 2.1 – 6 µM, which 
corresponds to the usual size of M. smegmatis. A higher frequency of cells between the 
ranges of 6.1 - 10 µM was found in the double knockout mutant strains. Both complemented 
strains behave similarly to the wild type strain, confirming that deletion of two DD-CPases 
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affects cell length. These observations, combined with the presence of cells with multiple 
septa, are suggestive of the inability to coordinate cell division in the absence of two DD-
CPases.  
Figure 3.25. Quantification of SEM cell length. The histogram portrays a change in the distribution of cell 
length found in the mutants when compared to the wild type. The frequency was calculated as the total 
population observed in three experiments with error bars indicating standard error. 
 
3.8 DD-CPases play a role in cell division 
3.8.1 Role of DD-CPases in septal formation/degradation 
The presence of multiple septa in our mutants were suggestive of division defects. To further 
assess if septa were completely formed or were found in multiplicity due to the fact that they 
were not degraded at the appropriate time, TEM was conducted as described in section 
2.12.8.2, to observe cross-sectioned images of cells and septa. All strains harboured the 
presence of fully formed septa, shown by the orange arrows in Figure 3.26. This data 
suggests that deletion of DD-CPases do not affect septal formation in M. smegmatis but rather 
timely degradation at the late stages of cell division. 
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Figure 3.26. Septum formation in wild type and double knockout mutant strains. (A) Wild type, (B) 
ΔMSMEG_1661 ΔMSMEG_2432, (C) ΔMSMEG_1661 ΔMSMEG_2432::MSMEG_1661, (D) 
ΔMSMEG_2433 ΔMSMEG_1661, (E) ΔMSMEG_2433 ΔMSMEG_1661::MSMEG_1661. TEM analysis 
A
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D E
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revealed that all strains had the ability to form proper septa, demonstrated by the orange arrow, indicated that 
septal formation of degradation processes are not affected in the absence of two DD-CPases. Picture is 
representative of three experiments. 
 
3.8.2 Role of DD-CPases in cell division 
Cell division and remodeling in mycobacteria is performed by a number of enzymes 
including DD-CPases (Hett and Rubin, 2008, Vollmer and Bertsche, 2008). In order to 
determine if deletion of the DD-CPases affects the spatial localization of new PG units, cells 
were stained with BODIPY fluorescent vancomycin as described in section 2.12.9.3. This 
stain allows for visualization of newly synthesized and incorporated PG. Mycobacterial 
growth occurs by incorporation of newly synthesized PG at the septum and poles (Brown et 
al., 2011) described in detail in section 1.5. We saw numerous patterns of fluorescence 
localization as seen in Figure 3.27, listed as follows: (i) Cells that displayed distinct staining 
at both poles or at one pole - termed bipolar and monopolar respectively, (ii) Cells that 
displayed distinct fluorescence at the ends and the middle of a cell - termed polar and septa 
and (iii) Cells that fluoresce in the middle - termed septal only. In the mutants, two additional 
groups were observed termed punctate and cells with multiple septa. Punctate cells were 
identified as cells that displayed distinct fluorescence spots throughout the cell, whereas cells 
with multiple septa were identified as cells that displayed distinct fluorescence septa 
throughout the cell. Cells with diffuse staining are defined as cells that were stained with the 
same intensity across the entire cell.  These phenotypes were quantified and a bar graph was 
generated, Figure 3.27B.  
The data indicated that bipolar and monopolar staining was decreased in the mutant strains. 
Cells carrying stain at the poles and septum were found at a similar frequency in all strains. A 
higher frequency of cells stained at the septa only was found in the ΔMSMEG_1661 
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ΔMSMEG_2432 strain – further confirming the observation of cells that were arrested at the 
late stages of cell division. No cells with punctate staining or multiple septa were observed in  
 
Figure 3.27. Vancomycin staining of wild type and double knockout mutants strains. (A) Observed 
phenotypes. [i] diffuse, [ii] bipolar, [iii] monopolar, [iv] polar and septal, [v] septal only, [vi] punctate, [vii] 
multiple septa. . (B) Quantification of observed phenotypes. Graph was generated using data from three 
independent experiments with error bars indicating the standard error margin.  
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the wild type strain. In contrast, a high percentage (~30%) of punctate stained cells was found 
in the ΔMSMEG_1661 ΔMSMEG_2432 strain and this phenotype was reverted to wild type 
when complemented with only one DD-CPase. A lower percentage (<5%) of punctate stained 
cells was found in the ΔMSMEG_2433 ΔMSMEG_1661 strain. Cells with multiple septa 
were found in both mutants. 
3.9 Recombinant expression of DD-CPases  
3.9.1 Preparation of gene insert fragments for cloning 
Genes of interest, MSMEG_6113, MSMEG_1661, MSMEG_2432 and MSMEG_2433, were 
amplified using Phusion DNA polymerase. The PCR reactions were electrophoresed on low 
melting (LM) agarose gels as shown in Figure D10 (page 132), and the appropriate band 
which corresponded to the correct size was gel extracted and purified as described in section 
2.6.2. The purified DNA fragments were then digested using NdeI and HinDIII. Digested 
fragments were electrophoresed on LM agarose gels as shown in Figure D12 (page 133), 
followed by gel extraction and purification.  
3.9.2 Preparation of protein expression vector pET29a 
A lab freezer stock of pET29a was used and in order to confirm that it was the correct vector, 
extensive restriction mapping was performed. Plasmid DNA was extracted as described in 
section 2.3.1.2 and a restriction profile of pET29a was generated using five restriction 
enzymes as shown in Figure D11 (page 133). All enzymes yielded the expected banding 
pattern.  
Following restriction confirmation, pET29a was digested, dephosphorylated and 
electrophoresed on a LM agarose gel shown in Figure D12 (page 134). This was followed by 
ligation of the vector with each gene and transformants were selected for on LA plates 
containing Kan. The vector pET29a carries a Kan coding resistance cassette therefore 
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successful transformants will be able to grow in the presence of the antibiotic. After an initial 
screen (data not shown), one clone of each gene was then chosen and analyzed by restriction 
mapping to confirm genetic integrity, as shown in Figures 3.28 – 3.31. These confirmed 
clones were then further analyzed by sequencing (data not shown). All clones displayed 
expected banding patterns, Figures 3.28 – 3.31, and sequencing results indicated that there no 
mutations occurred during cloning (data not shown).  
 
Figure 3.28. Restriction mapping of pET29a_DacB. (A) Expected fragment sizes for restriction digestions. 
(B)  Restriction digestions of pET29a_DacB with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, 
Lane 3: HinDIII, Lane 4: HinDIII + NdeI, Lane 5: NotI, Lane 6: PvuI, Lane 7: NspI, Lane 8: PvuII. All bands 
corresponded to the expected fragment sizes.  (C) Vector map of pET29a_DacB.  
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Figure 3.29. Restriction mapping of pET29a_1661. (A) Expected fragment sizes for restriction digestions. (B)  
Restriction digestions of pET29a_1661 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, Lane 3: 
HinDIII, Lane 4: HinDIII + NdeI, Lane 5: NotI, Lane 6: PvuI, Lane 7: NspI, Lane 8: PvuII. All bands 
corresponded to the expected fragment sizes.  (C) Vector map of pET29a_1661. 
 
Figure 3.30. Restriction mapping of pET29a_2432. (A) Expected fragment sizes for restriction digestions. (B)  
Restriction digestions of pET29a_2432 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, Lane 3: 
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HinDIII, Lane 4: HinDIII + NdeI, Lane 5: MluI, Lane 6: PvuII, Lane 7: NspI, Lane 8: BspHI. All bands 
corresponded to the expected fragment sizes.  (C) Vector map of pET29a_2432. 
 
Figure 3.31. Restriction mapping of pET29a_2433. (A) Expected fragment sizes for restriction digestions. (B)  
Restriction digestions of pET29a_2433 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, Lane 3: 
HinDIII, Lane 4: HinDIII + NdeI, Lane 5: NotI, Lane 6: PvuII, Lane 7: NspI, Lane 8: BspHI. All bands 
corresponded to the expected fragment sizes.  (C) Vector map of pET29a_2433. 
 
3.10 Transformation into expression host cell line 
Once clones were confirmed by restriction profiling and sequencing, they were transformed 
into the expression host cell line (E. coli BL21 (DE3) pLysS) and selected for on LA plates 
containing Kan and Camp. Two clones of each gene were selected and DNA was extracted. 
Clones were confirmed by PCR using the DH5α positive clones as a reference. BL21 
transformants of all four genes displayed the correct PCR band as demonstrated in Figures 
3.32 and 3.33.  
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3.11 Protein induction of DD-CPases 
Using one of the positive BL21 transformants each, IPTG induction of the MSMEG_1661, 
MSMEG_2432 and MSMEG_2433 DD-CPase proteins was carried out as described in 
section 2.13.2. Using the B-PER solution, cells were separated into soluble and insoluble 
fractions followed by visualization of SDS-PAGE gels stained with coomassie blue. 
 
Figure 3.32. PCR confirmation of DacB and MSMEG_1661 E. coli BL21 (DE3) pLysS transformants. (A) 
Agarose gel of possible clones. Lane 1 and 5: Marker VI, Lane 2 and 6: Positive DH5α clones, Lane 3-4 and 7-
8: possible transformants. (B) Vector map of pET29a_DacB with amplified region shown by red shaded arrow. 
(C) Vector map of pET29a_1661 with amplified region shown by red shaded arrow. 
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Figure 3.33. PCR confirmation of MSMEG_2432 and MSMEG_2433 E. coli BL21 (DE3) pLysS 
transformants. (A) Agarose gel of possible clones. Lane 1 and 5: Marker VI, Lane 2 and 6: Positive DH5α 
clones, Lane 3-4 and 7-8: possible transformants. (B) Vector map of pET29a_2432 with amplified region shown 
by red shaded arrow. (C) Vector map of pET29a_2433 with amplified region shown by red shaded arrow. 
 
 Induction with 0.3 mM or 1 mM IPTG did not result in induction of the MSMEG_1661, 
MSMEG_2432 or MSMEG_2433 proteins (data not shown). No further attempts at induction 
of these proteins were made. 
However, following a similar approach, induction at 37 °C with 0.3 mM and 1 mM IPTG 
resulted in expression of the DacB protein. This can be seen by the distinct 49 kDa band 
present in the 2 hour and 3 hour fractions, indicated by the red arrow in Figure 3.34, with 
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most of the protein found in the insoluble fraction. It was determined that an induction period 
of 3 hours would be used for purification of the protein.  
 
Figure 3.34. IPTG induction of DacB-His. Lane 1: Prestained protein ladder, Lane 2: uninduced, Lane 3: 1 hr 
induction, Lane 4: 2 hr induction, Lane 5: 3 hr induction, Lane 6: 3 hr induction insoluble fraction, Lane 7: 3 hr 
induction soluble fraction. Red arrow indicates expected protein. 
 
In an approach to get soluble protein, induction was performed at 30 °C with 0.3 mM and 1 
mM IPTG. This strategy was unsuccessful as protein was still being expressed in the 
insoluble fraction, demonstrated in Figure 3.35.  
 
Figure 3.35. IPTG induction of DacB-His at 30 °C. (A) Induction with 0.3 mM IPTG. (B) Induction with 1 
mM IPTG. Lane 1: Prestained protein ladder, Lane 2: uninduced soluble fraction, Lane 3: uninduced insoluble 
fraction, Lane 4: 1 hr induced soluble fraction, Lane 5: 1 hr induced insoluble fraction, Lane 6: 2 hr induced 
soluble fraction, Lane 7: 2 hr induced insoluble fraction, Lane 8: 3 hr induced soluble fraction, Lane 9: 3 hr 
induced insoluble fraction. Red arrow shows induced putative DacB-His protein. Red arrow indicates expected 
protein. 
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3.12 Protein purification of DacB-His 
The DacB-His protein was induced at 37 °C using 0.3 mM and 1 mM IPTG for 3 hours, 
followed by separation into soluble and insoluble fractions. This was followed by protein 
purification of the soluble fraction as described in section 2.13.4. The following samples were 
collected – soluble, insoluble, washes, resin-bound protein and elution. Thereafter, the 
samples were electrophoresed on two SDS-PAGE gels. One of the gels were stained using 
coomassie blue and the other was used for Western blotting as described in section 2.13.5. 
Both IPTG concentrations resulted in the protein being present in the insoluble fraction. Since 
pET29a carries a His-tag, the monoclonal Anti-poly Histidine antibody was used to identify 
the protein. Both Westerns blots indicated the presence of a ~70 kDa protein in the insoluble 
and wash fractions which did not correspond to the expected 49 kDa. The results for 1 mM 
IPTG induction is shown in Figure 3.36. The band that was over-expressed, did not bind the 
His-antibody, indicating that it was non-specific, or that the tag was being removed. The 
latter hypothesis was confirmed by the observation that no protein was detection on the SDS-
PAGE gel or western from the eluate off the HIS-bind resin.  
 
Figure 3.36. Purification of DacB-His at 37 °C. (A) SDS-PAGE gel showing induction of DacB-His. (B) 
Western blot of DacB-His. Lane 1: Prestained protein ladder, Lane 2: insoluble fraction, Lane 3: soluble 
fraction, Lane 4: Washes, Lane 5: resin-bound protein, Lane 6: Elution. 
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3.13 Cloning of DacB domain variants 
Since the full length DacB protein could not be expressed as a soluble protein, an alternative 
approach using three variants of DacB was investigated. These three variants included the 
DacB domain, the DacB domain lacking 50 amino acids and the DacB domain plus a 
flanking sequence, referred to as DacB domain, DacB
 
minus and DacB flank respectively. 
These regions of interest were amplified using Phusion DNA polymerase and electrophoresed 
on LM agarose gels as indicated in Figure D13 (page 134). The fragments were extracted and 
purified prior to digestion with NdeI and HinDIII. The pET29a vector was digested with the 
same enzymes and dephosphorylated followed by visualization of all the digested products on 
LM agarose gels as shown in Figure D14 (page 134). All products were extracted and 
purified and ligation reactions with the vector were set up for each variant. Ligation reactions 
were transformed into the cloning host cell line E.coli DH5α and selected for on LA plates 
containing Kan. An initial screen was performed to identify possible transformants (data not 
shown). One clone of each variant was chosen and analyzed by restriction mapping to 
confirm genetic integrity, as well as sequencing. All transformants displayed the expected 
banding patterns, Figures 3.37 – 3.39. Sequencing results indicated no base changes in any of 
the variants confirming that no mutations had occurred (data not shown).  
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Figure 3.37. Restriction mapping of pET29a_DacB domain. (A) Expected fragment sizes for restriction 
digestions. (B)  Restriction digestions of pET29a_DacB domain with several enzymes. Lane 1: Marker IV, Lane 
2: uncut DNA, Lane 3: HinDIII, Lane 4: BspHI, Lane 5: NspI, Lane 6: PvuI, Lane 7: PvuII. All bands 
corresponded to the expected fragment sizes. (C) Vector map of pET29a_DacB domain. 
 
 
Figure 3.38. Restriction mapping of pET29a_DacB minus. (A) Expected fragment sizes for restriction 
digestions. (B)  Restriction digestions of pET29a_DacB minus with several enzymes. Lane 1: Marker IV, Lane 
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2: uncut DNA, Lane 3: HinDIII, Lane 4: BspHI, Lane 5: NspI, Lane 6: PvuI, Lane 7: PvuII. All bands 
corresponded to the expected fragment sizes. (C) Vector map of pET29a_DacB minus. 
 
 
Figure 3.39. Restriction mapping of pET29a_DacB flank. (A) Expected fragment sizes for restriction 
digestions. (B)  Restriction digestions of pET29a_DacB flank with several enzymes. Lane 1: Marker IV, Lane 2: 
uncut DNA, Lane 3: PvuII, Lane 4: PvuI, Lane 5: NspI, Lane 6: BspHI, Lane 7: HinDIII. All bands 
corresponded to the expected fragment sizes. (C) Vector map of pET29a_DacB flank. 
 
Once clones were confirmed by restriction profiling and sequencing, they were transformed 
into the expression host cell line E. coli BL21 (DE3) pLysS and selected for on LA plates 
containing Kan and Camp. Two clones of each variant were selected and confirmed by PCR 
using the DH5α clone as a reference. All of the BL21 transformants matched their respective 
DH5α reference clones as shown in Figure 3.40 and was taken forward for induction.  
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Figure 3.40. PCR confirmation of E. coli BL21 (DE3) pLysS DacB variants. (A) DacB domain 
transformants. (B) Vector map of pET29a_DacB domain with amplified region shown by red shaded arrow. (C) 
DacB minus transformants. (D) Vector map of pET29a_DacB minus with amplified region shown by red shaded 
arrow. (E) DacB flank transformants. (F) Vector map of pET29a_DacB flank with amplified region shown by 
red shaded arrow.  Lane 1: Marker VI, Lane 2: no DNA, Lane 3: positive DH5α clone, Lane 4-5: possible 
transformants.  
 
3.14 Induction of DacB variants 
One clone of each variant was induced using 1 mM IPTG at 37 °C for 2 hours. Samples were 
separated into soluble and insoluble fractions before visualized on coomassie stained SDS-
PAGE gels as shown in Figure 3.40. Induction of DacB domain and DacB minus
 
variants 
resulted in no visible increase of protein expression, Figure 3.41. The DacB flank variant 
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showed induced expression after only one hour of induction as witnessed by the distinct 32.1 
kDa band in Figure 3.40. However, once again the recombinant protein was found in the 
insoluble fraction. Due to time constraints, no further attempts were made to obtain soluble 
preparations of DD-CPases from mycobacteria. 
 
Figure 3.41. IPTG induction of DacB variant proteins. (A) DacB domain. (B) DacB minus. (C) DacB flank. 
Lane 1: Prestained protein ladder, Lane 2: uninduced insoluble fraction, Lane 3: uninduced soluble fraction, 
Lane 4: 1 hr induced insoluble fraction, Lane 5: 1 hr induced soluble fraction, Lane 6: 2 hr induced insoluble 
fraction, Lane 7: 2 hr induced soluble fraction. 
  
27 kDA
27 kDA
27 kDA
35 kDA
A B
C
1   2   3   4  5  6  7 1   2   3  4   5   6   7
1  2  3   4   5   6   7
108 
 
4. Discussion 
The TB epidemic remains of global health concern due to the high numbers of associated 
deaths annually (WHO, 2015). The emergence of drug resistant strains is of particular 
concern considering that these cases account for the majority of deaths (CDC, 2015, WHO, 
2015). The inefficiency of the current TB regimen to treat these forms of drug resistant TB 
has exacerbated the global TB epidemic and appending morbidity. Additionally, LTBI poses 
a massive threat, as the majority of infected people are predicted to have this form of 
infection and pose a notable public health challenge as they continuously feed the pool of 
diseased individuals. It has been predicted that LTBI is characterized by the presence of 
dormant, metabolically quiescent organisms (Shleeva et al., 2002), which would be refractive 
to treatment, as most of the current TB antibiotics require active metabolism to achieve 
vulnerability in the drug target (WHO, 2015). However the fact that INH is efficacious at 
treating LTBI suggest that LTBI is most likely underpinned by a diversity of organisms that 
are in different states of growth/metabolic activity (Ferebee and Mount, 1962, Veening, 1968, 
Barry et al., 2009b, Mulyukin et al., 2009). This lack of clarity regarding bacterial physiology 
in LTBI, combined with the rapid emergence of drug resistance as created a dire need for 
new drugs to eradicate TB (WHO, 2015). In order to understand how to effectively combat 
the TB epidemic a better understanding of the mycobacterial processes that contribute to 
growth and survival needs to be developed.  
In this MSc, we focused on the mycobacterial cell wall with the aim of identifying new drug 
targets that can be exploited for further development. In addition to the PG, the mycobacterial 
cell wall is made up of additional layers such as the MAs and the AG, making the overall 
structure more complex than gram negative or gram positive cell walls (Hett and Rubin, 
2008). Disruption of the PG homeostasis affects permeability of the cell wall (Hett and 
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Rubin, 2008), which could possibly aid in entry of drugs that target components in the 
cytoplasm, as well as cell death. The targeting of enzymes that remodel PG in the periplasmic 
compartment of the cell is also advantageous as small molecules do not have to transverse an 
additional layer before reaching their targets (Crick et al., 2001, Hett and Rubin, 2008).  
This MSc study focuses on DD-CPases which are class C LMW PBPs responsible for 
regulating the amount of cross-linking found in the PG by removing the terminal D-Ala 
preventing formation of the 3→4 cross-linkages (Ghosh et al., 2008, Sauvage et al., 2008, 
Vollmer et al., 2008b). These are functionally redundant enzymes with a previous study 
conducted in our lab indicating that single deletion of the DD-CPase homologues had no 
observable effects on growth kinetics, biofilm formation, microscopy, exposure to cell wall 
stresses such as SDS and antibiotic susceptibility (Ealand et al., unpublished). As mentioned 
previously, deletion of multiple PBPs in E. coli were required before any phenotypic 
differences could be observed (Denome et al., 1999). These observations formed the basis of 
this study which involved the generation of double deletion mutants lacking different 
combinations of the M. smegmatis DD-CPases in an attempt to dissect the function of these 
proteins in mycobacteria and to validate them as possible future drug targets.  
A study conducted at the CBTBR revealed that the DD-CPases in M. smegmatis were 
expressed at different transcript abundances, an effect that was similar during all phases 
(early-log, mid-log and stationary) of broth culture. In this case, MSMEG_2433 always 
displaying the highest expression, followed by MSMEG_1661, DacB and finally 
MSMEG_2432, which was expressed at the lowest level (Ealand et al., unpublished). Our 
expression analysis profiling for the single deletion mutants was consistent with these results 
thus confirming a differential requirement for the various DD-CPases during growth. 
However, we also found that the expression of MSMEG_2433 was upregulated in the 
ΔMSMEG2432 strain, suggestive of compensatory gene expression effects that point to some 
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level of redundancy in function. In M. smegmatis, MSMEG_2432 and MSMEG_2433 have 
been shown to be duplications of the Mtb DacB protein which could further explain the 
compensatory effect and perhaps also suggest some form of coordinated gene regulation 
(Machowski et al., 2014). 
Bourai and colleagues (2011) constructed an Mtb mutant lacking DacB2 (ΔdacB2) and 
evaluated its growth in various liquid media. Growth of the ΔdacB2 strain was found to be 
similar to the wild type H37Rv strain when grown in 7H9 and Sauton’s minimal media (pH 
7) (Bourai et al., 2011). However, growth of the mutant in Sauton’s minimal media (pH 5.5) 
was severely impaired, with this phenotype more pronounced in stationary versus shaking 
cultures indicating that this protein is required under stress conditions, especially when 
oxygen is limited in stationary culture (Bourai et al., 2011). In addition, loss of DacB2 in this 
strain could have altered the PG structure/composition thus enhancing susceptibility to acid 
stress. Previous experiments conducted in our lab indicated that lack of any single DD-CPase 
in M. smegmatis did not alter growth kinetics in 7H9 broth. (Ealand et al., unpublished). Our 
study revealed that the loss of two DD-CPases, in two combinations, did not alter growth in 
7H9 broth or Sauton’s minimal media (pH 7.3). However, in Sauton’s minimal media (pH 
5.5), a single deletion lacking MSMEG_1661 resulted in impaired growth. The remaining 
single mutants (ΔMSMEG_2432 and ΔMSMEG_2433) as well as the double mutant lacking 
both MSMEG_2433 and MSMEG_1661 grew at similar rates to the wild type. The 
complemented strains and the ΔMSMEG_2432 ΔMSMEG_1661 double knockout strain 
showed better growth than the wild type in the late-log and stationary phases of growth. 
These results suggest a few possible theories: (i) MSMEG_1661 could possible play required 
under acid stress conditions, (ii) Deletion of another DD-CPase in the absence of 
MSMEG_1661 results in variable upregulation of another protein that may play a role under 
acid stress conditions and (iii) expression of MSMEG_1661 at a different locus provides 
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additional protection against acid stress. These findings could also point to MSMEG_1661 
functioning as part of a regulon which controls the growth and survival of M. smegmatis 
under stressful conditions.  
Changes in colony morphology, biofilm formation and sliding motility are often associated in 
many mycobacterial mutant strains (Martinez et al., 1999, Recht et al., 2000, Recht and 
Kolter, 2001, Ojha et al., 2002). Morphology changes in a colony can be caused by disruption 
of surface components of the cell that affect the cell wall structure and or hydrophobicity 
(Bourai et al., 2011). The overexpression of DacB2 resulted in smooth mucoid Mtb colonies 
indicating that the LMW PBPs may play a role in maintaining colony morphology (Bourai et 
al., 2011). E. coli single, double and triple mutants lacking PBP4, PBP5 and PBP7 were 
shown to have reduced biofilm formation while growth in planktonic culture was unaffected 
(Gallant et al., 2005), confirming that LMW PBPS either a play direct role in biofilm 
formation or interact with proteins required for biofilm formation or maturation. The high 
lipid content of mycobacterial species allows for the formation of biofilms on the surface of 
liquid media with these bacterial communities contributing to antibiotic tolerance (Etienne et 
al., 2002, Branda et al., 2005, Ghosh et al., 2013). Mycobacteria are non-motile organisms 
that lack flagella and have been shown to be able to move across solid surfaces by a sliding 
mechanism which requires the presence of glycopeptidolipids (Martinez et al., 1999). 
Deletion of one or two DD-CPases did not alter colony morphology or sliding ability of the 
bacteria suggesting that the presence of the remaining DD-CPases may be compensating for 
the loss. Biofilm formation was slightly affected in mutants lacking MSMEG_1661 and 
MSMEG_2433 displaying longer ruffles, demonstrating that these two proteins could either 
directly affect cell wall biosynthesis or interact with other proteins that are responsible for 
biofilm formation. Given that this observation is only qualitative, our explanation in this 
regard is largely speculative and requires further substantiation.  
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Lavollay and colleagues (2008) demonstrated that mycobacterial PG displays a difference in 
the amount of 3→4 and 3→3 cross-links found during the different stages of growth. E. coli 
predominantly contains 3→4 cross-links except in the stationary phase of growth, where the 
organism contains an increased ratio of 3→3 cross-links (Lavollay et al., 2008).  This was 
initially described for mycobacteria as well, with 80% of the crosslinks in the stationary 
phase being 3→3 crosslinks (Lavollay et al., 2008). However, a recent study demonstrated 
that these crosslinks predominate at a 3:2 (3→3: 4→3) ratio with no significant differences 
observed during the different growth phases (Kumar et al., 2012). As mentioned previously, 
the 3→3 cross-links are formed by Ldts whereas the 3→4 cross-links are formed by DD- 
transpeptidases which are generally HMW PBPs (Mainardi et al., 2002, Sauvage et al., 2008). 
The heavily 3→3 cross-linked  mycobacterial PG is necessary for maintenance of infection 
and plays a role in antibiotic stress (Kieser and Rubin, 2014) as evidenced by an Mtb mutant 
lacking LdtMt2. This LdtMt2 mutant was unable to persist during the chronic stage of infection 
in a mouse model and displayed increased sensitivity to β-lactams (Gupta et al., 2010). In 
Mtb, tetrapeptides are exclusively produced by DD-CPases and these tetrapeptides are the 
specific donor substrates used for the formation of the 3→3 cross-links by Ldts (Cordillot et 
al., 2013). Remodeling of the PG by cell wall associated proteins such as the DD-CPase 
DacB1 has been shown to be required for survival in hosts such as primates with mutation in 
these genes resulting in 38.58% attenuation (Dutta et al., 2010). Furthermore, these unique 
3→3 cross-links are important for survival in the host, maintenance of colony morphology, 
growth of Mtb in mouse models as well as viability and virulence of the organism (Gupta et 
al., 2010, Kumar et al., 2012).  Mtb is intrinsically resistant to β-lactams due to the 
production of class A β-lactamases (BlaC), consequently these drugs are not used to treat the 
TB disease (Dubee et al., 2012).  More recently carbapenems, a class of β-lactams, have been 
shown to inactivate Ldts and can target the DD-CPases as well (Mainardi et al., 2007, 
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Lavollay et al., 2008, Dubee et al., 2012). Consistent with this, treatment of Mtb with 
meropenem, which belongs to the carbapenem family, resulted in the accumulation of 
pentapeptides which suggested that a DD-CPase was being targeted (Kumar et al., 2012). It is 
likely that both 3→3 and 4→3 cross-links need to be targeted in order to effectively kill Mtb. 
A relationship between the LMW PPBs and antibiotic resistance has been established with 
the DacB enzyme of E. coli, which displays high levels of inherent resistance to ampicillin 
and presumably confers similar resistance properties to the organism (Gondre et al., 1973). 
As a result, the deletion of dacB with other PBPs has resulted in increased susceptibility of E. 
coli to antibiotics, specifically β- lactam antibiotics (Denome et al., 1999). Resistance to 
penicillin binding drugs has been shown to be exceptionally high during the stationary phase 
of growth and the shift in PG cross-linking is predicted to be responsible for this (Boshoff 
and Barry, 2006). During the stationary phase of growth, pbp3 of E. coli is down regulated 
while pbp6 is up regulated, coupled with an increase in the amount of 3→3 cross-links 
(Dougherty and Pucci, 1994, Boshoff and Barry, 2006). The Mtb DacB2 enzyme can bind 
penicillin but its catalytic activity is not affected by the antibiotic whereas meropenem has 
been shown to inhibit DacB (Bourai et al., 2011). A previous study conducted at the CBTBR 
demonstrated that deletion of individual DD-CPases from M. smegmatis did not sensitize 
mutants to antibiotics (Ealand et al., unpublished). Our results indicate that the absence of 
two DD-CPases results in increased sensitivity of the organism to various antibiotics, 
depending on the combination of DD-CPases that were deleted. In liquid media, both mutants 
showed increased sensitivity to vancomycin, cefoxitin, cefotaxime, and cefatriaxone with 
different MIC concentrations between strains. The strain lacking MSMEG_1661 and 
MSMEG 2432 displayed increased sensitivity to cefamandole whereas the strain lacking 
MSMEG_2433 and MSMEG_1661 showed increased sensitivity to imipenem. Both 
cefamandole and imipenem are β-lactam antibiotics with the latter been shown to be highly 
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resistant to β- lactamases. These data suggest some form of functional overlap between these 
enzymes. Our double deletion mutants were unaffected by rifampicin, erythromycin and 
vancomycin which inhibit RNA transcription, protein synthesis and PG cross-linking 
respectively. Additionally, sensitivity of both double deletion mutants to the β-lactams were 
increased on solid media as well. A possible explanation of why the mutants show variable 
sensitivity to imipenem could be due to the overexpression of a β-lactamase in the 
ΔMSMEG_1661 ΔMSMEG_2432 mutant. There is a precedent for this in E. coli where bolA 
regulates PBP5 and PBP6 expression thereby controlling normal morphology of the cell and 
the amount of precursors available for crosslinking by the transpeptidase PBP2 (Santos et al., 
2002). In addition, bolA regulates AmpC which is a β-lactamase thus linking the expression 
of DD-CPases to β-lactamase induction (Santos et al., 2002). Additional resistance 
mechanisms to β-lactams includes the compensatory expression of PBPs which have low 
binding affinity to antibiotics (Nikolaidis et al., 2013). Consequently, the lack of DD-CPases 
in our double mutants could reduce the bioavailability of PBPs in the cell and thereby allow 
enhanced binding of antibiotics to HMW PBPs, which have been shown to play an important 
role in PG assembly. This would ultimately result in increased sensitivity of the mutants to 
antibiotics due to disruption of the PG layer. Additionally, lack of the DD-CPases could result 
in a decrease of the 3→3 cross-links, which could also play a role in antibiotic susceptibility, 
Figure 4.1. 
The commonly used detergent, SDS, has a strong anionic dodecyl and is used for the 
degradation of lipids and proteins as well as lysis of cells. Since deletion of DD-CPases may 
result in altered of permeability of the PG, we hypothesized that our mutants would display 
enhanced susceptibility to SDS. Failure of SDS to differentially affect the mutants and the 
wild type indicates that lipid degradation or remodeling processes are not affected in the 
absence of DD-CPases, suggesting that (i) these enzymes do not play a role in controlling 
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these processes nor do they interact with proteins involved in lipid degradation/remodeling or 
(ii) the remaining DD-CPases are sufficient to maintain the cell wall and provide protection 
against SDS stress.  
 
Figure 4.1.Effect of DD-carboxypeptidase deletions on peptidoglycan cross-linking. (A) Peptidoglycan layer 
containing a 3:2 ratio of 3→3: 3→4 cross-links when LD-transpeptidases, high molecular weight penicillin 
binding proteins and DD-carboxypeptidases are present. (B) Loss of DD-carboxypeptidases results in a decrease 
of the 3→3 cross-links as the tetrapeptide substrate required by the LD-transpeptidases is not generated. This 
could result in the accumulation of pentapeptides as well as an increase in 3→4 cross-links generated by the 
high molecular weight penicillin binding proteins. 
 
Following elongation of mycobacterial cells, a multiprotein complex known as the divisome 
is responsible for the division at approximately midcell resulting in two daughter cells 
(Kieser and Rubin, 2014). The divisome coordinates the synthesis and subsequent cleavage of 
the septum (Kieser and Rubin, 2014) with polymerization of FtsZ initiating the division 
process (Mukherjee and Lutkenhaus, 1998). In E. coli, PBP1b and PBP3 are responsible for 
synthesis of the septa and the amidases AmiA, AmiB or AmiC are responsible for separation 
of the two daughter cells through degradation of septal PG (Typas et al., 2011). In 
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mycobacteria, FtsZ has been shown to interact with FtsW and PBP2 (homologous to E. coli 
PBP3), forming a complex and stabilizing the Z-ring at the future division site (Datta et al., 
2002, Datta et al., 2006, Typas et al., 2011). The cell division protein CrgA interacts with this 
complex, stabilizing it with loss of CrgA resulting in elongated cells and the inability of the 
cell to recruit PBP2 to the divisome (Plocinski et al., 2011). PBP2 is required for septum 
synthesis and has been shown to interact with Wag31 which localizes to the division site after 
the septum is formed (Mukherjee et al., 2009, Zhang et al., 2012, Santi et al., 2013). Another 
protein involved in the septum synthesis/degradation is the essential PG hydrolase RipA, with 
depletion resulting in chaining of cells that fail to grow (Hett et al., 2008). RipA has been 
shown to interact with RpfB (Hett et al., 2007) and then cleave PG (Hett et al., 2008) with the 
interaction of RipA and PBP1 counteracting the RipA-RpfB interaction, thus ensuring that 
septal synthesis is achieved before cleavage (Kieser and Rubin, 2014). Our TEM results 
reveal that the septal synthesis pathway is not affected in the M. smegmatis double deletion 
mutants. There are two possible reasons which explain this: (i) there is no interaction between 
the DD-CPases and the divisome complex or (ii) there is no disruption of HMW PBPs such as 
PBP2 which is recruited to the future division site during the early stages of cell division. 
In Mtb V-forms are proposed to be temporal structures as they only form part of a small 
subset of the population (Dahl, 2004). These structures form due to the inner PG layer 
expanding with the outer layer remaining intact during septum synthesis (Dahl, 2004). Once 
the septum is complete, the inner layer continues to grow exerting pressure on the outer layer 
which eventually ruptures on one side of the cell. This results in the bending of the two 
daughter cells, still attached at one side, yielding a V-form, Figure 4.2 (Dahl, 2004). 
Consistent with this, <3% of the cells in all our strains were found in this form.  
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Figure 4.2.V-snapping division of mycobacteria. Newly synthesized peptidoglycan is inserted at the poles as 
shown by light green and dark green colour which represents the old and new pole respectively. The 
peptidoglycan layer continues to expand while the outer layer remains intact during septum formation. Once 
septum synthesis is complete the peptidoglycan layer continues to exert pressure on the outer layer which 
eventually ruptures on one side resulting in the bending of the two daughter cells which are still attached to one 
another thus resulting in a V-form. (Dahl, 2004, Santi et al, 2013) 
 
Division scars have previously been described in Mtb as ridges that remain after cell division 
indicating where the cells have separated, with the newly synthesized PG appearing as a 
terminal bud (Dahl, 2004). A significant increase in the frequency of division scars was 
observed in the DD-CPase double deletion mutants, possibly indicating that once division is 
complete, PG processes such as remodeling, are still not functioning efficiently. As 
mentioned previously, the continuous remodeling of the mycobacterial cell wall is required 
for expansion. It is possible that loss of the DD-CPases affects remodeling of the PG which is 
required in the next division event for expansion of the cell. E. coli lacking PBP5 displayed 
slight morphological defects with the removal of additional PBPs resulting in cells with 
kinks, bends and branches (Typas et al., 2011). In our mutants the frequency of kinks 
increased, pointing to defects in polar PG synthesis. We consequently hypothesize that 
Elongation
Septum 
synthesis
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deletion of the DD-CPases results in a decrease of 3→3 cross-links and thus a decrease in the 
rigidity of the cell wall. This misregulation of cross-links could result in kinking due to an 
imbalance of PG synthesis occurring at one end of the cell. This hypothesis needs further 
confirmation. 
BODIPY vancomycin is a form of fluorescently labelled vancomycin which binds D-Ala-D-
Ala motif that is specifically found in newly synthesized PG (Hett and Rubin, 2008). It 
allows visualization of newly incorporated PG, which is usually found at the septum and 
poles in mycobacterial cells (Hett and Rubin, 2008). The deletion of two DD-CPases resulted 
in two interesting phenotypes (i) Cells with multiple septa, which was observed in SEM as 
well, indicating that cell division is hampered in these mutant strains and from the TEM data, 
this is most likely due to poor degradation of the septum (ii) Punctate localization of new PG, 
pointing to newly synthesized PG at the septum, poles and throughout the cell. Mycobacteria 
lack the negative regulatory systems required for placement of the Z-ring in E. coli and B. 
subtilis as discussed in section 1.5.  FtsZ, an essential protein, localizes at the division site to 
form the Z- ring which serves as a scaffold for recruitment of other cell division proteins such 
as FtsW and PBP2 and guides septal synthesis (Datta et al., 2002, Dziadek et al., 2003, Datta 
et al., 2006). Mycobacterial polar PG synthesis is controlled by Wag31 which is the 
homologue of the gram positive early cell division protein DivIVA (Cole et al., 1998). In 
mycobacteria, Wag31 is essential and localizes to the pole with depletion of the protein 
resulting in one end of the cell becoming rounded (Kang et al., 2008). Thus, Wag31 has been 
implicated in regulating cell shape, growth and cell wall synthesis by localizing PG synthesis 
to the poles and maintaining the rod shape of the bacteria (Kang et al., 2008). Wag31 has also 
been shown to localize to the septum during the later stages of cell division coinciding with 
cytokinesis (Santi et al., 2013). Together FtsZ and Wag31 guide PG synthesis to the septum 
and poles respectively ensuring that this process is controlled and the shape of the organism 
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is maintained (Kang et al., 2008, Typas et al., 2011). Since DD-CPase mutants displayed 
punctate localization of new PG precursors, it is possible that the functioning of FtsZ and 
Wag31 is disrupted in the absence of these enzymes, indicating a possible interaction 
between the LMW PBPs and the cell division proteins.  
Future studies 
Future work could entail dissecting the role of the remaining DD-CPases of M. smegmatis as 
well as investigating these enzymes in Mtb. The behavior of the essential DacB (Rv3627c) 
enzyme could be explored in the absence of the dispensable DD-CPases. This would involve 
the localization of DacB and the other DD-CPases in both M. smegmatis and Mtb mutants 
lacking different combinations of the DD-CPases. Additionally, a panel of mutants lacking 
both Ldts and DD-CPases can be created to explore the spatial localization of PG. The 
specific change in PG in DD-CPase mutants should be investigated in future work. 
Concluding remarks 
Collectively, this study identified the DD-CPases as important enzymes for regulated 
mycobacterial growth and division. This is evidenced by the dysregulated spatial distribution 
of new PG synthesis and lack of coordinated cell division observed in the mutants lacking 
two DD-CPases. Our results confirm an important role of the DD-CPases in maintaining 
antibiotic resistance, as witnessed by the increased sensitivity of mutants to a range of β-
lactam antibiotics. Together this and future studies may identify possible drug targets in the 
PG of mycobacteria that can be exploited to effectively treat TB.  
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5. Appendices 
Appendix A – Media and solutions 
Table A1. Culture media and supplements 
Media/ 
Supplement 
Components 
Luria- Bertani 
Agar (LA) 
5 g yeast extract, 10 g tryptone, 10 g NaCl and 1.5 g agar dissolved in 1 
L sdH20. 
Luria- Bertani 
Broth (LB) 
5 g yeast extract, 10 g tryptone and 10 g NaCl a dissolved in 1 L sdH20. 
2xTY 10 g yeast extract, 16 g tryptone and 10 g NaCl dissolved in 1 L sdH20. 
Middlebrook 7H9 4.7 g Difco Middlebrook 7H9 powder and 2 ml glycerol dissolved in 
986 ml sdH20. Autoclave. 10 ml 100 X glucose salts and 2 ml Tween80. 
Middlebrook 
7H10 
19 g Difco Middlebrook 7H10 powder and 5 ml glycerol dissolve in 985 
ml sdH20. Autoclave. 10 ml 100 X glucose salts. 
Sauton's minimal 
media  
0.5 g magnesium phosphate, 0.5 g potassium dihydrogenorthophosphate, 
2 g citric acid, 4 g L-asparagine, 1 ml 5% ferric ammonium acid, 100 µl 
1% ZnSO4 and 60 ml glycerol. Adjusted pH with ammonium hydroxide. 
Autoclave. 
Glucose salts 
(100X) 
20 g glucose and 8.5 g NaCl dissolved in 100 ml sdH20. 
Tween80 (25%) 10 ml Tween80 dissolved in 40 ml sdH20 
Sucrose (75%) 75 g sucrose dissolved in 100 ml sdH20 
X-gal (2%) 1 g X-gal dissolved in 50 ml deionized DMF 
  
Table A2. Solutions used for plasmid extractions from E. coli 
Solution Composition 
Solution I 50 mM glucose, 25 mM Tris-HCl (pH 8) and 10 mM EDTA dissolved in 
sdH20. Autoclave. 
Solution II 1% SDS and 0.2 M NaOH dissolved in sdH20. 
Solution III 3 M Potassium acetate and 11.5% acetic acid dissolved in sdH20. 
 
Table A3. Solutions used for DNA extraction from M. smegmatis 
Solution Composition 
TE buffer 10 mM Tris-HCl (pH 8) and 10 mM EDTA dissolved in sdH20. Autoclave. 
CTAB/ NaCl 4.1% NaCl and 10% N- cetyl- N, N, N - trimethyl ammonium bromide 
dissolved in sdH20. Filter sterilize. 
 
Table A4. Solutions used for precipitation of DNA 
Solution Composition 
Chloroform: 
Isoamyl alcohol 
24 ml chloroform and 1 ml isoamyl alcohol. 
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Sodium Acetate 3 M sodium acetate dissolved in sdH20 (pH5.2). Autoclave. 
 
Table A5. Solutions used for electrophoresis of DNA 
Solution Composition 
TAE  50 X stock solution: 242 g Tris base, 57.1 ml glacial acetic acid and 
100 ml EDTA (pH 8) made up to 1 L with sdH20. 
Ethidium bromide 10 mg/ml dissolved in sdH20. 
 
Table A6. Agarose gel recipes 
Gel percentage Amount of agarose in 50 ml TAE (g) 
0.8 0.4 
1 0.5 
2 1 
 
Table A7. Solutions used for E. coli competent cells preparation 
Solution Composition 
TfbI 30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium chloride, 
50 mM manganese chloride and 15% v/v glycerol made up in sdH20. Adjusted to 
pH 5.8 with acetic acid. 
TfbII 10 mM rubidium chloride, 75 mM calcium chloride, 10 mM MOPS and 15% v/v 
glycerol made up in sdH20. Adjusted to pH 6.5 with diluted NaOH. 
 
Table A8. Solutions used for Southern blotting 
Solution Composition 
Denaturation solution 1.5 M NaCl and 0.5 M NaOH dissolved in sdH20. 
Depurination solution 0.25 M HCl dissolved in sdH20. 
TBE (1X) 100 ml 10 X Tris-Borate-EDTA (Sigma) dissolved in 900 ml 
sdH20. 
SSC (20X) 0.3 M sodium citrate and 3 M NaCl dissolved in sdH20. 
SDS (10%) 10g SDS powder dissolved in 100ml sdH20. 
Solution I 0.1% SDS and 2 X SSC dissolved in sdH20. 
Solution II 0.1% SDS and 0.5 X SSC dissolved in sdH20. 
Maleic Acid Buffer 1.5 M NaCl and 1 M Maleic acid dissolved in sdH20. Adjusted to 
pH 7.5 with NaOH pellets. 
Wash buffer  0.1 M Maleic Acid Buffer and 0.3% Tween20. 
Blocking solution 
(Roche) 
1 X blocking solution dissolved in Maleic Acid Buffer. 
Detection buffer 0.1 M NaCl and 0.1M Tris-HCl dissolved in sdH20 (pH 9.5) 
Antibody solution 
(Roche) 
Dilute 1: 10000 in blocking solution. 
CSPD (Roche) Disodium 3-(4-methoxyspiro {1,2-dioxetane-3,2′-(5′-
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chloro)tricyclo [3.3.1.1
3,7
]decan}-4-yl)phenyl phosphate  
Stripping solution 0.2 M NaOH and 0.1% SDS dissolved in sdH20. 
 
Table A9. Solutions used for protein extractions 
Solution Composition 
B-PER Reagent Cell lysis reagent 
Protease inhibitor 
cocktail 
1 protease inhibitor cOmplete ultra tablet (Roche) dissolved in 10 ml B-
PER solution. 
 
Table A10. Solutions used for electrophoresis of proteins 
Solution Composition 
bis-acrylamide 40% working solution. 
Tris-HCl 0.5 M (pH 6.8) and 1.5 M (pH 8.8) made up in sdH20. Autoclave. 
SDS (10%) 10 g SDS dissolved in 100 ml sdH20. Autoclave. 
APS (10%) 0.1 g ammonium persulphate dissolved in 1 ml sdH20. Store at 4°C. 
TEMED N, N, N, N- tetramethyl- ethylenediamine. 
Loading buffer 
(5X) 
3.8 ml sdH20, 1.6ml 10% SDS, 1ml 0.5 M Tris-HCl (pH 6.8), 0.8 ml 
glycerol, 0.4 ml bromophenol blue and 0.4 ml β- mercaptoethanol. 
Running buffer 303 g Tris, 144 g glycine and 10 g SDS made up to 1 L in sdH20. 
Coomassie blue 40% ethanol, 10% acetic acid and 0.1% coomassie dissolved in sdH20. 
Destain 40% ethanol and 10% acetic acid dissolved in sdH20. 
 
Table A11. SDS-PAGE gel recipes 
Ingredient Gel Percentage 
 10% 15% 
bis-acrylamide 2.5 ml 3.75 ml 
Tris-HCl 3.75 ml 5.625 ml 
dH20 3.6 ml 400 µl 
SDS (10%) 100 µl 150 µl 
APS (10%) 50 µl 75 µl 
TEMED 5 µl 7.5 µl 
 
Table A12. Solutions used for purification of His-tagged proteins 
Solution Composition 
Ni-NTA resin Nickel-charged resin 
Buffer A 50 mM Tris, 500 mM NaCl, 20% glycerol and 10 mM imidazole dissolved 
in sdH20. Store at 4°C. 
Buffer B 50 mM Tris, 500 mM NaCl, 20% glycerol and 250 mM imidazole dissolved 
in sdH20. Store at 4°C. 
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Table A13. Solutions used for Western blotting 
Solution Composition 
Transfer buffer 28.8 g glycine, 6 g Tris, 2 g SDS and 400 ml methanol dissolved in 2 L 
sdH20. 
TBS (10X) 80 g NaCl and 24.2 g Tris dissolved in 1 L sdH20 (pH 7.6). 
TBST 1X TBS and 0.1% Tween20 made up in sdH20. 
Blocking solution 5% nonfat dry milk (Cell signal) dissolved in TBST. 
CPS Reagent 
(Sigma) 
Chemiluminescent Peroxidase Substrate 
 
Appendix B – Primers 
Table B1. Primers used for PCR confirmation of knockout mutants 
Gene Primer name  Sequence Amplicon 
Wild type Mutant 
MSMEG_1661 Δ1661_F AATCACAAGATTCACACG 
1394 bp 236 bp 
Δ1661_R1 TGGCGGCCAGCGTGTTGA 
Δ1661_R2 GTGCGTCGCGCACACGAC 701 bp  
MSMEG_2432 Δ2432_F GGACCGTTCGGCGAGCAT 
1028 bp 236 bp 
Δ2432_R1 GCATGTTGGCCGCGTCGT 
Δ2432_R2 CGGCGACTGGATCGACCG 500 bp  
MSMEG_2433 Δ2433_F GCAGTCGAATAGTCCACC 
1091 bp 236 bp 
Δ2433_R1 CCGCGTCGTTGCCCGACG 
Δ2433_R2 GTTGTCGGGGCGCAGATG 500 bp  
 
Table B2. Primers used for generation of Southern blot probes 
Gene Primer name Sequence (5' - 3') 
MSMEG_1661 1661_USF CGCGAAGCTTGCGAGGCCGTCGAGAGCG 
1661_USR CGCGCATATGCACCGCGCGTCGCGTCAT 
1661_DSF CGCGCATATGCAGCGCCCGCAGCACTGA 
1661_DSR CGCGGGTACCGTAGCCGACCGTGAGAGCGA 
MSMEG_2432 2432_USF CGCGAAGCTTCCGGGAACGCAGGCAGC 
2432_USR CGCGCATATGCGCCGCGAACAGTCTTCGCAC 
2432_DSF CGCGCATATGGACTACGGCTTCAGCCAGTAG 
2432_DSR CGCGGGTACCGGCCGACTTCGACCTGTCG 
MSMEG_2433 2433_USF CGCGAAGCTTACGATCCCGCGGACCAGG 
2433_USR CGCGCATATGCCCGAAGGCGTACCTCCACAT 
2433_DSF CGCGCATATGGCGAGCATCGGGGCGCTCTGA 
2433_DSR CGCGGGTACCATCGGCCACGGCCGCATC 
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Table B3. Primers used to confirm site specific integration of complementing vector 
Primer name Sequence (5' - 3') Amplicon 
attBS2 ACAGGATTTGAACCTGCGGC 
320 bp 
attL4 AATTCTTGCAGACCCCTGGA 
attBS1 ACGTGGCGGTCCCTACCG 
282 bp 
attL1 CTTGGATCCTCCCGCTGCGC 
 
Table B4. Primers used for gene expression analysis by qPCR 
Gene Primer name Sequence (5' - 3') Amplicon 
MSMEG_1661 1661_qF GAGCATCATCAAGGTCCTCA 
148 bp 
1661_qR CAGCAGATCGTTGATCGTGT 
MSMEG_2432 2432_qF GCTGAACTATCCGGTGATCG 
202 bp 
2432_qR GTACATCTGCACCACCACCA 
MSMEG_2433 2433_qF GCTGGTCAACCAGAACGAGT 
153 bp 
2433_qR TCTTTCACCAGGCCGTACAT 
 
Table B5. Primers used for amplification of genes for protein expression 
Gene Primer name Sequence (5' - 3') Amplicon 
MSMEG_DacB DacB_pF CATATGCTGTTCACCGGCAAACAC 
1293 bp 
DacB_pR CAAGCTTTGCGCCGCATCCGCAGCT 
DacB_domF CATATGGAATCGGTGATGCTCGAC 
693 bp 
DacB_domR AAGCTTCGCGGCCAGAGCGTCGAT 
DacB_minusF CATATGGGCGGCACCACAATCGCC 
543 bp 
DacB_minusR AAGCTTCGCGGCCAGAGCGTCGAT 
DacB_flankF CATATGGCCCGCATCAGCGACCTC 
867 bp 
DacB_flankR AAGCTTTGCGCCGCATCCGCAGCT 
MSMEG_1661 1661_pF CATATGCCCGGCTGGACTGCCCA 
1110 bp 
1661_pR AAGCTTGTGCTGCGGGCGCTGATT 
MSMEG_2432 2432_pF CATATGCCGGCCGCCGCACCGGCG 
744 bp 
2432_pR AAGCTTCTGGCTGAAGCCGTAGTC 
MSMEG_2433 2433_pF CATATGGCCGACATCCAGCAGGTC 
798 bp 
2433_pR AAGCTTGAGCGCCCCGATGCTCGC 
 
Table B6. Primers used for sequencing of pET29a vectors 
Construct Primer name Sequence (5' - 3') 
pET29a_dacB dacB_sF1 CCGACACCTGGTACAAGG 
dacB_sF2 CCGTGAGGTCGCCGAGGC 
pET29a_1661 1661_sF1 TCAACGATCTGCTGCACG 
1661_sF2 CGCGGTGTTGCTCAAGGG 
pET29a_2432 2432_sF1 CCGCATCGCCGTCGGGTC 
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pET29a_2433 2433_sF1 TGGTCACCCCCTCGGGAC 
 
Appendix C – Molecular Weight Markers 
 
 
DNA molecular 
weight Marker IV
DNA molecular 
weight Marker VI
Page RulerTM Plus 
Prestained Protein Ladder 
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Appendix D – Figures 
 
Figure D1. Restriction mapping of p2NIL_PAC_1661. (A) Expected fragment sizes for restriction digestions. 
(B)  Restriction digestions of p2NIL_PAC_1661 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, 
Lane 3: NotI, Lane 4: PvuII, Lane 5: MluI, Lane 6: EcoRI, Lane 7: PvuI, Lane 8: BamHI. All bands correspond 
to expected sizes. (C) Vector map of p2NIL_PAC_1661. 
Restriction enzyme Fragment sizes (bp)
NotI 6010, 5978, 1580, 906, 333, 16
PvuII 10940, 2557, 819, 363, 144
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Figure D2. Restriction mapping of p2NIL_PAC_2432. (A) Expected fragment sizes for restriction digestions. 
(B)  Restriction digestions of p2NIL_PAC_2432 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, 
Lane 3: NotI, Lane 4: PvuII, Lane 5: MluI, Lane 6: EcoRI, Lane 7: PstI, Lane 8: BamHI. All bands correspond 
to expected sizes. (C) Vector map of p2NIL_PAC_2432. 
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Figure D3. Restriction mapping of p2NIL_PAC_2433. (A) Expected fragment sizes for restriction digestions. 
(B)  Restriction digestions of p2NIL_PAC_2433 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, 
Lane 3: NotI, Lane 4: PvuII, Lane 5: MluI, Lane 6: EcoRI, Lane 7: AccI, Lane 8: BamHI. All bands correspond 
to expected sizes. (C) Vector map of p2NIL_PAC_2433. 
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Figure D4. Generation of MSMEG_1661 probes for Southern blots. (A) upstream, (B) downstream. Lane 1: 
Marker VI, Lane 2: No DNA, Lane 3: unlabeled fragment, Lane 4: DIG labeled fragment. Green box indicates 
unlabeled probes and orange box indicates DIG labeled probes. 
 
Figure D5. Generation of MSMEG_2432 probes for Southern blots. Lane 1: Marker VI, Lane 2 and 5: No 
DNA, Lane 3: unlabeled upstream fragment, Lane 4: DIG labeled upstream fragment, Lane 6: unlabeled 
downstream fragment, Lane 7: DIG labeled downstream fragment. Green box indicates unlabeled probes and 
orange box indicates DIG labeled probes. 
 
Figure D6. Generation of MSMEG_2433 probes for Southern blots. (A) upstream probe, (B) downstream 
probe. Lane 1: Marker VI, Lane 2: No DNA, Lane 3: unlabeled fragment, Lane 4: DIG labeled fragment Green 
box indicates unlabeled probes and orange box indicates DIG labeled probes. 
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Figure D7. Restriction mapping of pMV1661. (A) Expected fragment sizes for restriction digestions. (B)  
Restriction digestions of pMV1661 with several enzymes. Lane 1: Marker IV, Lane 2: uncut DNA, Lane 3: 
MluI + PstI, Lane 4: MluI + PvuI, Lane 5: NotI, Lane 6: AatII. All bands correspond to expected sizes. A partial 
digest was seen in Lane 4 as witnessed by the band that corresponds to the uncut sample. (C) Vector map of 
pMV1661. 
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Figure D8. Melt curves of amplicons from qPCR for MSMEG_1661. (A) Curve showing wild type - black, 
Δ\MSMEG_1661 - pink, ΔMSMEG_2432 - orange, ΔMSMEG_2433 - purple, 
ΔMSMEG_1661ΔMSMEG_2432 - red, ΔMSMEG_2433 ΔMSMEG_1661 - blue and ΔMSMEG_1661 
ΔMSMEG_2432::MSMEG_1661 - green. (B) Curve showing ΔMSMEG_2433 
ΔMSMEG_1661::MSMEG_1661 - light pink. Red arrow indicates example of non-specific peak which 
appeared in all mutant strains lacking MSMEG_1661. 
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Figure D9. SEM phenotypes observed in wild type, double knockout mutants and complemented strains. 
All strains produced p values higher than what was considered statistically significant. Graph represents the 
average of three experiments with error bars showing standard error. 
 
 
Figure D10. Phusion PCR of gene fragments to be cloned into pET29a. (A) PCR fragments of DacB and 
MSMEG_1661. Lane 1: Marker VI, Lane 2: no DNA, Lane 3: DacB, Lane 4: no DNA, Lane 5: MSMEG_1661. 
(B) PCR fragments of MSMEG_2432 and MSMEG_2433. Lane 1: Marker VI, Lane 2: no DNA, Lane 3: 
MSMEG_2432, Lane 4: no DNA, Lane 5: MSMEG_2433. Red boxes indicate fragments that were excised and 
purified.  
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Figure D11. Restriction analysis of pET29a expression vector. (A) Expected fragment sizes for restriction 
digests. (B) Restriction digests of pET29a with several enzymes. Lane 1: Marker VI, Lane 2: Uncut DNA, Lane 
3: BamHI, Lane 4: BspHI, Lane 5: NspI, Lane 6: PvuII, Lane 7: AccI. All bands corresponded to the expected 
sizes. (C) pET29a vector map. 
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Figure D12. Digested fragments for cloning. (A) DacB, MSMEG_1661 and pET29a digested with HinDIII 
and NdeI. Lane 1: Marker VI, Lane 2, 4, and 6: no sample, Lane 3: DacB, Lane 5: MSMEG_1661, Lane 7: 
pET29a, Lane 8: Marker IV. (B) MSMEG_2432, MSMEG_2433 and pET29a digested with HinDIII and NdeI. 
Lane 1: Marker VI, Lane 2, 4, and 6: no sample, Lane 3: MSMEG_2432, Lane 5: MSMEG_2433, Lane 7: 
pET29a, Lane 8: Marker IV.  
 
Figure D13. Phusion PCR of DacB variants to be cloned into pET29a. Lane 1: Marker VI, Lane 2, 4 and 6: 
no DNA, Lane 3: DacB domain, Lane 5: DacB minus, Lane 7: DacB flank. Red boxes indicate fragments that 
were excised and purified.  
 
 
Figure D14. Digested DacB variant fragments for cloning. (A) pET29a and DacB domain digested with 
HinDIII and NdeI. Lane 1: Marker IV, Lane 2 and 4: digested pET29a, Lane 3, 5, and 7: no sample, Lane 6: 
digested DacB domain, Lane 8: Marker VI. (B) DacB flank and DacB minus digested with HinDIII and NdeI. 
Lane 1: Marker VI, Lane 2, 4, and 5: no sample, Lane 3: digested DacB flank, Lane 6: digested DacB minus. 
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